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Abstract 
Rheumatoid arthritis (RA) is a chronic progressive systemic inflammatory disease, 
characterized by synovial inflammation and localized destruction of cartilage and 
bone. Heterogeneity in the clinical presentation of RA and uncertainty about which 
patients will respond to treatment makes diagnosis and management challenging. 
Fluorescent imaging in the near infrared (NIR) spectrum significantly decreases tissue 
autofluorescence offering unique potential to detect specific molecular targets in vivo. 
E-selectin or endothelial adhesion molecule-1 (ELAM-1), a 115kDa glycoprotein 
induced on endothelial cells in response to pro-inflammatory cytokines involved in 
RA, such as interleukin (IL)-1 and tumour necrosis factor  (TNF. E-selectin has 
been well validated as a potential biomarker of disease activity. 
My study aimed to investigate whether E-selectin targeted optical imaging in vivo 
could be developed as a sensitive, specific and quantifiable preclinical molecular 
imaging technique, and also whether this approach could be used to delineate the 
molecular effects of novel therapies. I utilised anti-E-selectin antibody labelled with 
NIR fluorophore in a mouse model of paw swelling induced by intra-plantar injection 
of TNFand in acute collagen-induced arthritis (CIA) in DBA/1 mice, a widely used 
model of RA. E-selectin generated signal, localised to points of maximal clinical 
inflammation in the inflamed mouse paw in both models with significant differences 
to control antibody. Binding of anti-E-selectin antibody was also demonstrated by 
immunohistochemistry in both models. The ability of E-selectin targeted imaging to 
detect sub-clinical endothelial activation was also investigated, demonstrating that E-
selectin may be an excellent way of determining subclinical vascular activation in 
CIA. Finally the effect of novel targeted therapy – RB200 which blocks epidermal 
growth factor (EGF) signalling was investigated. This demonstrated that E-selectin 
targeted signal could be absolutely abrogated to a level seen in unimmunised healthy 
control animals, following combination treatment with RB200 and the TNF inhibitor 
etanercept. 
E-selectin targeted optical imaging is a viable in vivo imaging technique that can also 
be applied to quantify disease and investigate the effects of novel molecular therapies. 
It holds significant promise as a molecular imaging technique for future translation 
into the clinic for patients with rheumatoid arthritis and other inflammatory diseases.
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1 INTRODUCTION 
Musculoskeletal disorders such as rheumatoid arthritis (RA) and osteoarthritis (OA) 
are a common cause of pain and disability. Despite the introduction of novel 
biological therapies that target tumour necrosis factor- (TNF in RA, a significant 
proportion of patients do not respond positively to treatment. In addition, the pattern 
of disease in patients may change over time, and alternative therapy may be required 
at different times. In vivo molecular imaging techniques are therefore of paramount 
importance for elucidating pathogenesis and quantifying the effects of therapy at the 
preclinical stage in animal models of disease. The significant potential for translating 
these techniques into patients with arthritis and other inflammatory diseases also 
holds future promise. 
This thesis examines the potential of in vivo optical imaging by targeting fluorescently 
labelled anti-E-selectin monoclonal antibody to localise endothelial activation in 
inflamed tissues in vivo. The study aimed to demonstrate that this approach is a 
sensitive, specific and quantifiable preclinical molecular imaging technique for 
inflammatory models of RA, and further examined whether it can be used to delineate 
the specific effects of targeted biological therapy. 
1.1 Rheumatoid Arthritis 
RA is a chronic systemic inflammatory disease, primarily characterized by inflamed 
synovial tissue in multiple joints leading to localized destruction of cartilage and bone 
(Figure 1-1). It is a severe disabling disease that affects approximately 1% of the 
population on a worldwide basis (Feldmann, Brennan et al. 1996). The early diagnosis 
of RA is made problematic by heterogeneity in its clinical presentation and lack of 
sufficiently specific and sensitive laboratory tests. Conventional imaging strategies 
such as plain X-ray imaging are widely used to assess disease, and to measure 
progression and response to treatment (Guillemin, Billot et al. 2005). Because X-rays 
rely on relatively late features such as bone erosion and joint space narrowing, these 
may only show any significant changes after many months from disease onset (van 
der Heijde, van Leeuwen et al. 1995). Sensitive and specific methods of imaging are 
required for the detection of early inflammatory changes to the synovium in patients 
with arthritis and for monitoring treatment. Greater joint damage at baseline is 
Chapter 1 
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associated
 
with poorer physical function and less improvement after treatment 
underlying the importance
 
of early detection and intervention to slow the progression 
of joint destruction (Breedveld, Han et al. 2005). Magnetic resonance imaging (MRI) 
can directly visualize the bone and soft tissues in three dimensions and has the 
potential to measure inflammatory activity and joint destruction. Synovitis volume, 
bone marrow oedema and bone erosions are all potentially suitable for serial 
measurement (Hodgson, O'Connor et al. 2008), but none of these scoring systems is 
yet in routine clinical practice. Ultrasound and bone scintigraphy are other useful 
techniques for assessing RA. Ultrasound is useful for rapidly assessing multiple joints 
and is well established in the clinical assessment of synovitis and tenosynovitis; it 
may be combined with power Doppler ultrasound to provide further information on 
disease activity (Taylor, Steuer et al. 2004). Bone scintigraphy has been used for 
many years to detect inflammatory arthritis, but while it is a relatively sensitive 
technique it lacks specificity, has poor anatomical resolution and cannot accurately 
detect erosions (Weiss, Maxfield et al. 1965). Information on the character of the 
initial destructive events in RA is limited, since the affected structures are not directly 
accessible in early disease and because the above techniques do not offer insight into 
the cellular and molecular processes involved early in the cause of disease 
pathogenesis. 
Significant advances in understanding the underlying aetiology of RA have been 
made. These point to a predominant role for major histocompatibility complex (MHC) 
class II dependent immune activation. This association has been brought to the fore by 
powerful evidence for antibody reactivity to proteins modified by citrullination 
(Klareskog, Ronnelid et al. 2008). Epidemiological and genetic studies of RA in 
relation to anti-citrulline immunity have demonstrated significant differences in 
subsets of patients with and without the presence of antibodies to citrullinated protein 
antigens (ACPA). Antibodies to citrullinated proteins can be found in approximately 
60% of RA patients but only in 2% of the normal population making them highly 
specific for RA (Schellekens, Visser et al. 2000; Vincent, Nogueira et al. 2002; van 
Gaalen, Linn-Rasker et al. 2004). The occurrence of ACPA is closely linked to the 
HLA-DRB1 shared epitope alleles (Klareskog, Stolt et al. 2006). In addition to the 
previously established risk posed by smoking (Silman, Newman et al. 1996), there are 
further associations between those who are HLA-DRB1 positive and a close 
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segregation with those who are anti-cyclic citrullinated peptide antibody positive 
(Klareskog, Stolt et al. 2006). A recent study has demonstrated citrullinated -enolase 
as a potential disease specific autoantigen in RA, although it remains unclear as to 
how antibodies to a ubiquitously expressed enzyme such as -enolase may cause 
inflammation localised to the joints and other organs (Mahdi, Fisher et al. 2009). 
 
 
Figure 1-1 Progressive joint destruction in Rheumatoid Arthritis 
Rheumatoid arthritis is characterised by progressive joint destruction. Panel a) demonstrates severe 
synovitis around metacarpal-phalangeal joints (arrowed) leading to progressive joint irreversible joint 
deformity and loss of joint function. Panel b): Late stage changes in RA showing severe joint 
deformity. 
 
As our understanding of the molecular basis of RA improves, it has become possible 
to develop more sophisticated and sensitive techniques for imaging disease and 
detecting pathological change at an early stage. In particular, molecular imaging may 
also provide insight into disease mechanisms and elucidate the mode of action of 
therapeutic agents. In vivo imaging in the animal model is therefore of vital 
importance in developing these techniques helping to both understand the mechanism 
of action of novel therapies, as well as validating their use in ameliorating arthritis by 
developing reproducible objective measures of scoring disease activity and 
monitoring disease activity in vivo. 
a b
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1.1.1 RA: Chronic Inflammation of The Synovium 
Rheumatoid synovium is characterized by hyperplasia of the synovial lining layer and 
marked infiltration by lymphocytes, macrophages and plasma cells. Locally produced 
inflammatory mediators and the subsequent up regulation of adhesion molecules at 
sites of inflammation are pivotal to RA pathogenesis (Tak, Taylor et al. 1996). These 
are discussed in the following sections. 
1.1.1.1 Histopathological changes to synovial architecture in RA  
Normal synovium is a highly vascular tissue that protects the joint, and provides 
oxygen, and nutrients to the synovial tissue, and to the relatively avascular cartilage 
(FitzGerald and Bresnihan 1995). The normal synovium consists of an intimal lining, 
which is composed of macrophage- and fibroblast-like cells that are loosely 
associated without a definite underlying basement membrane, and a relatively 
acellular sublining, which merges with the joint capsule and contains loose connective 
tissue containing fibroblasts, macrophages, adipocytes, and vascular endothelial cells 
(EC) (Buch and Emery 2002). Synovial fibroblasts synthesise hyaluronic acid, the 
major component of the synovial fluid, and express vascular cell adhesion molecule 
(VCAM)-1, which distinguishes them from normal fibroblasts (FitzGerald and 
Bresnihan 1995). Synovial macrophages are phagocytic cells that help to clear debris 
from the joint space and act as sentinels for microbial encounters (Noss and Brenner 
2008). In RA, the synovium is altered to a thickened and invasively growing tissue 
several cell layers thick, which covers and erodes the adjacent cartilage, bone and 
tendon. Histologically, the inflamed synovium shows pronounced angiogenesis, 
cellular hyperplasia, and influx of inflammatory cells (Lee and Weinblatt 2001). This 
is demonstrated in Figure 1-2. 
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Figure 1-2 Comparison of normal and arthritic joint architecture in rheumatoid 
arthritis 
The normal synovium (A), contains a lining layer that consists of macrophages and fibroblast-like 
synoviocytes. In the inflamed arthritic joint (B), there is an increase in the number of cells in the 
synovial-lining layer, infiltration of the synovium with inflammatory cells, development of bone 
erosions, and the establishment of pannus (granulation) tissue that invades the joint irreversibly 
changing its architecture (Lipsky 2007). 
 
1.1.1.2 Cellular and soluble mediators of joint damage in RA 
There are both cellular and soluble mediators of joint damage: antigen activated 
CD4+ T cells stimulate monocytes, macrophages and synovial fibroblasts to produce 
key cytokines and matrix metalloproteinases through cell surface signalling as well as 
through the release of soluble mediators that include TNF (Choy and Panayi 2001). 
Cytokines are local protein mediators that are involved in almost all biological 
processes, including cell growth and activation, inflammation, immunity and 
differentiation. The synovial fluid is rich in many of cytokines, some of which also 
have immunoregulatory roles (Feldmann, Brennan et al. 1996; Choy and Panayi 
2001). The central role of TNF and its evolution to being a key mediator, that when 
blocked, could abrogate arthritis is discussed below. With further advances in 
understanding the immunopathology of RA and other autoimmune diseases have 
A
B
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come specific therapeutic targets that have in turn highlighted the effects of blocking 
particular cellular or molecular pathways. The role of B cells in RA pathology for 
example evolved in part by the clinical improvements seen in RA patients receiving 
B-cell depleting therapies such as rituximab, an anti-CD20 antibody, as discussed 
below. 
1.1.2 Targeted Therapeutic Approaches for the Treatment of RA 
A number of different agents that have broad ranging effects on the immune system 
are used to treat patients with RA. Conventional therapy includes the administration 
of anti-inflammatory drugs followed by disease modifying anti-rheumatic drugs 
(DMARDs). While traditionally these were used sequentially, evidence then 
supported their use in combination (O'Dell, Haire et al. 1996). However analysis of 
cytokine mRNA and protein in RA revealed that many proinflammatory cytokines 
such as TNF, interleukin (IL)-1, IL-6, IL-8 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) were present in all patients regardless of therapy 
(Feldmann, Brennan et al. 1996). It was initially demonstrated that blockade of TNF 
downregulated IL-1(Brennan, Chantry et al. 1989) and subsequently GM-CSF, IL-6, 
IL-8, half of the chemokines tested and many active molecules such as matrix 
metalloproteinases (Haworth, Brennan et al. 1991; Butler, Maini et al. 1995). From 
these observations evolved the first targeted drug that was shown to be successful for 
treating collagen induced arthritis (CIA) (Williams, Feldmann et al. 1992), providing 
the rationale for the clinical development of anti-TNF therapy (Maini, Breedveld et al. 
1998). TNF was therefore the first cytokine to be fully validated as a therapeutic 
target for RA. In 1993 this led to a clinical study of the therapeutic efficacy of a 
chimeric IgG1 monoclonal antibody (infliximab) in RA (Elliott, Maini et al. 1993) 
with a randomised double blind placebo controlled trial performed in in the following 
year (Elliott, Maini et al. 1994). The development of TNF inhibitors have 
revolutionised the management of RA, since they unequivocally reduce disease 
activity in the majority of patients treated (Weinblatt, Kremer et al. 1999; Lipsky, van 
der Heijde et al. 2000; Feldmann and Maini 2003; Weinblatt, Keystone et al. 2003; 
Keystone, Heijde et al. 2008; Keystone, Genovese et al. 2009; Smolen, Landewe et al. 
2009). Different approaches for engineering proteins to block TNF have been 
developed (Isaacs 2009). These include a chimeric IgG1 monoclonal antibody 
(infliximab), monoclonal antibodies (MoAb)with fully human amino acid sequences 
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produced by phage display (adalimumab) or from mice transgenic for the human 
immunoglobulin locus (golimumab), an engineered P75 TNFRII dimer with a fully 
human amino acid sequence linked to the Fc portion of human IgG1 (etanercept) 
(Moreland, Baumgartner et al. 1997; Moreland, Schiff et al. 1999; Moreland, McCabe 
et al. 2000); and a pegylated Fab’ fragment that lacks an Fc portion (certolizumab). 
These agents vary in their mechanisms of action, to block free and membrane bound 
TNF, induction of apoptosis, antibody and complement dependent cell lysis and 
effects on secretion of pro-inflammatory cytokines from TNF-producing cells. 
Despite the differences in structure of these agents, broadly similar favourable 
outcomes are reported. This underscores the tenant that TNF has a central role the 
network of molecular and cellular events in the pathogenesis of RA. (Tracey, 
Klareskog et al. 2008). 
Cytokines other than TNF have also been validated as therapeutic targets. These 
include IL-1 which is targeted by anakinra, a recombinant form of naturally occurring 
IL-1 receptor antagonist (IL-1ra) (Bresnihan, Alvaro-Gracia et al. 1998); however this 
has shown limited efficacy in RA even in combination with methotrexate (Cohen, 
Hurd et al. 2002). IL-6 has shown significant promise as a therapeutic target for the 
treatment of RA, and anti-IL-6 receptor antibody tocilizumab has been given approval 
for the treatment of moderate to severe RA in Europe (Maini, Taylor et al. 2006; 
Genovese, McKay et al. 2008; Smolen, Beaulieu et al. 2008). Another approach is to 
target cells producing the pro-inflammatory cytokines. Strong evidence for a critical 
role for B-cells in the immunopathogenesis of RA came from an open label study of 
Rituximab in combination with cyclophosphamide and corticosteroids (Edwards and 
Cambridge 2001). Rituximab is a genetically engineered chimeric anti-CD20 MoAb 
that is approved for the treatment of relapsed or refractory, low grade or follicular 
CD20+ B-cell non-Hodgkin’s lymphoma. CD20 is a B-cell surface antigen that is 
expressed only on pre-B and mature B cells. It is not present on stem cells and is lost 
before differentiation of B cells into plasma cells. Therefore rituximab causes a 
selective transient depletion of the CD20+ B-cell subpopulation. The clinical efficacy 
of rituximab was confirmed in a multicentre randomised double blind controlled study 
in patients with active RA. This showed that rituximab provided significant 
improvement in disease (Edwards, Szczepanski et al. 2004). Despite the ongoing 
success of rituximab, other observations have supported a central role for T-cells in 
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the pathogenesis of RA. These include the induction of an inflammatory arthritis by 
transfer of CD4+ T cells from patients with RA when they were transferred into 
severe combined immunodeficient mice (Mima, Saeki et al. 1995). Clinically, drug 
therapy designed to interrupt T-cell activation via a co-stimulation pathway has been 
shown to be effective in RA. Abatacept is a recombinant fusion protein that blocks the 
co-stimulatory signal mediated by the CD28-CD80/86 pathway which is required for 
T-cell activation (Buch, Vital et al. 2008). Other targeted approaches have been 
directed to the treatment of RA. These include blocking angiogenesis. Vascular 
endothelial growth factor (VEGF) blockade in mice has been shown to be highly 
effective (Miotla, Maciewicz et al. 2000; Sumariwalla, Cao et al. 2003) and this is 
discussed further in Section 1.2.3. 
1.2 The Vascular Endothelium: An Interface for the Interaction 
between Cytokines and Cell Surface Receptors 
The activated endothelium is central to the initial and ongoing recruitment of 
inflammatory cells to sites of inflammation and it has long been recognized that 
endothelial activation plays a pivotal role during inflammatory responses. The 
endothelial adhesion and transendothelial migration of leukocytes is a well regulated 
sequence of events that involves a multitude of adhesion molecules and chemokines. 
Primarily selectins, integrins and members of the immunoglobulin superfamily of 
adhesion receptors are involved in leukocyte ‘tethering’, ‘rolling’, activation and 
transmigration (Sections 1.2.1 and 1.2.2). Vascular permeability and damage also 
occur through other mechanisms at all stages of the arthritic process. EC secrete 
several vasodilatory mediators including nitric oxide, prostacyclin (PGI2), platelet 
activating factor, histamine and others (Szekanecz and Koch 2008). The vascular 
permeability changes occurring in RA are described in Section 1.2.4. The neoangenic 
process that both occurs as a result of these vascular changes and is ultimately the 
cause of abnormal vascularity in RA is described in Section 1.2.3. 
1.2.1 The Adhesion Cascade: A Complex Multistep Process 
Leukocyte rolling, adhesion and transmigration through the activated endothelium 
were all described as early as the 19
th
 century, when it was demonstrated that 
leucocytes extravasted through the lining of blood vessels in response to injury. The 
work of Julius Friedrich Cohnheim focused on the mechanisms involved in the 
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extravasation of leukocytes from the blood vessels in the inflamed mesentery of the 
frog. This work described time dependent alterations, namely dilatation of the arteries 
and veins, adhesion of colourless cells to the EC and their subsequent transmigration 
from capillaries and venules into the interstitial space (Cohnheim 1889). The 
physiological trafficking of lymphocytes through high endothelial venules of 
lymphoid organs was demonstrated in 1969 by Ford and Gowans (Ford and Gowans 
1969). It was subsequently demonstrated that leukocytes could physically adhere to 
lymph node high endothelial venules within frozen sections (Stamper and Woodruff 
1976). L-Selectin was then discovered as a leukocyte adhesion molecule mediating 
this interaction (Gallatin, Weissman et al. 1983). Following the primary culture of 
human umbilical vein EC (Jaffe, Nachman et al. 1973) work centered on the notion 
that EC are subject to different activation states influenced by proinflammatory 
cytokines that could render them more adhesive for leukocytes. This led to the 
identification of endothelial surface molecules responsible for this interaction 
including E-selectin (Bevilacqua, Pober et al. 1985). As adhesion molecules were 
progressively discovered that were involved in the leukocyte-EC interactions they 
were classified into families based on molecular structure and function (Bevilacqua, 
Butcher et al. 1991). Leukocyte extravasation was shown to be a step by step process 
of initial tethering, rolling along the endothelial surface (mediated largely by selectins 
and their ligands), arrest and firm adhesion (mediated by integrins and their ligands) 
and finally transmigration across the endothelium. This sequence is termed the 
adhesion cascade as shown in Figure 1-3. This is reviewed comprehensively in (Ley 
and Kansas 2004)). 
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Figure 1-3 Key steps in the adhesion cascade 
Important steps in leukocyte adhesion are: rolling, which is mediated by selectins, activation, which is 
mediated by chemokines, and arrest, which is mediated by integrins. Key molecules involved in each 
step are indicated in boxes. ESAM, endothelial cell-selective adhesion molecule; ICAM1, intercellular 
adhesion molecule 1; JAM, junctional adhesion molecule; LFA1, lymphocyte function-associated 
antigen 1 (also known as L2-integrin); MAC1, macrophage antigen 1; MAdCAM1, mucosal 
vascular addressin cell-adhesion molecule 1; PSGL1, P-selectin glycoprotein ligand 1; PECAM1, 
platelet/endothelial-cell adhesion molecule 1; PI3K, phosphoinositide 3-kinase; VCAM1, vascular 
cell-adhesion molecule 1; VLA4, very late antigen 4 (also known as 41-integrin) (Ley and Kansas 
2004). 
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1.2.2 E-Selectin: A Pivotal Endothelial Cell Adhesion Molecule for Leukocytes 
E-selectin is expressed on the luminal surface of vascular EC in response to 
inflammatory stimuli including TNF and IL-1 (Pober, Gimbrone et al. 1986; 
Wellicome, Thornhill et al. 1990). It acts as an adhesion molecule for the recruitment 
of circulating leukocytes into tissues during inflammatory responses (Springer 1990; 
Butcher 1991). As part of a complex multistep process, selectins promote the initial 
attachment (tethering) and subsequent moving (rolling) of leukocytes where they 
become activated as a result of locally produced chemokines (Springer 1994). 
The primary sequences of three independently studied cell surface glycoproteins 
found on endothelium, platelets and leukocytes were first published in 1989 
(Bevilacqua, Stengelin et al. 1989; Johnston, Cook et al. 1989; Lasky, Singer et al. 
1989; Siegelman, van de Rijn et al. 1989). The term selectin highlights the presence 
of the lectin domain and the selectivity and function of these molecules. The selectin 
is prefixed by the cell type on which it was originally identified: E-selectin 
(endothelium), P-Selectin (platelets) and L-Selectin (lymphocytes) (Bevilacqua, 
Butcher et al. 1991). 
L-selectin was first found as the murine lymph node homing receptor or MEL-14 
antigen, defined by the MEL 14 MoAb which blocked the binding of lymphocytes to 
lymph node high endothelial venules in lymph node tissue (Gallatin, Weissman et al. 
1983). Later, L-selectin was also found on neutrophil granulocytes and monocytes 
and was found to be generally involved in leukocyte entry in sites of inflammation. E-
selectin was also found by a MoAb approach during the search for cytokine inducible 
surface proteins on EC that would mediate the binding of EC (Bevilacqua, Pober et al. 
1987). P-selectin was originally found as a membrane protein in platelet storage 
granules that was of unknown function that was also later detected in EC (Hsu-Lin, 
Berman et al. 1984). 
The selectins were found to contain 3 common protein domains. The NH2 terminus of 
each selectin is formed by a 120-amino acid domain which has homology with the 
lectin domain of the C-type animal lectins (Drickamer 1988). This is followed by a 
35-40 amino acid repeated sequence similar that was first found in epidermal growth 
factor (EGF). The six cysteines in this element are located at equivalent positions to 
form ‘EGF repeats’. The single EGF element is followed by a varying number of 
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repetitive elements each about 60 amino acids long, resembling motifs found in 
complement regulatory proteins. All 3 selectins are anchored in the cell membrane by 
a single transmembrane region which is followed by a short cytoplasmic tail (Somers, 
Tang et al. 2000). A truncated recombinant form of E-selectin containing only the 
lectin domain and the EGF repeat has been crystallized, with the 3-dimensional 
structure determined (Graves, Crowther et al. 1994). 
The ligands of selectins are mainly proteins that are posttranslationally modified by 
specific oligosaccharides which define physiological function (Varki 1994). The 
primary bases of adhesion are relatively weak calcium dependent interactions between 
the lectin domain and glycan ligands on apposing cells (Somers, Tang et al. 2000). 
Selectins and their specific ligands are also known to mediate signal transduction, 
besides having a direct role in leukocyte capturing (Crockett-Torabi 1998). Selectin 
ligands are carbohydrate-containing molecules and a variety of glycosyltransferases 
that have a role in their biosynthesis have been identified. These contribute to the 
formation of the sialyl lewis x structure on P-selectin glycoprotein ligand-1 (PSGL-1). 
Although E-selectin can bind PSGL-1, it does not appear to be the main E-selectin 
ligand and other ligands remain poorly defined (Ley and Kansas 2004). The inducible 
acquisition of selectin ligands is a key component in mediating T-cell recruitment to 
extra-lymphoid sites. 
1.2.2.1 E-selectin expression during the inflammatory response 
E-selectin is transcriptionally induced on EC by cytokines such as IL-1, TNF and by 
bacterial lipopolysacharide. Early work demonstrated that surface expression of the 
protein on cultured human EC reached maximal levels 4-6 hours after stimulation and 
rapidly declined to basal levels after another 12-16 hours (Pober, Lapierre et al. 1987; 
Wellicome, Thornhill et al. 1990). Similar expression kinetics were also shown on 
mouse endothelioma cell lines, with maximal cell surface expression at 4 hours when 
stimulated with TNF (Weller, Isenmann et al. 1992; Hahne, Jager et al. 1993). 
Acute and chronic disease states, in various animal models and different tissue sites 
have demonstrated differing kinetics for E-selectin expression. The role of E-selectin 
in leukocyte accumulation in vivo has been studied extensively in the pig (Binns, 
Licence et al. 1992; Binns, Licence et al. 1996; Binns, Whyte et al. 1996), 
demonstrating that in pig skin there is constitutive expression of E-selectin (not seen 
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in the mouse as described below), as well as early upregulation of E-selectin levels. 
These earlier studies demonstrating the dependence of leukocytes on E-selectin for 
trafficking into inflamed tissue as well as the early recognition of their 
interdependence on other factors for localization and transmigration. 
By contrast, in the murine contact hypersensitivity model where luminal endothelial 
selectin expression was quantified via radiolabelled administration of MoAb, 
persistence of both E- and P-selectin upregulation has been demonstrated (Harari, 
McHale et al. 1999). In this model the kinetics of selectin expression demonstrated 
both an early phase of upregulation peaking at 4-6 hours as well as a later phase at 24-
48 hours. The early upregulation was distinguished by being dose dependent and 
postulated to be due to an ‘irritant’ response to the effect of administering oxazolone, 
with the later phase antigen specific and dependent on prior sensitization. 
1.2.2.2 E-selectin imaging in animal models of inflammatory disease 
The initial studies of labelled cell entry in vivo (Binns, Licence et al. 1992) and 
immunohistology were followed by labelling, anti-E-selectin MoAb with indium 111 
or technetium 99m. Intravenously injected 111In-labelled anti-E-selectin MoAb 
(1.2B6) was taken up into inflammatory sites within pig skin stimulated with IL-1, 
TNF or phytohemagglutinin (PHA), correlating with leukocyte accumulation and 
endothelial expression of E-selectin observable immunohistologically (Keelan, 
Harrison et al. 1994; Whyte, Haskard et al. 1994). This was further confirmed by 
showing that radiolabelled anti-E-selectin MoAb 1.2B6 whole molecule can be used 
to image localized endothelial activation in a porcine arthritis model induced by the 
intrarticular injection of PHA (Keelan, Licence et al. 1994). Because of the potential 
clinical complications with the use of a whole molecule MoAb due to non-specific 
Fc-mediated reactions, radiolabelled F(Ab)2 fragments were also shown to 
demonstrate the in vivo expression of E-selectin on synovial endothelium during the 
evolution of crystal induced arthritis in the porcine model, again using a radiolabelled 
antibody fragment (Chapman, Jamar et al. 1994). E-selectin expression on activated 
vascular endothelium has also been evaluated using MRI in an in vivo mouse model 
(Reynolds, Larkman et al. 2006). This study utilized the conjugation of ultra small 
superparamagnetic iron oxide nanoparticles as a contrast agent on an oxazolone 
induced contact hypersensitivity model and effectively depicted activated vascular 
endothelium in murine inflammation in vivo with MRI. A further example is the use 
Chapter 1 
30 
of NanoSPECT/CT imaging in the SCID mouse engrafted with human synovial 
tissue,using a radiolabelled anti-E-selectin antibody to give quantifiable 3D images of 
E-selectin targeted signal following stimulation with TNF (Garrood, Blades et al. 
2009) 
1.2.2.3 E-selectin expression in RA 
The endothelium in human RA synovium is known to express E-selectin (Corkill, 
Kirkham et al. 1991). Specific expression has been demonstrated in venules and 
capillaries in inflamed synovia of patients with RA but not by other cell types or by 
normal synovium (Koch, Burrows et al. 1991; Kriegsmann, Keyszer et al. 1995). The 
endothelial expression and serum levels of E-selectin and its downregulation have 
also been demonstrated in patients with RA treated with anti-TNF therapy (Paleolog, 
Hunt et al. 1996; Tak, Taylor et al. 1996). These clinical data highlighted the key 
importance of TNF in the inflammatory cascade, with its blockade down-regulating 
cytokine inducible adhesion molecules including E-selectin as well as VCAM-1 and 
being associated with a reduction in synovial infiltration. 
It has previously been shown that EC induced to express E-selectin by stimulation 
with cytokines (TNF and IL-1) peaked in their expression at 4-6 hours and that by 
24 hours the molecule was no longer detectable on the cell surface (Pober, Bevilacqua 
et al. 1986; Wellicome, Thornhill et al. 1990). This raises the possibility that a 
proportion of E-selectin may be shed from the EC surface. This was confirmed in a 
later study showing that EC in culture shed a small proportion of the total E-selectin 
that they synthesize into the culture medium (Newman, Beall et al. 1993). These 
investigators also showed that the soluble form of E-selectin is detectable in the serum 
of normal individuals, suggesting a constitutive production in the vasculature. This 
study also confirmed in small sample sizes elevated levels of soluble E-selectin in 
patients with septic shock. Deactivation of vascular endothelium by anti-TNF 
antibody in patients with RA has also been shown to decrease serum E-selectin levels, 
with the earliest detectable changes on days 1-3 after anti-TNF infusion. There was 
also a significant correlation between the decrease in serum levels of E-selectin and 
observable clinical benefit compared with those patients who failed to show a 
beneficial response to anti-TNF (Paleolog, Hunt et al. 1996) The possible in vivo 
role of soluble adhesion molecules remain unclear although immobilized VCAM-1 
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and E-selectin have been found to support the binding of human leukocytes and 
leukocyte cell lines (Lobb, Chi-Rosso et al. 1991; Lobb, Chi-Rosso et al. 1991; 
Wellicome, Kapahi et al. 1993). Soluble E-selectin is chemotactic for monocytes 
(Kumar, Hosaka et al. 2001) and neutrophils (Lo, Lee et al. 1991) and increases 2 
integrin mediated adhesion (Lo, Lee et al. 1991; Ruchaud-Sparagano, Drost et al. 
1998; Ruchaud-Sparagano, Walker et al. 2000). Soluble E-selectin and VCAM-1 have 
also been demonstrated to promote angiogenesis in rat cornea and induce chemotaxis 
of human EC (Koch, Halloran et al. 1995). The levels of circulating E-selectin have 
been measured prospectively in patients with early RA over a five year period 
demonstrating that soluble E-selectin levels could be correlated with other markers of 
inflammation as well as showing an association with the degree of joint damage 
(Kuuliala, Eberhardt et al. 2002). The circulating soluble E-selectin levels in this 
study, however, were almost within the normal range compared to healthy control 
subjects, with other studies confirming similar results (Carson, Beall et al. 1994; 
Blann, Herrick et al. 1995; Voskuyl, Martin et al. 1995; Veale, Maple et al. 1998). It 
is postulated that even levels within the normal range may have a role in chronic 
inflammation and have been shown to occur for example in patients with clinically 
relevant atherosclerosis (Frijns, Kappelle et al. 1997; Fassbender, Bertsch et al. 1999). 
1.2.3 Angiogenesis is Central to Promoting and Maintaining RA 
The development of the vascular system is one of earliest events that occur during 
embryogenesis. Two different processes contribute to the formation of blood vessels: 
vasculogenesis and angiogenesis. The former refers to the de novo formation of 
vessels from progenitor cells whereas the latter is due to the formation of capillaries 
from pre-existing vessels (Carmeliet 2000). There are a number of pathological 
conditions where neovessel formation is a key factor in disease pathogenesis. These 
include cancer, retinopathy and RA (Carmeliet 2003). In extensive histological studies 
Fassbender et al concluded that one of the earliest and most striking changes in the 
rheumatoid synovium occurred in the microvasculature. The development of pannus 
tissue was seen to occur in three stages: synovial lining hyperplasia, pannus formation 
accompanied by the in-growth of a new vascular network, and further consolidation 
of the pannus leading to a relatively avascular fibrotic tissue (Fassbender and 
Simmling-Annefeld 1983). It is therefore widely accepted that angiogenesis is central 
to both promoting and maintaining RA (Weber and De Bandt 2000). The increased 
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tissue mass, increased endothelial surface area and disrupted architecture of 
pathological new vessels are all associated with increased expression of cytokines 
such as TNF, transforming growth factor (TGF)- as well as angiogenic factors such 
as VEGF which are highly upregulated in the diseased synovium and peripheral blood 
of RA patients (Fava, Olsen et al. 1994; Koch, Harlow et al. 1994; Paleolog, Young et 
al. 1998; Ballara, Taylor et al. 2001). Other pro-angiogenic factors expressed in RA 
include fibroblast growth factors (FGF) and platelet derived growth factor (PDGF) 
(Sano, Forough et al. 1990; Remmers, Sano et al. 1991; Remmers, Sano et al. 1991; 
Sano, Engleka et al. 1993). 
VEGF is a growth factor that binds to heparin in the extracellular matrix and plays a 
central role in neovascularisation. Raised serum VEGF levels have been shown to be 
associated with destructive change in inflammatory arthritis with serum VEGF levels 
significantly higher in patients with early RA than in patients with self limiting 
arthritis. This implicates VEGF in the persistence of inflammatory arthritis and 
supports the hypothesis that expansion of synovial vasculature is important for the 
development of joint destruction in RA (Ballara, Taylor et al. 2001). Although it is 
generally accepted that angiogenesis plays a central role in the pathogenesis of RA, it 
is still debatable, whether the synovial vascular density is actually increased, 
decreased or unaltered at various stages of disease. Histological analysis of blood 
vessels in synovial membrane biopsy specimens revealed that tissue obtained from 
patients with early RA (disease duration
 
less than three years), who had clinical and 
histological evident
 
knee synovitis, were characterized by prominent vascular
 
proliferation and an increase in the number of blood vessels per area
 
(390 
vessels/mm
2
) as compared to postmortem control samples (270 vessels/mm
2
) 
(FitzGerald, Soden et al. 1991). Examination of the synovial
 
microvasculature in 
patients with chronic
 
RA (mean disease duration 15 years) demonstrated that synovial 
capillaries are distributed more deeply in the rheumatoid synovium. Further, these 
patients exhibited a diminished capillary density
 
within the synovium compared with 
normal controls, providing an anatomic explanation for chronic hypoxia in the 
rheumatoid synovium (Stevens, Blake et al. 1991). This observation further suggests
 
that either natural vessel regression takes place, or synovial tissue growth outpaces 
neovessel formation, (although treatments might have influenced the synovial vessel 
density in this study as described in a more recent study below). Nevertheless, these 
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findings suggests that the synovial microvasculature in RA is reorganised, leading to 
reduced vascular densities adjacent to the joint space and increased vascular densities 
in the deeper synovium (Walsh 1999). Other studies demonstrate that the rate of 
neovascularisation seems to be increased in RA as demonstrated by 
immunohistological assessment of the synovial microvessel density using the 
expression of vascular markers CD31 or von Willebrand factor (vWf) in the synovium 
of arthritic joints (Giatromanolaki, Sivridis et al. 2001; Paleolog 2002). The number 
of synovial blood vessels has been found to correlate with synovial cell hyperplasia, 
mononuclear cell infiltration and indices of joint tenderness (Rooney, Condell et al. 
1988). More recent evidence has also suggested that immature blood vessels are 
selectively depleted in response to anti-TNF therapy. Synovial arthroscopic biopsies 
were taken from RA, OA and normal control patients and analysed by double 
labelling of the endothelium and pericytes/smooth vessel mural cells to identify and 
quantify mature/immature blood vessels. In this study, a longitudinal analysis was 
also performed in 25 patients with active disease rebiopsied after TNF therapy. This 
demonstrated that the density of immature but not mature blood vessels were depleted 
by anti-TNF therapy (Izquierdo, Canete et al. 2009). Taken together these studies 
demonstrate that pathological neovascularisation occurs in RA but its phenotype may 
change over the time course of disease. 
Collagen induced arthritis (CIA) is a mouse model of RA that has been used 
extensively to assess neovascular changes and determine the effects of vascular 
targeted therapy (Peacock, Banquerigo et al. 1992; Oliver, Banquerigo et al. 1994; 
Oliver and Brahn 1996). The latter study demonstrated that CIA can be suppressed by 
the addition of an angiogenesis inhibitor (AGM-1470) in combination with 
cyclosporine. Treatment with a soluble VEGF receptor has also been demonstrated to 
reduce disease severity in murine collagen induced arthritis by decreasing both VEGF 
levels, and bone and cartilage destruction as assessed by histology. A study in CIA 
has demonstrated that treatment with a soluble form of the Flt-1 VEGF receptor type 
1 (sFlt-1) which was polyethylene glycol (PEG) linked significantly reduced both 
clinical score and paw swelling, compared with untreated or control treated animals. 
This study also demonstrated that the amount of VEGF increased as arthritis 
progressed and positively correlated with both clinical score and paw swelling 
(Miotla, Maciewicz et al. 2000). A further study has also demonstrated that adenoviral 
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delivery of Flt-1 abrogates disease activity in murine CIA. The effect of sFlt-1 
expression on signs of disease was paralleled by reduced joint destruction and 
decreased expression of the vascular marker vWf. This study concluded that the 
actions of sFlt-1 were likely to be mediated by reduced synovial neovascularization, 
supporting the concept that VEGF blockade may be an effective therapeutic adjunct 
for the treatment of RA. Clinically, the most widely used drug that directly targets the 
vasculature is bevacizumab – a humanised MoAb that recognises and blocks vascular 
endothelial growth factor A (VEGF-A) (Los, Roodhart et al. 2007). This drug is used 
for the treatment of advanced stage metastatic malignancy of the GI tract, lung and 
breast. A further PEGylated anti-VEGF compound, pegaptanib, is licensed for the 
treatment of age related macular degeneration. Trials of VEGF inhibitors for the 
treatment of rheumatoid arthritis have thus far not generated a drug which is in routine 
clinical practice.  
The epidermal growth factor (EGF) ligand/receptor family has also been postulated to 
play a role in RA pathogenesis (Shiozawa, Shiozawa et al. 1989; Kusada, Otsuka et 
al. 1993). The human epidermal growth factor receptor family (EGFR; also known as 
ErbB and human epidermal growth factor receptor, HER) belongs to the receptor 
tyrosine kinase (RTK) superfamily. The RTKs are well validated targets for cancer 
therapy but may also have broad therapeutic potential across a range of autoimmune 
and inflammatory conditions. The first approved RTK therapeutic Herceptin™ 
(trastuzumab, Genentech) is a MoAb that targets HER-2 and has been highly effective 
for the treatment of receptor positive breast cancer (Baselga, Tripathy et al. 1996). 
The EGFR includes four members (HER-1/ErbB1, HER-2/ErbB2, HER-3/ErbB3 and 
HER-4/ErbB4). The gene symbol, ErbB, is derived from the name of a viral oncogene 
to which these receptors are homologous: Erythroblastic Leukemia Viral Oncogene. 
Insufficient ErbB signalling in humans is associated with the development of 
neurodegenerative diseases, such as multiple sclerosis and Alzheimer’s disease. In 
mice, loss of signalling by any member of the ErbB family results in embryonic 
lethality with defects in organs including the lungs, skin, heart and brain. Excessive 
ErbB signalling is associated with the development of a wide variety of solid tumours. 
ErbB-1 and ErbB-2 are found in many human cancers and their excessive signalling 
may be critical factors in the development and malignancy of these tumours (Bublil 
and Yarden 2007). The EGFR are bound by a large family of ligands including EGF, 
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transforming growth factor- (TGF-), heparin-binding EGF like growth factor (HB-
EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), epigen (EPG), and 
neuregulins (NRG or heregulins) (Riese and Stern 1998). Ligand binding induces the 
formation of homo- or heterodimers between the receptors and, depending on the type 
of dimer formed, transphosphorylation of intracellular regions occurs and leads to the 
activation of numerous downstream signalling pathways. These include the many 
components of the mitogen activated protein kinase (MAPK) cascade, the 
phosphoinositide 3-kinase pathway and the phospholipase C pathway, resulting in cell 
proliferation, repair, survival and differentiation (Yarden and Sliwkowski 2001; 
Jorissen, Walker et al. 2003; Shepard, Brdlik et al. 2008; Huang, Brdlik et al. 2009). 
Mutations that lead to the dysregulation of the HER proteins and their ligands have 
been discovered in many different types of cancers and malignant proliferation 
(Mendelsohn and Baselga 2003; Hynes and Lane 2005). Most notable examples of 
relevance clinically include the finding that HER-2 is over expressed in a proportion 
of patients with breast cancer. This led to the development of the drug trastuzumab, a 
MoAb that targets the extracellular domain of HER-2. This is approved for the 
adjuvant treatment of HER-2-overexpressing, node-positive or node-negative breast 
cancer (Slamon, Leyland-Jones et al. 2001). In contrast, cetuximab (Erbitux™, 
Merck, Germany) is a MoAb that targets HER-1, and is used for metastatic colorectal 
cancer and head and neck malignancies. Several others targeting HER-1, HER-2 and 
HER-3 are currently in development (Johnston, Navaratnam et al. 2006). However, 
resistance to agents that target single HER can occur due to compensation by or up-
regulation of other HER family members (Huang, Brdlik et al. 2009). Furthermore, 
homodimerisation and heterodimerisation among members of the HER/ErbB family 
of receptors has been described, thus complicating therapies directed against a single 
HER receptor (Olayioye, Neve et al. 2000). 
A number of studies suggest that EGFR family signalling may have a role in the 
development of RA. For example, Hallbeck et al have demonstrated that one of the 
primary ligands for the EGFR, TGF- has increased mRNA and levels of protein 
expression in RA synovial tissue. Interestingly, in this study, TGF- was present in 
knee synovial fluid samples of RA patients and levels were significantly higher 
compared to post-traumatic control samples (Hallbeck, Walz et al. 2005). High levels 
of another EGFR ligand, EGF, in synovial fluid samples of RA patients have also 
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been demonstrated (Kusada, Otsuka et al. 1993). Expression of HER-2/ErbB2 in the 
synovium of RA patients has further been described (Satoh, Kikuchi et al. 2001; 
Hallbeck, Walz et al. 2005). However, another study reported the expression of AR, 
but not of EGF, ERG, EPG, BTC, NRG1 or HB-EGF at the mRNA level in RA when 
compared to OA tissue, but the reason for the discrepancy between this report and 
other studies is unclear (Yamane, Ishida et al. 2008). The functional significance of 
the EGF/EGFR pathway in RA is also at present unknown. Activation of EGFR 
signalling may contribute to hyperplasia of the arthritic synovium, which is a major 
pathological feature of RA that precedes clinical presentation and prevails throughout 
the disease (Mor, Abramson et al. 2005). In support of this, trastuzumab, which binds 
the HER-2/ErbB2 receptor, and the tyrosine kinase inhibitors genistein and imatinib, 
have been shown to inhibit RA synovial cell growth (Satoh, Kikuchi et al. 2001; 
Kameda, Ishigami et al. 2006). EGF, when combined with pro-inflammatory 
mediators including TNF and IL-1, increased expression by RA fibroblasts of matrix 
metalloproteinases such as MMP-1, MMP-3 and MMP-13, as well as release of IL-6 
(Huber, Kunzler et al. 2008). Since EGF and these cytokines are all expressed in RA 
synovium, these findings suggest that EGF may synergise with other cytokines in RA. 
Moreover, these responses were abrogated by a small molecule inhibitor of HER-
2/ErbB2. A recent study also reported that EGF stimulated ERK1/2 MAPK and NFB 
pathways to stimulate cycoloxygenase-2 and prostaglandin E2 (Nah, Won et al. 2009). 
EGFR over-expression may also contribute to RA progression by increasing 
angiogenesis through the production of pro-angiogenic factors such as vascular 
endothelial growth factor, IL-8 and basic fibroblast growth factor (Schreiber, Winkler 
et al. 1986; Goldman, Kim et al. 1993; Kumar and Yarmand-Bagheri 2001; 
Ravindranath, Wion et al. 2001). Angiogenesis is significantly increased in RA and 
results in the infiltration of inflammatory cells into the synovium, thus accelerating 
disease (Paleolog 2009). A treatment modality that inhibits both synovial hyperplasia 
and angiogenesis would be an attractive option in the immunotherapy of RA. 
The highly unique compound RB200 is a bispecific ligand trap, composed of full 
length extracellular domains of HER-1 and HER-3 EGF receptor. Due to its pan-HER 
specificity, RB200 inhibits responses mediated by HER-1, HER-2 and HER-3 in vitro 
and in vivo. 
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The potential of utilising an antagonist (RB200) that targets all members of the EGF 
receptor family is discussed further in section 5.1.2. 
1.2.4 Increased Vessel Permeability in RA: Cause or Consequence? 
Multiple factors influence the leakage of substances from blood vessels. The major 
physiological mechanisms include the luminal surface area, permeability of the vessel 
wall and concentration of driving forces (hydrostatic and osmotic gradients) as well as 
the blood flow across the endothelium (Michel and Curry 1999; Bates, Heald et al. 
2001). Early pathological studies identified vasodilation and increased vessel 
permeability from biopsies of arthritic joints (Kulka, Bocking et al. 1955; Schumacher 
and Kitridou 1972). As the vascular permeability increases this leads to plasma 
extravasation, oedema formation and swelling of the joint. This is mediated by a 
number of pro-inflammatory agents with evidence for an early neurogenic 
component. The contribution of sensory efferents and sympathetic afferents to joint 
injury and thus a possible neurogenic component for joint swelling has been 
investigated by examining the effect of nerve transection which was shown to reduce 
hyperalgesia, swelling and joint destruction in a rat arthritis model (Levine, Dardick et 
al. 1986). Earlier work demonstrated a role for substance P which belongs to the 
tachykinin neuropeptide family (Walsh, Mapp et al. 1992). Substance P is a potent 
mediator of increased microvascular permeability in species that include the mouse, 
through its action on postcapillary EC. Substance P induced oedema formation has 
been investigated by the use of knockout mice (Cao, Gerard et al. 1999). This model 
was also used to show that substance P also has a potent effect on cellular 
accumulation including neutrophil accumulation (Cao, Pinter et al. 2000). Other 
models have been used to dissect the role of substance P has in both acute and chronic 
inflammation of the footpad in NK receptor knockout mice. A study by Kidd et al 
examined the effect of intense inflammation produced by the intraplantar 
administration of Mycobacterium Tuberculosis (Kidd, Inglis et al. 2003). This 
demonstrated changes in mechanical hyperalgesia, soft tissue swelling and 
histological scores were significantly reduced in animals with selective NK-1 receptor 
deletion but that these responses were not seen at early time points. A further study by 
Keeble and collegues (Keeble, Blades et al. 2005) has demonstrated increased plasma 
extravasation from 18-72 hours in an inflammatory model of arthritis generated by the 
intra-articular administration of complete Freund’s adjuvant (CFA) into the murine 
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knee. It is also likely that many of these substances have peripheral actions that are 
mediated by pathways centred on the regulation endothelial nitric oxide synthetase 
(eNOS). These pathways have been further elucidated since the pioneering 
experiments of Furchgott and Zawadzki into the biological actions of nitric oxide for 
which they were awarded the Nobel prize in 1998 (Furchgott and Zawadzki 1980). 
The direct effect of substance P on nitric oxide release was investigated in rheumatoid 
synoviocytes and also in WT and NK1 knockout mice again following injection of 
Mycobacterium Tuberculosis into the mouse paw. This demonstrated that substance P 
induces NO in both rheumatoid synoviocytes and experimental models of 
inflammation with comparable effects to both TNF and IL-1β (O'Shaughnessy, 
Vetsika et al. 2006).  
Pathologic neoangiogenic vessels also have increased leakiness compared with 
normal vessels. This effect is well documented in neoangiogenic tumour tissue and is 
thought to also occur in RA due to increased blood perfusion and vascular 
permeability as part of both the ongoing inflammatory process and disordered 
architecture of new vessels. This may lead to as much as a forty fold increase in 
macroglobulin permeability in the inflamed joint (Levick 1981; Andersson, Johansson 
et al. 1998). Other evidence also suggests that local vascular permeability may be an 
early immune complex driven, vasoactive amine dependent process. The mechanisms 
underlying organ specific autoimmune disease are incompletely understood and it 
remains unclear how or whether autoantibodies can cause inflammation preferentially 
in certain tissues. It is recognised that there is a loss of immune tolerance relating to 
endogenous and exogenous antigens. Local vascular permeability may play an early 
significant role in this process (Pitzalis and Garrood 2006). Binstadt and colleagues 
have demonstrated by using intravital imaging that following the transfer of 
arthritogenic antibodies from K/BxN mice macromolecular vasopermeability is 
localised to sites that would be expected to develop arthritis in normal mice. (Mice 
expressing the KRN T cell receptor transgene and the MHC class II molecule A(g7) 
(K/BxN mice) develop severe inflammatory arthritis, and serum from these mice 
causes similar arthritis in a wide range of mouse strains, owing to pathogenic 
autoantibodies to glucose-6-phosphate isomerase (GPI)). This study also suggested an 
important function for histamine and serotonin in immune mediated vascular leak. 
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These vasoactive amines are well known to cause the formation of large gaps between 
EC, particularly in post capillary venules (Binstadt, Patel et al. 2006). 
A number of approaches have been employed to make use of changes in vascular 
permeability by altering the pharmacokinetics of systemically administered 
compounds in order to improve their therapeutic index. One possibility is the direct 
conjugation of a drug to another larger molecule. An example of this is conjugation to 
polyethelene glycol. This approach has been successfully deployed for a number of 
drugs in routine clinical use such as the PEGylated forms of interferon- and 
doxorubicin for the treatment of hepatitis C and breast cancer respectively (Harris and 
Chess 2003). In RA this approach has demonstrated improved localisation to sites of 
inflammation: A recent study has demonstrated increased levels of fluorescence in 
inflamed paws with a fluorescently labelled PEGylated anti-TNF agent compared to 
non-PEGylated TNF inhibitors (Palframan, Airey et al. 2009). It was postulated that 
this differential uptake may be due in part to the macromolecular structure of the 
PEGylated agent leading to greater diffusion into inflamed hyperpermeable tissue. 
Thus far however, it is not clear whether this confers any overall improved clinical 
efficacy compared to other ant-TNF agents (Kavanaugh, Smolen et al. 2009; Smolen, 
Landewe et al. 2009). Albumin-based drug delivery has also been investigated as a 
novel therapeutic approach for methotrexate use in RA. Large amounts of 
methotrexate are eliminated by the kidneys within a short period resulting in a short 
plasma half life and low drug concentration in the target tissue. Initial investigations 
in tumours have demonstrated that methotrexate albumin conjugates show superior 
accumulation in tumour bearing rat models (Stehle, Wunder et al. 1997). 
Methotrexate has been conjugated to human albumin (MTX-HSA) thereby taking 
advantage of increased extravasation, uptake and metabolism of albumin in inflamed 
synovial tissue. This method has demonstrated significantly increased levels of the 
conjugate in tissue (Wunder, Muller-Ladner et al. 2003), and in a further study the 
effectiveness of MTX-HSA in CIA was shown to be superior to MTX alone and that 
this effect in part was due to the local accumulation of the conjugate in inflamed 
tissue. 
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1.3 In Vivo Molecular Imaging Approaches in Arthritis 
In vivo imaging of specific cells or molecules using non invasive methods helps to 
provide visualisation and quantification of specific molecular changes over time, 
shedding light on local and systemic mechanisms involved in acute and chronic 
inflammation, such as those described in preceding sections. It may also provide real 
time monitoring of cellular and molecular events involved in disease pathogenesis as 
well as provide specific quantification of the effect of novel therapies. Various 
imaging modalities are available such as CT, ultrasound, MRI and nuclear imaging 
methods such as single photon emission computed tomography (SPECT) and positron 
emission tomography (PET). These methods differ with respect to spatial resolution, 
ability to produce three dimensional images, depth limit, and sensitivity, the 
possibility of quantification and availability of imaging agents that can be coupled to 
specific molecular perturbations. Techniques that are in routine clinical use such 
radiography, CT and Ultrasound can provide high resolution images at the anatomical 
level whereas anatomical detail provided by molecular imaging techniques may be 
lacking. It can therefore be helpful to combine or co-register images to produce both 
functional imaging with anatomical localisation. (Weissleder and Mahmood 2001; 
Herschman 2003; Massoud and Gambhir 2003; Wunder, Straub et al. 2005). 
Conventional imaging techniques such as radiography can detect contrast but large 
amounts are required at the target site. The adverse effects of ionising radiation can 
then become restrictive, especially if imaging at multiple time points is required. 
Ultrasound has successfully been deployed to give information about blood flow 
using colour duplex sonography (Taylor, Steuer et al. 2004) but is a dynamic study 
that may be difficult to quantify at different time points. Targeted contrast agents for 
MR imaging have been developed. This includes using an iron oxide particle attached 
to E-selectin (Reynolds, Larkman et al. 2006). This approach can be advantageous as 
both anatomical and molecular information can be acquired simultaneously. Nuclear 
imaging methods are highly sensitive and can provide detailed quantitative 
information, but have greater limits regarding spatial resolution. Enhanced glucose 
metabolism has been successfully imaged by 18F-fluorodeoxyglucose PET imaging 
(Herschman 2003; Roivainen, Parkkola et al. 2003; Beckers, Ribbens et al. 2004; 
Beckers, Jeukens et al. 2006). Clinically, conventional imaging techniques such as 
technetium scanning act as surrogate measures of local blood flow and increased 
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permeability. The oldest radiopharmaceutical proposed for imaging inflammation is 
Gallium-67 citrate and this remains an established technique for imaging pulmonary 
and musculoskeletal inflammation especially in sarcoidosis. (Although interestingly 
this particular agent appears to bind directly to transferrin which then binds to 
activated leucocytes) (Oyen, Boerman et al. 1996). Other examples of so called non 
targeted approaches include radioloabelled liposomes, dextran, nanocolloid and HIg 
((Dams, Oyen et al. 2000; Adams, Al Attia et al. 2001; Arzu Gencoglu, Aras et al. 
2003; Kaya, Tuna et al. 2004). Other specific molecular targeting techniques have 
been developed but can be affected by the non-specific localization of agents to 
inflamed tissues. An example includes 
123
I-labelled IL-1ra that did not show increased 
localisation compared to radiolabelled albumin (Barrera, van der Laken et al. 2000). It 
would appear in this study that, at the doses of labelled IL-1ra used, the most 
substantial effect was for local changes to reflect non-specific trafficking of the 
molecule due to local permeability changes in areas of inflammation. The therapeutic 
efficacy of IL-1ra in RA requires repeated administration of the cytokine at 1000-fold 
the doses used in the above imaging study, so it may be that higher doses were 
required to generate a specific component to the imaging compared to radiolabelled 
albumin. However, increasing the dose of imaging agent to that level would lead to 
unacceptable levels of radiation. The scintographic detection of radiolabelled TNF 
MoAb has also been investigated. This demonstrated a specific component to 99mTc 
labelled anti-TNF MoAb since uptake radiolabelled signal could be abrogated by 25% 
when excess anti-TNF was coadministered (Barrera, Oyen et al. 2003). This suggests 
that 75% of the signal is non-specific accumulation of labelled tracer at sites of 
inflammation. Interestingly, in RA, other workers have demonstrated that 99mTc-
anti-CD3 scintigraphy can be used to differentiate between autoimmune rheumatic 
diseases and strongly correlates with clinical findings for patients with RA (Lopes, de 
Azevedo et al.). The therapeutic potential of anti-CD3 MoAb has been demonstrated 
in collagen induced arthritis, as discussed in Section 1.4.1. E-selectin has also been 
demonstrated to be an excellent target for specific targeting of activated endothelium 
and this is discussed in the following section. Having a molecular imaging strategy 
and a novel therapy directed against that imaging target may be an effective away of 
monitoring the effect of therapy. 
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1.3.1 E-Selectin: An Excellent Target for Molecular Imaging in RA 
Scintigraphy utilizing a 
99m
Tc-anti-E-selectin-Fab has been used to successfully image 
synovitis in patients with RA, in this case demonstrating improved specificity 
compared to a conventional tracer for bone and joint 
99m
Tc-oxidronate (Tc-HDP), 
with particular specificity for targeting active joint inflammation (Jamar, Houssiau et 
al. 2002). Tc-HDP displays abnormal uptake over both currently inflamed and 
chronically damaged joints and is very sensitive for the detection of joint and 
subchondral bone abnormalities (Desaulniers, Fuks et al. 1974; Helfgott, Rosenthall et 
al. 1982), but it cannot distinguish accurately between actively and chronically 
inflamed joints (Fogelman 1980). The absence of signal uptake in normal joints by E-
selectin targeted imaging described above allows for markedly improved detection of 
active joint disease in RA as shown in Figure 1-4. The MoAb described in this study 
is of murine origin, which raises the possibility of host immunogenicity. However the 
small amounts of MoAb required for imaging and also the use of the Fab fragment 
devoid of Fc portions, which are thought to be responsible for immunisation may 
reduce the likelihood of a human anti mouse antibody (HAMA) response. In this 
study patients were not tested for a HAMA response, but some were imaged again 
with 
99m
Tc-anti-E-selectin-Fab 2-4 months later with no detectable change in the 
biodistribution of labelled antibody. In a previous study of fourteen patients with RA 
that received 
111
In-labeled F(ab’)2 fragment of E-selectin HAMA responses were 
measured by ELISA comparing blood samples taken pre and post (14 days) 
immunisation. No HAMA were detectable following injection.  
The endothelial expression and serum levels of E-selectin and its downregulation 
have also been demonstrated in patients with RA treated with anti-TNF therapy 
(Paleolog, Hunt et al. 1996; Tak, Taylor et al. 1996). This clinical data highlighted the 
key importance of TNF in the inflammatory cascade, and that its blockade down-
regulates cytokine inducible adhesion molecules including E-selectin (as well as 
VCAM-1) and is associated with a reduction in synovial infiltration. Hence E-selectin 
may be a very effective way of monitoring specific responses to TNF blockade in RA. 
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Figure 1-4 Comparison of 
99m
Tc-1.2B6-Fab and 
99m
Tc-HDP radiolabelled imaging 
in RA 
Images obtained 4hrs after injection of Tc-1.2B6 Fab (a,b) and Tc-HDP (c,d) in two patients with RA. 
Demonstrating focal uptake in inflamed joints and less bone and subchondral uptake for the MoAb 
compared to conventional Tc –HDP scanning (Jamar, Houssiau et al. 2002). 
 
1.3.2 In Vivo Fluorescence Imaging And Optical Imaging 
In vivo molecular optical imaging has significant potential to delineate and measure at 
the macroscopic level in vivo biologic processes that are occurring at the cellular and 
molecular level (Biswal, Resnick et al. 2007). Optical imaging has already been 
developed for in vitro and ex vivo applications in molecular and cellular biology (e.g. 
fluorescence confocal microscopy), but is still at an early stage of development as a 
whole animal in vivo imaging technique, particularly in the context of arthritis. Both 
sensitivity and spatial resolution remain incompletely defined (Weissleder and Pittet 
2008). The future however, holds considerable promise for non invasive visualisation 
of specific molecular targets which can be synergised with other imaging modalities 
such CT or MRI. 
1.3.2.1 Principles of fluorescent imaging  
Fluorescence is the excitation of a molecule (fluorophore) by light to a higher energy 
state, and its subsequent decay, resulting in emission of light at a higher wavelength. 
The difference between the emission and excitation wavelengths is termed the Stokes 
Shift, after Sir George Stokes who first described fluorescence in 1852. Some small 
a)
b)
c)
d)
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biological molecules (e.g. Nicotinamide adenine dinucleotide (NADH) and 
tryptophan) and proteins (e.g. phycoerythrin or green fluorescent protein (GFP)) are 
naturally fluorescent (intrinsic fluorophores), whereas extrinsic fluorophores are 
derived from many common dye families, such as xanthenes, cyanine and coumarin 
derivatives. Extrinsic fluorophores may be attached to proteins of interest by chemical 
modification of specific functional groups such as amino, carboxyl or thiol groups.  
Fluorescence is visualised by excitation at an appropriate wavelength and capture of 
the emitted photons usually by a charge coupled detector (CCD). Advances in CCD 
design have enabled accurate detection of low levels of light. CCDs are constructed of 
thin silicon crystal sheets that operate by converting light photons into a tiny charge 
that can be measured and converted into a digital signal. Older CCD cameras had 
problems with noise from thermal energy turning into electrical signal (Spibey, 
Jackson et al. 2001). Thermal energy is dramatically reduced if the chip is adequately 
cooled. Early fluorescence imaging in animals was invasive, with intravital 
microscopy being the commonest tool. In contrast, fluorescence reflectance imaging 
allows non invasive in vivo real time images of the whole animal to be taken. 
However, images from a planar CCD are two dimensional and therefore lack tissue 
depth information. The high degree of absorption and scattering of light by biological 
samples limits the penetration of both the excitation and resulting emission signal 
(Mahmood and Weissleder 2003). Studies have suggested that fluorescent signals 
may be reduced by up to ten-fold per cm of depth, although this will vary with tissue 
type, wavelength and dye brightness (Contag, Contag et al. 1995). Accurate image 
acquisition may also be improved by either combining multiple images from different 
CCDs or by rotating a single CCD (Chen, Tung et al. 2002) in a tomographic manner 
allowing regions of interest to be visualised in a 3-dimensional plane. The use of 
tomography and early photon detection may also be a way of increasing signal 
specificity (Ntziachristos, Ripoll et al. 2005; Niedre, de Kleine et al. 2008). 
In addition to the absorption and scattering of light (Mahmood and Weissleder 2003), 
biological samples autofluoresce at the wavelengths used for traditional extrinsic dye 
families (300-500 nm). Newer dyes better suited for in vivo studies fluoresce at higher 
wavelengths, close to the infra-red range (700-900 nm) as demonstrated in Figure 1-5. 
Examples include members of the Cyanine series of dyes from GE Healthcare and 
some of the Alexa Fluor series of dyes from Invitrogen. The intrinsically fluorescent 
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protein, GFP has a peak emission wavelength of 509nm and is therefore subject to 
significant autofluorescence from surrounding tissue if used for in vivo fluorescent 
imaging. However, several mutants of the monomeric red fluorescent protein that 
fluoresce at wavelengths above 600 nm have been produced (Tsien 2009). These have 
been used in a study by Winnard PT et al., where cancer cells labelled with the 
Tomato fluorescent protein was more readily detected compared with the same cells 
labelled with GFP (Winnard, Kluth et al. 2006). Advances in CCD technology and 
use of near infrared fluophores (NIRFs) will therefore allow for better image 
resolution. This has the potential to provide non-invasive imaging of molecular 
targets, and physiological process in vivo. In vivo fluorescence imaging also has 
several important advantages over other imaging techniques; there is no exposure to 
harmful radiation, it is relatively cheap, and images can be acquired rapidly (Massoud 
and Gambhir 2003). The following Table 1-2 is a summary of different molecular 
reporter technologies. 
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Figure 1-5 Absorption of light versus wavelength: tissue autofluorescence 
Figure demonstrates the absorption spectra of water, deoxygenated and oxygenated haemoglobin as 
well as the emission spectral wavelength of some commonly used fluorescent dyes adapted from 
(Mahmood and Weissleder 2003). (GFP –green fluorescent protein, FITC- fluorescein isothiocyanate, 
Cy5.5 cyanine 5.5) 
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Table 1-1 Summary of fluorescence molecular reporter technologies 
Technique Description Advantages Disadvantages 
Molecular 
Techniques 
Non-specific dye 
tracking 
Significant signal increase 
at sites of inflammation 
Non-specific tracking not 
reflecting underlying molecular 
pathway 
Antibody based 
targets 
Multitude of potential 
antibody targets 
No signal amplification 
Non-specific antibody tracking 
Activatable probes Continuous signal 
amplification 
Reduced or no fluorescence 
if not cleaved 
Possible probe activation in non 
target areas, less spatial 
resolution 
Quantum dots 
(inorganic 
nanoparticle based 
probes 
Photostable, intense 
luminosity, narrow 
emission/excitation 
wavelengths reduces 
background light scattering 
Larger than traditional 
fluorophores 
Potential for long term toxicity 
Transgenic 
Fluorescent 
protein 
expression 
Fluorescence 
reporter proteins e.g. 
GFP 
 
Direct visualisation of gene 
expression 
Limited/no likelihood of use in 
humans Lower wavelength 
proteins most frequently used 
therefore increased tissue 
autofluorescence although higher 
wavelengths becoming available 
Bioluminescence 
 
Ability to report on gene 
expression for lifetime of 
animal 
Highly sensitive imaging 
equipment and long exposure 
times required for signal 
quantification 
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1.3.2.2 Potential molecular approaches for in vivo fluorescence imaging 
Optical imaging of small animal cancer models has been the focus of a significant 
proportion of optical imaging investigations (Adams, Ke et al. 2007; Kovar, Simpson 
et al. 2007). A wide variety of targeted optical probes have been described in the 
literature. Targets have included cell surface receptors, metabolic pathways, hormone 
receptors, apoptotic markers and enzymatic activities (Kelloff, Krohn et al. 2005). 
The following section highlights some instructive examples of how imaging in this 
field has evolved and how these are likely to inform the use of fluorescent imaging in 
other diseases, including RA and OA. A summary of potential targets for optical 
imaging is included in Table 1-2 
1.3.2.2.1 Targeted approaches for dye deposition 
Antibodies directed against cell surface molecules which are over-expressed in cancer 
cells can be tagged by fluorophores. This targets the fluorescence to the diseased 
tissue. For example, specific antibody targeted resolution of tumours raised in a 
mouse model was achieved using Cy5.5 labelled tumour targeting antibodies (Ballou, 
Fisher et al. 1995). In a similar way tumour growth and neoplastic progression have 
been quantified using a label attached to epidermal growth factor (Kovar, Johnson et 
al. 2006). Other antibodies that have been used to target fluorescent signals include 
those against growth factor receptors (Koyama, Hama et al. 2007; Rosenthal, 
Kulbersh et al. 2007; Sampath, Kwon et al. 2007; Xu, Baidoo et al. 2007; Gleysteen, 
Newman et al. 2008; Withrow, Newman et al. 2008), cancer embryonic antigen 
(Fidarova, El-Emir et al. 2008; Gleysteen, Newman et al. 2008; Kaushal, McElroy et 
al. 2008; Lisy, Goermar et al. 2008; Newman, Gleysteen et al. 2008; McElroy, 
Hayashi et al. 2009) and cell surface receptors (Newman, Gleysteen et al. 2008; 
McElroy, Hayashi et al. 2009; Zou, Xu et al. 2009). 
To minimise background signal, viable cancer cells have been imaged in vivo by a 
combinatorial approach of tagging antibodies with pH-activatable probes. These 
probes are activated after cellular internalisation by sensing the pH change in the 
lysosome (pH 5-6, compared to 7.4 of the cytoplasm). This was used in conjuction 
with the MoAb trastuzumab, which targets the human epidermal growth factor 
receptor type 2. Upon internalisation via the endosomal-lysosomal degradation 
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pathway, the probe is activated in the acidic environment yielding increased tumour 
specific/background signal (Urano, Asanuma et al. 2009). 
1.3.2.2.2 Protease activity probes 
The detection of proteolytic enzyme activity by compounds that have come to be 
called activity based probes (ABPs) has become an expanding avenue of tumour 
detection, particularly of those that are metastasizing. Activity based probes consist of 
dye and a quencher attached to opposite ends of a peptide linker. When the peptide 
sequence is cleaved by the targeted protease the fluorophore is separated from its 
quencher thereby increasing the fluorescent signal. This also allows the possibility of 
signal amplification when the probe is continuously cleaved as shown in  
Figure 1-6. These compounds broadly target two families of protease activity. These 
are cathepsin activity (Joyce, Baruch et al. 2004; Figueiredo, Alencar et al. 2006; 
Blum, von Degenfeld et al. 2007; Melancon, Wang et al. 2007; Gounaris, Tung et al. 
2008; Blum, Weimer et al. 2009; Sheth, Upadhyay et al. 2009) and the matrix 
metalloproteinase activity (Scherer, VanSaun et al. 2008). Apart from cancer, these 
ABPs have also been used to look at proteolytic activity in myocardial infarction 
(Chen, Tung et al. 2005) and atherosclerosis (Chen, Tung et al. 2002; Deguchi, 
Aikawa et al. 2006). 
 
 
 
Figure 1-6 Principle of activity based probe showing quenched unquenched state 
Activity based probe in quenched (A) and unquenched (B) state. Following cleavage of the target 
peptide sequence, fluorescence is increased. Fluorescence may be targeted to the protease using 
chemistry directed against the active site. F-fluorophore, Q-quencher. 
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One problem of this technique is that following protease activity diffusion of the 
cleaved ABP from the protease will occur. A method to keep the signal in close 
vicinity is to utilise polycationic (negatively charged) sequences that are taken up by 
cells. These have been termed cell penetrating peptides. In the absence of proteases 
their association with the cell surface is prevented by a polyanionic (positively 
charged) sequence that binds to the cationic sequence. The polyanionic sequence also 
contains a quencher which prevents fluorescence. The two sequences are linked by a 
peptide with a specific protease cleavage site. Upon cleavage by tissue proteases, the 
two strands separate, causing release of the fluorescent probe (now unquenched) and 
uptake by the cell (Jiang, Olson et al. 2004).  
1.3.2.2.3 Bioluminescence  
Bioluminescence is the conversion of chemical energy to light in living organisms. 
The luciferase enzymatic system is the most commonly found biological process to 
achieve this conversion. The enzymes in this pathway convert the luciferin substrate 
in the presence of several co-factors and adenosine triphosphate to generate 
oxyluciferin and light (Wilson and Hastings 1998). Bioluminescence has been most 
widely used in reporter gene assays, where the promoters of genes under study have 
been linked to the luciferase gene, and the resultant light is a direct measure of 
promoter activity.  
The luciferase enzyme needs to be transfected into cells, limiting its use to animal 
models or transgenic animals. Its expression however, can be tightly controlled when 
linked to the appropriate promoter. The most commonly used luciferase enzyme 
system used comes from the firefly. The emission maximum of the firefly system is at 
578 nm at 25
o
C in vitro, but shifts to 612 nm at 37
o
C (Zhao, Doyle et al. 2005), which 
may be troublesome for use in vivo due to the high levels of tissue absorption. 
Mutation of another luciferase from Luciola cruciata has allowed a shift in the 
emission maximum from 560nm to 613 nm and 605 nm, allowing a greater diversity 
of colours (Nakatsu, Ichiyama et al. 2006). This raises the possibility of obtaining 
further mutants that operate in the NIR spectrum. The luciferin substrate also needs to 
be delivered to where the enzyme is expressed, which may restrict the visualisation of 
certain organs. Use of different substrates with different pharmacokinetic profiles will 
also yield different dynamics of light production (Bhaumik and Gambhir 2002).  
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1.3.3 Fluorescent Imaging in Arthritis 
Rheumatoid synovium is characterized by hyperplasia of the synovial lining layer and 
marked infiltration by lymphocytes, macrophages and plasma cells. Locally produced 
inflammatory mediators and the subsequent up-regulation of adhesion molecules at 
sites of inflammation are pivotal to RA pathogenesis (Tak, Taylor et al. 1996). 
Sensitive and specific methods of imaging are required for the detection of early 
inflammatory changes to the synovium in patients with arthritis and for monitoring 
response to treatment. In vivo imaging in the animal model is of vital importance in 
developing these techniques. Novel therapies can be better evaluated using sensitive, 
reproducible imaging of disease activity that reflects underlying molecular changes. 
1.3.3.1.1 Invasive In Vivo Optical Imaging 
Intravital fluorescence microscopy in inflammatory arthritis was first performed in 
1993. This technique allows measurement of microhaemodynamic parameters as well 
as leukocyte EC interactions (Menger and Lehr 1993). Blood vessel diameter 
(Veihelmann, Szczesny et al. 1998; Veihelmann, Harris et al. 1999) and capillary 
density (Schmitt-Sody, Landes et al. 2003) were measured in the synovial 
microcirculation of the mouse knee joint following surgical exposure of the area of 
interest. The inhibitory effect of recombinant anti-leukoproteinase, a physiological 
inhibitor of granulocyte serine proteases on blocking the interactions of leukocytes on 
the endothelial lining was investigated by microscopic imaging of leukocyte rolling 
and adhesion in vivo (Sehnert, Gierer et al. 2006). A limitation of this technique is the 
need to expose surgically the area for direct microscopy. 
1.3.3.1.2 Non- targeted imaging in animal models of arthritis 
Disordered new vessels have increased vascular leakiness to macromolecules 
compared to normal vessels (Levick 1981) This is discussed in Section 1.2.4. Due to 
these local permeability changes non-specific dye deposition was used to visualise the 
arthritic joint in vivo. Enhanced localised deposition of free dye (not bound to a 
disease specific antibody or other target) in the arthritic joints of animals with induced 
arthritis has been examined in several studies. The NIR fluorophore Cy5.5 was 
visualised in arthritic knee joints following induction of antigen induced arthritis in 
mice (Hansch, Frey et al. 2004). This demonstrated an approximate 1.5 fold increase 
in signal in arthritic compared to non arthritic joints. Two other NIR dyes were 
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evaluated in a murine Borrelia-induced Lyme arthritis model (Fischer, Gemeinhardt 
et al. 2006). These techniques rely on the generalised increased blood perfusion and 
‘vascular leakiness’ that are recognised to be present around the inflamed joint 
(Andersson, Johansson et al. 1998). This may lead to as much as a forty fold increase 
in macroglobulin permeability in the inflamed joint (Levick 1981). In such cases 
native dye most likely accumulates in the inflamed synovial membrane following 
phagocytosis by activated macrophages. Another study has demonstrated increased 
levels of fluorescence in inflamed paws with a fluorescently labelled PEGylated anti-
TNF agent compared to a non-PEGylated TNF inhibitor (Palframan, Airey et al. 
2009). There is also a recognised non-specific autofluorescence change in the 
absorption emission spectra of inflamed tissue (Hansch, Sauner et al. 2003), although 
this phenomenon is likely to be more limited at wavelengths in the NIR spectrum. 
1.3.3.1.3 Targeting of specific molecular changes in arthritis 
In vivo targeting of specific molecules that have been identified as being key 
components in the inflammatory cascade may help to increase specificity in assessing 
disease activity levels and differentiating subsets of arthritis. 
Specific deposition of dye in the arthritic joint of antigen-induced arthritic mice has 
been achieved by targeting macrophages with Cy5.5 labelled anti-F4/80 antigen. The 
F4/80 antigen is expressed on the macrophages when they accumulate in inflamed 
joints (Hansch, Frey et al. 2004). There was however, a small increase in signal in the 
uninflamed contralateral knee joints as well as increased uptake in inflamed knee 
joints with the Cy5.5 labelled isotype control antibody. A similar study targeting 
folate receptors on activated macrophages, demonstrated a 2.3-fold increase in signal 
in inflamed compared to uninflamed joints (Chen, Mahmood et al. 2005). This 
increase was greater than that obtained following injection of free dye. Arthritis has 
also been detected with allogeneic leukocytes that were labelled ex vivo with 
fluorescent dye and re injected into arthritic mice (Simon, Daldrup-Link et al. 2006). 
Treatment with steroid reduced the signal intensity obtained. However, the degree of 
quantitative analysis was hampered by a relatively small change in signal intensity 
compared to the background signal.  
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1.3.3.2 Activity-Based Probes in Arthritis 
Amplification of fluorescent signal at the site of inflammation using protease 
activatable probes may hold significant promise for in vivo imaging of arthritis, 
especially of OA, as local perturbations in proteolytic activity may be comparatively 
small. Cathepsins have been associated with arthritis and bone degeneration (Lang, 
Horler et al. 2000). A cathepsin B activatable NIR fluorescent probe was used in a 
mouse model of osteoarthritis and showed a 3-fold difference in signal intensity 
between normal and osteoarthritic joints (Bhaumik and Gambhir 2002; Lai, Chang et 
al. 2004). This particular probe has also been applied to tumour detection (Weissleder, 
Tung et al. 1999) as well as the localisation of atherosclerotic plaques in vivo (Chen, 
Tung et al. 2002). A similar probe was used to demonstrate that Methotrexate could 
abrogate some of the increased signal found in arthritic joints (Wunder, Tung et al. 
2004). A further study also demonstrated that specific signal could be reduced and 
correlated with a decrease in clinical disease indices such as redness and measurable 
paw swelling (Izmailova, Paz et al. 2007). However, these studies did not examine 
whether an uncleavable form of peptide demonstrated similar signal or whether any 
specific inhibitor of the protease could prevent cleavage in the arthritic joint.  
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Table 1-2 Comparison of optical imaging techniques 
 
 
Technique Description Resolution Depth Time Advantages Disadvantages 
Intravital 
microscopy 
Imaging 
technique 
based on 
fluorescence 
microscopy 
adapted for in 
vivo use 
1µm <400-
800µm 
Minutes 
to hours 
Quantification 
of individual 
cellular 
changes 
Invasive 
microscopic 
technique 
Fluorescence 
Reflectance 
Imaging 
(FRI) 
 
Non invasive 
whole body 
imaging, 
obtaining 
two-
dimensional 
planar images 
2-3mm <1cm Seconds 
to 
minutes 
Comparatively 
low cost, 
images rapidly 
acquired. May 
have 
significant use 
for detecting 
peripheral 
arthritis 
Signal 
quantification 
challenging 
Limited depth 
resolution 
Fluorescence 
Molecular 
Tomography 
(FMT) 
Non invasive 
imaging, 
obtaining 
three-
dimensional 
mapping of 
fluorescent 
signal 
1mm <10cm Minutes 
to hours 
3 dimensional 
imaging, able 
to limit effects 
of light 
scattering by 
analysing 
images from 
multiple 
angles 
Longer 
acquisition times 
for whole body 
imaging. Single 
animal able to be 
imaged at a time 
Bioluminesc
ence imaging 
Non invasive 
imaging, 
signal 
detected as a 
result of 
luciferase 
expression 
2-3mm <10cm Minutes Ability to 
report on gene 
expression for 
lifetime of 
animal 
Genetic 
modification of 
host required 
Limited 
quantification of 
signal 
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1.4 Animal Models of RA and Inflammation 
1.4.1 Collagen Induced Arthritis: A Well Validated Pre Clinical Model of RA 
Animal models of arthritis are of paramount importance as experimental tools for 
many aspects of research including the evaluation of novel therapies, searching for 
markers of disease progression and evaluating novel imaging techniques, such as 
those described in preceding sections. RA and other inflammatory joint disorders 
remain an important target for drug development and animal models of arthritis have 
been widely used in testing novel therapies. CIA is an animal model of RA, in which 
disease is induced in genetically susceptible mice with type II bovine collagen. This 
technique was first described in rats in 1977 (Trentham, Townes et al. 1977), and 
subsequently established in mice (Courtenay, Dallman et al. 1980). Type II collagen 
is a major constituent protein of cartilage in the diarthrodial joints, the predominant 
site of inflammation in RA (Myers, Rosloniec et al. 1997). Intradermal immunisation 
of genetic susceptible mouse strains, mainly DBA/1 or B10RIII mice, with bovine 
type II collagen (CII) emulsified in CFA triggers an autoimmune response to mouse 
CII that leads to inflammatory arthritis. Susceptibility to collagen-induced arthritis is 
associated with MHC class II genes, although non-MHC genes also play a role. Both 
B- and T-lymphocytes are important in the pathogenesis of collagen-induced arthritis. 
Histologically, hallmarks of both CIA and RA are infiltration of the subsynovial 
tissue by inflammatory cells, synovial hyperplasia, angiogenesis as well as erosion of 
cartilage and bone by a pannus-like tissue (Trentham, Townes et al. 1977; Wooley, 
Luthera et al. 1981; Lee and Weinblatt 2001). Heterologous (e.g. bovine or chicken) 
CII is used for the immunisation. Arthritis tends to follow an acute, self-limiting 
disease course. The arthritis starts approximately three to four weeks after 
immunisation, usually in a limited number of joints and gradually spreads to multiple 
joints (Holmdahl, Bockermann et al. 2002). In mice, immunisation with bovine, 
chicken, or rat type II collagen usually leads to a relatively acute form of arthritis. By 
contrast, immunisation with murine collagen results in a more chronic disease. This 
difference may be due to the extent to which the immune response is targeted at self 
collagen, as opposed to the collagen used for immunisation (Holmdahl, Jansson et al 
1986; Holmdahl, Andersson et al 1989). CIA been widely used to study mechanisms 
involved in the arthritic process and to identify potential new therapies for RA. Pro-
inflammatory cytokines, such as TNF and IL-1 are expressed in the arthritic joints 
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of both murine CIA and RA. A number of studies initially focussed on the effects of 
TNF blockade during the induction phase of CIA (Piguet, Grau et al. 1992; 
Thorbecke, Shah et al. 1992) subsequently the effect of anti-TNF treatment in mice 
with established CIA was demonstrated. This showed that in mice treated with 
intraperitoneal injection of anti-TNF MoAb there was a dose dependent reduction in 
the severity of arthritis and that joints were protected from erosive changes (Williams, 
Feldmann et al. 1992). While CIA is well validated it does have some unique 
components to disease pathogenesis and has classically been a strain dependent model 
of arthritis, with H-2
q
 and H-2
r
 stains in DBA/1 mice showing the greatest degree of 
susceptibility. One issue, for example is that the T-cell proliferative response to type 
II collagen in immunised DBA/1 mice peaks a significant amount of time before the 
onset of arthritis and is in decline by the time of disease onset and that the disease 
course is generally relatively acute, peaking at 4 to 5 weeks following immunisation 
and then gradually resolving. For this reason a protocol for the induction of arthritis in 
C57BL/6 mice utilising chicken type II collagen has been developed (Inglis, Simelyte 
et al. 2008). The development of arthritis in this model is associated with a very 
strong T-cell response to collagen that remains elevated for up to 3 months post 
immunisation (Inglis, Criado et al. 2007). Interestingly this disease also has other 
differences in phenotype with less swelling and a more gradual increase in clinical 
score, with a later (6-8 weeks after onset) more significant inflammatory cell 
infiltration compared to DBA/1 mice. A further limitation of the classic CIA model in 
DBA/1 mice is that most transgenic and knockout strains of mice are on a C57BL/6 
background (H-2
b
) hence the further usefulness of having a reliable method of 
arthritis induction in BL/6 mice.  
Animal models of arthritis provide a vital ongoing test bed for developing novel 
molecular targets for the future treatment of inflammatory disease. For example, 
several possible inhibitors of angiogenesis, including soluble VEGFR1, have been 
shown to reduce disease severity in CIA (Miotla, Maciewicz et al 2000; Afuwape, 
Feldmann et al 2003; Sumariwalla, Cao et al 2003). More recently it has been 
demonstrated that anti-CD3 therapy is highly effective for the treatment of CIA with 
the capacity to generate antiarthritic CD8+ Treg cells and expand the relative numbers 
of CD4+ Treg cells (Notley, McCann et al.). These examples demonstrate the 
requirement for both an effective animal model of RA and the need for targeted 
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molecular therapy that can be monitored in vivo and in the future translated from the 
animal model into human studies.  
1.4.2 Acute Models of Inflammation 
In addition to models of arthritis such as CIA, a number of different models that 
induce acute paw oedema in mice or rats have been developed. Initial studies focused 
on examining the nocioceptive and inflammatory alterations in rodents and 
subsequently on evaluating the efficacy and mechanism of action of compounds such 
as anti-inflammatory drugs. Rat paw oedema was first characterised using carageenin 
induced inflammation. Carageenan derived from red algae produces a local 
inflammation following local injection (Winter, Risley et al. 1962; Di Rosa 1971; Di 
Rosa 1971; Di Rosa, Papadimitriou et al. 1971). It was demonstrated that carrageenan 
intraplantar injection in rats produces a monophasic oedematous response in the rat 
paw that is accompanied by inflammatory cell migration, marked nocioceptive 
alterations and increased NO levels (Salvemini, Wang et al. 1996). In this study rat 
paw oedema was found to be maximal by six hours and remained elevated by 10 
hours and could be abrogated by constitutive and inducible nitric oxide synthetase 
inhibitors with concomitant decreases in neutrophil infiltration. This group have 
examined in more detail the participation of TNF in the inflammatory and 
nocioceptive responses evoked by carrageenan injected into the mouse paw. The 
intraplantar injection of carrageenan (300μg) confirmed a marked and biphasic paw 
oedema with peaks at 6 hours and 72 hours with significant increases in 
myeloperoxidase activity that peaked at 6 hours in C57/BL6 mice. All of this activity 
was significantly abrogated in TNF p55 receptor knockout mice. The systemic 
administration of anti-TNF antibody produced similar decreases in paw oedema, 
allodynia and myeloperoxidase (MPO) activity. Interestingly the inflammatory 
responses of carreegenan were also abrogated when mice were previously treated with 
the preferential inhibitor of TNF synthesis thalidomide. Another study has examined 
the role of neutrophil migration in carreegenan induced paw oedema determined by 
MPO staining by examining the effect of fucoidin an inhibitor of neutrophil rolling 
that binds L-selectin (Cunha, Verri et al. 2008). Another technique has been to inject 
zymosan into the mouse paw (Keystone, Schorlemmer et al. 1977; Gado and Gigler 
1991). Zymosan is a component of the bacterial cell wall that induces an intense 
inflammatory response (Lundberg and Arfors 1983). This model has again been used 
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to test the short term efficacy of anti inflammatory compounds. Gado and Gigler 
injected 0.1ml of a 2% suspension of zymosan into the rat paw. This caused a 90% 
increase in paw volume, with a biphasic time course. The paw swelling reached a 
maximum 45 minutes after injection with a second peak of swelling after 6 hours. 
Zymosan has also been used as an acute model of arthritis to examine the effects of 
Tenascin C, an endogenous activator of Toll like receptor 4, that has been found to be 
essential for maintaining inflammation in arthritic disease (Midwood, Sacre et al. 
2009). In this model rapid paw swelling was reached after 24 hours, maintained for 24 
hours, with swelling still seen at 4 days with histological evidence of arthritis 
demonstrating cellular infiltration and cartilage loss. Injection of TNF into the hind 
paw of the rat has also been utilised to demonstrate the role of TNF in the 
development of acute inflammatory hyperalgesia (Cunha, Poole et al. 1992). This 
study used doses of TNF between 0.0025 and 2.5pg in 100μl of vehicle. Paw 
swelling was not measured in this study. A subsequent study by Woolf and colleagues 
again in rats examined the role of TNF in contributing to inflammatory sensory 
hypersensitivity by inducing IL-1β and nerve growth factor (NGF)(Woolf, Allchorne 
et al. 1997). This study by comparison, used much higher doses of TNF (50-500ng). 
This demonstrated that IL-1 and NGF were TNF dependent at early (6 hours) but 
not late (24 hours) time points, but again paw swelling was not measured in this 
study. A further study by Campos and colleagues examined the relationship between 
pretreatment with TNF and injection of bradykinin (Campos, Souza et al. 1998). 
This study used a dose of 5ng per paw of TNF as a pretreatment which in itself did 
not cause significant increases in paw volume. Subsequent injection of bradykinin did 
cause significant increases in paw swelling suggesting that the prior injection of 
cytokines IL-1β or TNF into the rat paw resulted in a rapid onset and significant 
upregulation of B1 receptors, characterised by marked and dose dependent oedema 
formation in response to further injection of bradykinin. Colleagues at The Kennedy 
Institute of Rheumatology have demonstrated that TNF induces hyperalgesia and 
neutrophil migration as measured by the myeloperxidase assay following injection of 
20ng of TNF in 10μl of vehicle in the paws of C57Bl/6 mice. While the injection of 
higher doses of TNF was noted to cause swelling the complete dose dependence of 
TNF on paw swelling had not been fully delineated. They have however shown that 
IL-17 induced hyperalgesia was dependent on neutrophil migration and that TNF 
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induced paw swelling could be abrogated in p55 TNF receptor knockout animals. 
These effects could also be blocked by the prior administration of fucoidin 
(unpublished observations).  
1.5 Hypothesis and Objectives 
The targeting of E-selectin on activated vascular endothelium has previously been 
well validated in both animal and human studies. My hypothesis was that fluorescent 
imaging utilising E-selectin as a target holds significant potential as a non invasive, in 
vivo molecular imaging technique in murine arthritis. 
My objectives were to: 
1. To establish proof-of-principle imaging of joints of mice with inflammatory 
arthritis using fluorescently labelled anti-E-selectin in vivo 
2. To apply fluorescence imaging to investigate the in vivo mode of action of 
vascular-targeted therapies in murine inflammatory arthritis. In particular to 
determine the treatment response and changes in E-selectin targeted 
fluorescent imaging following administration of a novel EGF receptor 
antagonist (RB200) in CIA. 
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2 MATERIALS AND METHODS 
2.1 Chemical Components 
If not otherwise specified, chemicals were obtained from VWR International Ltd 
(Lutterworth, UK), Sigma Aldrich (Dorset, UK) or Merck Chemicals Ltd 
(Nottingham, UK) in analytical grade quality. 
2.2 Cell Lines 
Hybridoma cell lines expressing  rat anti-mouse E-selectin IgG2a MoAb (MES-1) and 
rat IgG2a isotype control antibody against dinitrophenol (DNP) were kind gifts from 
Dr Derek Brown (UCB, Slough, UK) and Professor David Gray (University of 
Edinburgh). The method used for cell culture is described in Section 2.4.1. 
2.3 Fluorescence Reflectance Imaging Device 
Optical imaging experiments were performed using a fluorescence reflectance 
imaging (FRI) device (Kodak In-vivo Multispectral System FX Pro). This utilizes a 
175W Xenon illumination source coupled to an automated multi-wavelength series of 
excitation filters with a range of 390-770nm and emission filters between 480-830nm. 
This allows a wide range of fluorescent dyes of varying wavelengths to be tested. 
Fluorescence emission is captured using a monochrome interlined cooled CCD with a 
pixel density of 2048x2048 pixels (Figure 2-1). Image acquisition and analysis has 
been performed using proprietary Kodak software (version 5.0). 
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Figure 2-1 Fluorescence Reflectance Imaging: Kodak In Vivo Imaging System FX 
Pro  
The above photograph describes the experimental set up described in the text. A) Light source and 
excitation filters. B) Emission filters and CCD C) Animal chamber and anaesthetic apparatus D) X-ray 
device.  
2.4 Production of Anti-E-Selectin and Anti-DNP Isotype Control 
Antibodies 
2.4.1 Cell Culture for Anti-E-Selectin and Anti-DNP Antibodies 
Cell lines were cultured in RPMI media (Sigma Aldrich, St Louis, USA) containing 
heat-inactivated 10% foetal calf serum (FCS) (Invitrogen, Renfrew, UK), 100U/ml 
penicillin, 50g/ml streptomycin and 4.5g/l L-glutamine (Sigma-Aldrich, Poole, UK). 
The hybridoma was divided and culture media added. The colony was expanded to as 
many 175cm
2
 flasks as were required. Cells were grown to confluency and divided 
into equal volumes of media every 1-2 days. After appropriate growth, the cells were 
left in an incubator without feeding and allowed to die off (cells shrivelled and media 
yellow). I aimed for 25-50% viability before aiming to spin down. Cell death was 
assessed by counting the proportion of live and dead cells following application of 
Trypan Blue stain (0.1ml of 0.4%). By maintaining uniform cell viability this ensured 
similar batches of antibody yield from sequential cultures as demonstrated in Figure 
A
B
C
D
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2-2. This demonstrates the mean cell viability and total protein yields for 3 sequential 
cell cultures demonstrating consistent protein yield. The cells and supernatant were 
then collected and spun at 4,000rpm for 15 minutes to get rid of cell debris.  
 
 
 
 
 
 
Figure 2-2 Cell viability and yield of anti-DNP antibody 
Graph demonstrating the mean cell viability prior to antibody harvest and mean total protein yield of 
DNP antibody following purification from the cultured hybridoma cell line after 3 sequential cultures. 
Similar results were obtained for E-selectin antibody. 
2.4.2 Affinity Purification of Cultured Antibodies 
Affinity purification utilises specific non-covalent binding interactions between ligand 
and target molecules. The target molecules to be purified are added to a solid support 
allowing them to bind by their specific affinity to the immobilized ligand molecules. 
The non-bound components are then washed away and the captured target molecules 
eluted from the ligand molecules using buffer conditions that disrupt the affinity 
interaction. 
The collected supernatant from hybdridoma cultures was initially pre-cleared on 
sepharose beads to remove non-specifically sticky proteins. 5 mls of 80% sepharose 
4B was placed into a glass chromatography column and equilibrated with phosphate 
buffered saline (PBS). The supernatant was then applied to the column using a 
peristaltic pump at a flow rate of 1 to 5mls/min. The sepharose 4B beads were then 
discarded. The pre-cleared supernatant was then applied to a protein G column (3 mls 
of 80% slurry placed in column and equilibrated with 10x gel bead volume of PBS). 
The pre-cleared supernatant was then applied at a flow rate of 1.5mls/min. The 
column was then washed with 5x gel bed volume (12 mls) of PBS to remove any 
unbound proteins from the column. The last 1 ml wash fraction was analysed by 
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measuring the absorbance at 280nm (A280) to ensure all non-bound proteins were 
removed, with the spectrophotometer set at zero using the same PBS used to wash the 
column. If the A280 was >0.05 then the wash step was repeated until the A280 was 
<0.05. 
Antibodies were then eluted with 5x gel bed volume (i.e. 12 mls) of Glycine-HCl pH 
2 in a tube containing 200µl of 1M tris(hydroxymethyl)aminomethane (Tris) pH 8.8 
per ml of eluent. This acts to neutralize the antibodies preventing 
degradation/inactivation at high pH. The last 1 ml of eluent was analysed at A280 to 
ensure all bound antibodies have been eluted (spec: zero with mixture made up of 1 
ml Glycine-HCl pH 2 added to 200µl 1M Tris pH 8.8 mixture, aim A280 <0.05). The 
elution was repeated with one further gel bed volume of Glycine-HCl pH 2 until all 
bound antibodies were eluted. All antibodies were pooled together and the yield 
determined at A280 (spec: zero with mixture made up of 2 x 2.4 mls PBS added to 3x 
2.4 mls Glycine-HCl pH 2 and 2.4 mls 1M Tris pH 8.8). A VivaSpin® (Sartorius, 
Aubagne, France) device with molecular weight cut-off 50,000 or 100,000, buffer 
exchanged with PBS was utilized to concentrate the purified antibodies. The protein 
G column was washed with 10x gel bed volume (24 mls) of Glycine-HCl pH 2. 
2.4.3 Measurement of Antibody Concentration Following Production and 
Purification to Ensure Accurate Quantification for Labelling and 
Imaging 
The concentration of purified antibody was calculated by measuring absorbance at 
280nm at the end of the purification process. More accurate protein concentration 
measurements were also made using the Pierce BCA protein assay kit (Thermofisher, 
Loughborough, UK). This method utilises the reduction of Cu
2+
 to Cu
1+
 by protein in 
an alkaline medium. The subsequent detection of Cu
1+
 can then be made by using a 
colourmetric reagent, bicinchoninic acid (BCA), the resultant complex showing 
strong absorbance at 562nm. This was utilised to accurately determine the amount of 
protein required for each individual labelling reaction; ensuring optimum conditions 
for labelling and for optimising the dye/protein ratio and standardising protein 
concentrations between target and control antibodies, in turn ensuring that comparable 
amounts are used when injecting under in vivo conditions. 25μl of standard or 
unknown sample was loaded onto duplicate wells of a 96 well polystyrene plate. 
200μl of the working reagent, comprising of a 50:1 mixture of BCA reagent A:B were 
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added to the individual wells and the plate covered and incubated at 37ºC for 30 
minutes. Absorbance measurement was performed at 540nm using a plate reader and 
the protein concentrations within test samples were calculated by Ascent software 
(Version 2.6, Thermo Labsystems) using the 9 point standard curve as a reference. 
2.4.4 Determination of Antibody Purity by SDS PAGE Prior to Labelling 
The purity of anti-E-selectin and anti-DNP antibodies obtained from cell culture was 
determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS 
PAGE; NuPAGE Novex Bis-Tris Mini Gel, Invitrogen, Paisley, UK). This is a 
technique used to separate proteins according to their electrophoretic mobility. The 
preparation of samples, running buffer, gel loading and running conditions were 
performed according the manufacturer’s protocol. 10µl of the sample (either DNP or 
E-selectin antibody at a concentration of 50µg/ml) was combined with 2.5µl of 
loading buffer and 2µl of reducing agent (either NUPAGE sample reducing agent, 
Invitrogen, Paisley, UK or Beta-Mercaptoethanol (2µl of 10mM solution)) and made 
up to a total volume of 20μl with deionised water. Samples were then heated at 70ºC 
for 10 minutes. Samples were loaded onto the gel and the gel chambers loaded with 
running buffer. Electrophoresis was run at a constant 150V for 1 hour. A protein 
standard molecular weight marker was used to determine the molecular weight of 
component parts. 0.2% Coomasie brilliant blue stain was applied for 60 minutes. The 
gel was destained, by placing in 100 mls 30% methanol. This was replaced with fresh 
destain solution every half an hour for 1-2 hours. Mass spectrophotometry was 
performed following excision of gel fragments (Waters Micromass Xevo QTof, 
Milford, Massachusetts, USA) (courtesy of Dr Robin Wait, Kennedy Institute of 
Rheumatology). 
2.4.5 Fluorescent Labelling of Anti E-Selectin and Control Antibodies 
Fluorescent labelling is the process of attaching a fluorophore to another molecule 
such as a protein or nucleic acid. Generally, this is accomplished by using a reactive 
derivative of the fluorophore that can selectively bind to a functional group on the 
target molecule. Common reactive groups include amine reactive isothiocyanate 
derivatives such as FITC and TRITC (derivatives of fluorescein and rhodamine) 
amine reactive succinimidyl esters such as NHS-fluorescein, and sulfhydryl reactive 
maleimide activated fluors such as fluorescein-5-maleimide. Reaction of any of these 
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reactive dyes with another molecule results in a stable covalent bond formed between 
a fluorophore and a labelled molecule. 
Following a fluorescent labelling reaction, it is necessary to remove any non reacted 
fluorophore from the labelled target molecule. This can be accomplished by size 
exclusion chromatography, taking advantage of the size difference between 
fluorophore and labelled protein, nucleic acid, etc. Fluorophores may interact with the 
separation matrix and reduce the efficiency of separation. For this reason, specialized 
dye removal columns that account for the hydrophobic properties of fluorescent dyes 
are sometimes used. Reactive fluorescent dyes are available from many sources. They 
can be obtained with different reactive groups for attachment to various functional 
groups within the target molecule. They are also available in labelling kits that contain 
all the components to carry out a labelling reaction. Various proprietary fluorescein 
derivatives have been developed to increase signal intensity, photostability or with 
different attachment groups to bind a variety of different molecules. The most 
common reactive group present for antibody labelling is an active NHS ester reactive 
group that will couple to primary amines forming stable conjugates. Three different 
proprietary NIR dye antibody labelling kits were assessed when performing 
preliminary in vivo imaging experiments. The Thermofisher DyLight 750nm dye 
labelling kit was selected for further in vivo imaging experiments because it had an 
efficient and reproducible conjugation reaction, confirmed effective removal of free 
dye and was relatively inexpensive. 
2.4.5.1 Techniques of fluorescent labelling 
Anti-E-selectin and anti-DNP antibodies were prepared for conjugation according to 
manufacturer’s instructions. The protocol used for fluorescent labelling of antibody 
for in vivo experiments is also included in more detail in Appendix 2.2. 1mg of 
protein (either anti-E-selectin or anti-DNP antibody) was used for labelling at a 
concentration of 2 mg/ml. The correct concentration of protein was achieved by 
adding labelling buffer. This was made by diluting Borate Buffer (0.67M) to 0.05M in 
PBS: 75 μl of Borate Buffer (0.67M) was added to 925 μl of PBS. 0.5 mls of the 
prepared protein was added to the vial of DyLight Fluorophore reagent and vortexed 
gently. The reaction mixture was then incubated for 60 minutes at room temperature 
protected from light. The samples were then mixed with purification resin and then 
centrifuged for 45 seconds at ~1,000 × g to remove the storage solution. 
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2.4.5.2 Measurement of the fluorescent labelling reaction 
Following protein labelling and purification it is necessary to measure the fluorophore 
to protein ratio. This can be calculated by measuring absorbance ratios using a 
spectrophotometer. Quantification of protein: dye conjugation is essential for 
predicting the amount of probe necessary to gain adequate signal intensity in an 
experiment and for controlling signal intensity between experiments. While a greater 
number of fluorescent molecules per target molecule may increase specific signal 
intensity, over labelling can cause quenching as a result of fluorescent emissions from 
one dye molecule being absorbed by neighbouring dye molecules. Over labelling may 
also cause loss of biological activity of a molecule or decreased solubility. By contrast 
under labelling will lead to a weakened fluorescent signal and a weakened fluorescent 
probe. 
2.4.5.2.1 Quantification of fluorophore labelling 
The principles of absorbance are outlined below: 
The ratio of the radiant power (P) transmitted to the radiant power incident (Po) on 
the sample is called the transmittance, T: 
Absorbance (A) is defined as the log of the reciprocal of transmittance: 
A= -logT = log (1/T) 
In a spectrophotometer the transmittance and absorbance of a sample depends on the 
molar concentration (c), light path length in centimetres (L) and molar absorptivity (ε) 
for the dissolved substance at the specified wavelength (λ) (Dean 1992). 
A λ= ε c L 
Beer’s Law states that molar absorbtivity is a constant (and the absorbance is 
proportional to the concentration) for a given substance dissolved in a given solute 
measured at a given concentration. Molar absorptivities are therefore called molar 
absorption co-efficients or molar extinction co-efficients. Transmittance and 
absorbance are unitless and therefore the units for molar absorptivity cancel with units 
of measure in concentration and light path and have units of M
-1 
cm
-1
. Therefore, with 
a 1cm cuvette: 
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A λ = ε c L = ε c when L=1cm 
While there is no single correct molar extinction co-efficient for a complex molecules 
such as immunoglobulins, it is possible to calculate these for the published literature 
(Gill and von Hippel 1989). Differences in buffer type, pH etc can all have an effect. 
Most immunoglobulins have protein extinction co-efficients (ε percent) in the range 
of 12-15. Therefore in typical antibody solutions it has been assumed A280
1%
 = 14 or 
A280
0.1%
 = A280 1mg/ml = 1.4 For a typical IgG, with molecular weight 150,000, 
this value corresponds to a molar extinction co-efficient (ε) equal to 210,000 M-1cm-1 
2.4.5.2.2 Procedure for determining the dye:protein ratio 
The maximum absorbance of the fluorescent dye molecule is described to an extent 
by its extinction co-efficient (έ). Amax is the absorbance (A) of a dye solution 
measured at the wavelength maximum (λmax). Together the Amax and (έ) may be 
used to calculate the molar concentration of dye in a sample. Standard absorbance at 
280nm (A280) is used to determine the protein concentration in a sample. However 
because fluorescent dyes also absorb at 280nm a correction factor must be used to 
adjust for the amount of A280 contributed by the dye. The correction factor (CF) 
equals the A280 of the dye divided by its Amax. In practice this number will be very 
small when dyes are used that are in the NIR range (where there will be minimal 
effect from the dye on the A280 value) (Gill and von Hippel 1989; Pace, Vajdos et al. 
1995). 
Following removal of excess dye from the sample by dialysis as described in the 
protocol the absorbance was measured at 280nm using a spectrophotometer (Perkin 
Elmer lambda Bio 20, Massachusetts, USA) with a 1cm light path.  
Absorbance of the protein dye conjugate was then measured at the λmax for the dye 
molecule. Calculation of protein molarity and degree of labelling was measured using 
the following parameters: 
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Parameters for determining dye/protein ratio 
E protein molar extinction co-efficient (for IgG ~ 
210,000 M
-1
cm
-1
) 
Amax Absorbance of a dye solution at the maximum 
wavelength λmax for the dye molecule 
CF correction factor - any absorbance at A280 caused 
by the dye 
Dilution Factor The extent to which the dye:protein sample has 
been diluted for absorbance measurement. 
έ molar extinction co-efficient of fluorescent dye 
 
Critical values for Thermoscientific Pierce fluorescent dye at 750nm wavelength: 
Wavelength 
maximum (λmax) 
Extinction co-
efficient (έ) 
Correction Factor 
753nm 220,000 M
-1
cm
-1
 0.0200 
 
Dye/protein ratio calculation 
 
 
 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  𝑀                                               =  
A280 −  AMax  ×  CF 
E  protein 
 X dilution factor 
 
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑑𝑦𝑒 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛                                 =  
Amax  of  labelled  protein
έ ×protein  conc  (M)
       X dilution factor 
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The sample was dialysed to ensure that no free dye following dye protein conjugation 
was present in the sample this is considered to be especially important because free 
dye can be visualised as having tracked to sites of inflammation (Hansch, Frey et al. 
2004). 50µl of sample was diluted in 450µl of PBS and placed into a 10,000MW cut-
off dialysis cassette (Pierce Slide-A-Lyzer 10K cut-off cat no 66380) and placed in 3l 
of 1x PBS for 4 hours. 3l of PBS was buffer exchanged after 4 hours and then left for 
12 hours in a cold room. The sample was removed from the cassette and absorbance 
was remeasured at A280 and the Amax of the dye to determine whether there had 
been any change in the dye-protein ratio. 
2.4.6 Measurement of The Immunoreactivity of DNP and E-Selectin Antibodies 
Pre and Post Labelling by ELISA 
Enzyme linked immunoabsorbent assay (ELISA) is an immunoassay frequently 
applied to determine the concentration of a specific protein in a sample. The method 
of sandwich ELISA makes use of two antibodies that bind to epitopes that do not 
overlap on the antigen of interest. During the first step, a highly purified antibody 
(capture antibody) is non-covalently adsorbed onto plastic microtiter plates creating a 
solid phase. Excess antibody is removed by washing and samples are applied to the 
plate. Diluted standard samples of the antigen are employed to constitute a standard 
curve for calculation of the antigen concentration in tissue samples. The immobilized 
antibodies serve to specifically capture soluble proteins present in unknown samples. 
After washing away unbound sample, the captured antigens are detected by biotin-
conjugated antibody (detection antibody) that binds to a second epitope on the 
antigen. Streptavidin-labelled horseradish peroxidase (HRP) binds to the biotin which 
is linked to the detection antibody. Following the addition of a chromogenic substrate, 
the absorbance of coloured product generated by the bound, enzyme-linked detection 
reagents is measured spectrophotometrically on an ELISA plate reader at an 
appropriate optical density (OD).  
ELISA was performed to confirm the immunoreactivity of anti-E-selectin antibody 
before and after conjugation. Following each step the ELISA plate was washed with 
0.1% PBS/Tween. The plate was coated with 100μl of recombinant mouse E-selectin 
at a concentration of 3g/ml (recombinant mouse E-selectin, CD62E, Fc chimera, 
R&D Systems, Minneapolis, USA). The plate was covered and left overnight. Wells 
were then blocked with 200µl of 2% BSA/PBS and incubated for 1-2 hours at room 
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temperature on a rotating platform. 100µl of either anti-DNP or E-selectin antibody 
was added at a concentration of 2ng/ml and the plate left for 1hr at room temperature. 
This was followed by the addition of 100µl of biotinylated rabbit anti-rat IgGa at a 
concentration of 0.5μg/ml (Vector, Burlingame, CA, USA) and left for a further hour. 
0.5g/ml of streptavidin conjugated to horseradish peroxidase (HRP; R&D Systems, 
Minneapolis, USA) was left for a maximum of 1 hour. 100µl of 3,3’,5,5’-
tetramethylbenzidine (TMB) (KPL, Gaithersburg, USA) was used as substrate (equal 
volumes of substrates A and B). 50µl of stop solution (2M H2S04) was then added 
resulting in a colour change from turquoise to yellow. The reaction was then read at 
450nm on a Multiskan Plate Reader (Thermoscientific, Loughborough, UK). Binding 
was quantified using a standard curve of rat anti-mouse E-selectin IgG2a MoAb 
(R&D Systems, Minneapolis, USA). This was calculated by the accompanying 
computer software Ascent, version 2.6 (Thermoscientific, Waltham, MA, USA). 
2.4.7 Endothelial PY4.1 Cell Culture 
The endothelial cell line (EC) used in this study was PY4.1, a mouse EC line derived 
from hemangiomas induced by the expression of the polyoma early region in 
transgenic mice. Cells were a kind gift from Dr Victoria Bautch, University of North 
Carolina, Chapel Hill, USA. The cells retain EC properties such as a characteristic 
cobblestone appearance at confluency, contact-inhibited growth, and active uptake of 
acetylated low density lipoprotein. Expression analysis shows that the cells express 
both the polyoma transgene and the von Willebrand factor, an EC marker. These 
properties confirm the endothelial nature of this cell line (Dubois, Kolpack et al. 
1991; RayChaudhury, Frazier et al. 1994). In addition PY4.1 cells stimulated with 
TNF demonstrate increased lymphocyte binding, following upregulation of 
cytokines (Heyward, Dubois-Stringfellow et al. 1995). Cells were maintained in 
Dulbecco’s modified eagles medium (DMEM) (ATCC, Teddington, UK) 
supplemented with 10% FCS (Gibco, Invitrogen, Paisley, UK) and 100 U/ml 
penicillin and 0.1 mg/ml streptomycin (PAA, Yeovil, UK) as recommended by 
ATCC. The cell line was maintained in a humidified incubator at 37C and 5% CO2.  
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Figure 2-3 Phase contrast images of the PY4.1 endothelial cell line 
Representative images of PY4.1 cells showing a confluent monolayer, panel (a) and a sub-confluent 
monolayer of cells panel (b) (Magnification x40).  
2.4.7.1 Measurement of reactivity for anti-E-selectin and anti-DNP antibodies to 
endothelial cells before and after stimulation with TNF 
PY4.1 cells were plated out at 90% confluency into 30mm
2
 well tissue culture plates, 
and allowed to adhere overnight and reach full confluency. Cells were checked under 
a microscope to insure a confluent monolayer had been reached. Cells were 
stimulated with Murine TNF (PeproTech, Inc, Rocky Hill NJ, USA) for 5 hours, to 
induce expression of E-selectin. Murine TNF was diluted in serum-free DMEM 
medium. Cells were incubated at 37C and 5% CO2. After stimulation cells were 
carefully washed with serum free medium and then fixed for 6 minutes with 4% 
paraformaldehyde (PFA)/PBS. The cells were washed with PBS/2%BSA three times, 
care being taken not to disturb the monolayer. To prevent non-specific binding the 
cells were incubated over night at 4C in 2%BSA/PBS on a rocking platform. Cells 
were washed three times with PBS/2% BSA. Cells were then incubated on a shaking 
platform for 1 hour with anti-E-selectin or anti-DNP or no antibody as a control. Cells 
were then washed three times with PBS/2% BSA. Cells were then incubated on a 
(a)
(b)
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shaking platform for 1 hour with biotinylated rabbit anti-rat IgGa (Vector, 
Burlingame, CA, USA) at a concentration of 0.5μg/ml. Cells were washed three times 
with PBS/2% BSA. Streptavidin HRP (R&D Systems, Minneapolis, MN USA) 
diluted 1:400 was added to the plates and incubated for 45 minutes on a shaking 
platform. Cells were washed three times with PBS/2% BSA. TMB substrate and TMB 
substrate B (KPL, Gaithersburg, Maryland, USA) mixed together in equal volumes 
were then added to the plate and blue colour allowed to develop. Acid Stop solution 
(2M H2SO4) was added to terminate the reaction and change the plate contents to 
yellow so that colouration could be read on a plate reader at 450nm. 
For fluorescence imaging, cells were plated at 90% confluence onto Lab-Tek 
Flaskette glass slides (Nalge Nunc, New York, USA), followed by stimulation in the 
absence or presence of TNF for 5 hours. Following blocking overnight, cells were 
incubated with anti-DNP or anti-E-selectin antibodies at a concentration of 2μg/ml. 
Cells were washed and incubated with biotinylated rabbit anti-rat IgGa (Vector, 
Burlingame, CA, USA; 0.5μg/ml) for 1 hour, followed by streptavidin Alexa Fluor 
488 (0.1g/ml; Invitrogen, Renfrew, UK). Cells were mounted using VectaShield 
Mounting Medium with DAPI nuclear counterstain (Vector Laboratories Inc, 
Burlingame, CA, USA) and images were acquired on a Nikon T2000u microscope, 
(Nikon, Belmont, CA, USA). 
2.5 Animal Models of Inflammation for In Vivo Imaging 
Experiments 
2.5.1 Laboratory Animal Care and Regulatory Approval 
Male DBA/1-Ola/Hsd mice (H-2q) aged 8-12 weeks were purchased from Harlan 
Laboratories UK (Blackthorn, Bicester, UK) for the collagen induced arthritis model. 
Male C57BL/6J (H-2
b
) mice aged 6 weeks were purchased for the TNF induced paw 
oedema model. Mice were housed in groups of 6, and were maintained at 21°C ± 2°C 
on a 12-hour light/dark cycle with food and water ad libitum. They were maintained 
under standard conditions at the Biological Service Unit (BSU) of the Kennedy 
Institute of Rheumatology. All studies were performed in accordance with the UK 
Animals (Scientific Procedures) Act 1986 regulations for the handling and use of 
laboratory animals and performed under PPL 70/6533: Identifying and targeting 
mediators of inflammation.  
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2.5.2 Collagen Induced Arthritis 
The most widely used mouse model to study RA is collagen-induced arthritis (CIA). 
Type II collagen-induced arthritis was first described in rats in 1977 (Trentham, 
Townes et al. 1977), and subsequently established in mice (Courtenay, Dallman et al. 
1980) as described in Section 1.4.1. 
2.5.2.1 Purification of type II collagen 
Experimental arthritis can be induced in susceptible mouse strains by immunisation 
with either heterologous (e.g. bovine, chicken) or homologous type II collagen. Type 
II collagen is the most abundant collagen found in hyaline cartilage (e.g. in synovial 
joints, sternum, respiratory tract), comprising 80-90% of the total collagen content. 
For all experiments, type II collagen was purified from bovine articular cartilage, 
obtained from the femoral heads of 2-3 month old calves, following the method 
originally performed by Miller (Miller 1972) and adapted from (Inglis, Simelyte et al. 
2008). 
The bovine articular cartilage were powdered using a liquid nitrogen freezer-mill 
(Spex Industries Inc, Metuchen, NJ, USA). To remove proteoglycans, 5 volumes of 
4M guanidine hydrochloride in 0.05M Tris (pH 7.5) were added to the powdered 
cartilage and left stirring over night at 4°C. The cartilage was pelleted at 12,000 rpm 
for 1 hour at 4ºC. The insoluble residue was washed 2-3 times by stirring in 0.5M 
acetic acid followed by centrifugation. The pellet was then washed in 20 volumes of 
0.5M acetic acid to eliminate the remaining guanidine. The pH was adjusted to pH 2.8 
using 70% formic acid. 1g of pepsin was added for every 20g of cartilage (wet 
weight). This was left stirring for 48 hours at 4ºC. The sample was then centrifuged 
and the supernatant retained. To precipitate type II collagen from the supernatant 
NaCl (powder) was added gradually with stirring to produce a final concentration of 
0.89 M. This was left to equilibrate overnight at 4ºC and then centrifuged at 14,000g 
for 1 hour at 4ºC. The pellet dissolved in 0.1M acetic acid. The residual pepsin was 
inactivated by dialysing against 0.02M Na2PO4 (pH 9.4). This was then centrifuged 
and then the pellet redissolved in 0.5M acetic acid. Finally this was dialysed 
exhaustively (at least 10 changes of solution) against 10 litres acetic acid (0.5M). The 
collagen was freeze-dryed and stored in a dessicator at 4°C or -20°C. For 
immunization, collagen was dissolved at 4 mg/ml in 0.1M acetic acid overnight.  
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2.5.2.2 Induction of arthritis 
To induce arthritis in male DBA/1 mice, animals were administered a combination of 
Isofluorane (4%) and Oxygen (1l/min) by a gaseous anaesthetic delivery device 
(Vetech, UK) and shaved at the base of the tail. In-house prepared bovine type II 
collagen as described above was emulsified with an equal volume of complete 
Freund’s adjuvant (CFA; DIFCO, Detroit, MI, USA). Each mouse received an 
intradermal injection of 200 µg bovine type II collagen (bCII) emulsified in CFA into 
the base of their tail. 
2.5.2.3 Evaluation of arthritis 
In order to determine onset and development of arthritis in the acute CIA models, 
mice were examined daily 14 days following immunisation. Arthritis was 
characterised by evaluation of joint properties and inflammation of surrounding 
tissues. Disease onset was considered as the day that paw swelling or erythema in the 
paws could be observed. The disease severity was recorded for each paw daily using 
the following scoring system based on the visual signs of arthritis: 0 = normal paw, 1 
= mild swelling and/or erythema of the joint or individual digits; 2 = moderate 
swelling and erythema, 3 = moderate swelling and erythema accompanied with joint 
rigidity. An arthritis score (range 0 - 12) was assigned to each mouse by summing up 
the score of each paw. For clinical monitoring of CIA development in conjunction 
with the arthritis score, paw swelling was assessed by measuring the diameter of the 
hind paws using microcallipers (Röhm BG Ltd, Kingston-upon-Thames, UK).  
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Figure 2-4 Representative clinical scores of mice with CIA 
Panel (a) Normal hind paw (clinical score 0). (b) Hindpaw with mild swelling (clinical score 1). (c) 
Hindpaw with pronounced oedematous swelling (clinical score 2). (d) Hindpaw with ankylosis (joint 
fusion) (clinical score 3). 
2.5.2.4 Protocols for determining effect of therapy in CIA 
2.5.2.4.1 Effect of etanercept in CIA 
Disease was induced in 40 male DBA/1 mice (12 weeks old) as described in Section 
2.5.2.2. Human TNF type II receptor fusion protein (etanercept) (Wyeth 
Pharmaceuticals, Taplow, UK) was administered intraperitoneally (i.p.) (100μg) on 
days 1, 4, and 7 following the onset of arthritis in treatment groups (n=8 per group for 
either anti-E-selectin or anti-DNP-antibody injected groups). Mice were selected for 
imaging either with matched clinical score or at day 10 following arthritis onset and 
were transferred to the optical imaging device and anaesthetised as per the protocol in 
Section 2.7. 
2.5.2.4.2 Effect of RB200, an EGF receptor construct, in CIA  
Disease was induced in 60 male DBA/1 mice (12 weeks old) as described in Section 
2.5.2.2. Rb200 (gift from Dr Michael Shepard, Halozyme Therapeutics, San diego, 
USA) was administered (i.p.) on day of disease onset (day 1), and then on days 4 and 
7 of disease, at a dose of 0.5mg/kg or 10mg/kg, with equal volumes of PBS equivalent 
to etanercept given to control animals (N=6 per group. Etanercept was given (i.p.) on 
the day of disease onset (day 1), and then on days 4 and 7, at a dose of 1mg/kg or 
5mg/kg, (equivalent to either 20 or 100g per animal respectively) with an equal 
volume of PBS equivalent to Rb200 in control animals. Combination treatment of 
0.5mg/kg Rb200 plus 1mg/kg etanercept was given i.p. on day of disease onset (day 
1), and then on days 4 and 7. Arthritis assessed by paw swelling or as clinical scores 
a b
c d
0 1
2 3
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based on all 4 paws. Fluorescence imaging in vivo was performed on day 10, animals 
were injected with anti-mouse E-selectin MoAb labelled with Thermofisher DyLight 
750nm near infrared probe (excitation/emission spectra 752nm/778nm respectively). 
In vivo imaging studies were undertaken at 2-24 hours following intravenous (i.v.) 
injection of labelled antibody using a near infrared optical in vivo imaging system, as 
described in Section 2.7. 
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2.5.3 TNF Induced Paw Oedema 
Paw swelling was induced by the intraplantar injection into the right hind paw of 
recombinant murine TNF (5-50ng) (PeproTech Inc, London, UK). This was 
administered in a vehicle of 1% mouse plasma diluted in PBS. For administration of 
TNF into the paw anaesthesia was induced with a combination of isofluorane (2-
4%) and oxygen (1-2l/min) using a gaseous anaesthetic delivery system as described 
in Section 2.7. Animal groups (n=5) were then either injected with Anti-E-selectin or 
DNP antibody labelled with DyLight 750nm (i.v) (5-50μg/200μl). Paw thickness was 
measured with microcalipers (Röhm BG Ltd, Kingston-upon-Thames, UK) or in vivo 
optical imaging was performed at 2, 8 and 24 hours as per the protocol described in 
Section 2.7. 
2.5.3.1 Protocols for determining effect of therapy in TNF induced paw oedema 
2.5.3.1.1 Effect of etanercept in TNF induced paw inflammation 
Human TNF type II receptor fusion protein (100μg) (etanercept) (Wyeth 
Pharmaceuticals, Taplow, UK) was administered intraperitoneally (i.p.) 12 and 4 
hours prior to injection of dye labelled antibodies and induction of paw swelling. 
Animal groups (n=5) were then either injected with anti-E-selectin or DNP antibody 
labelled with DyLight 750nm i.v. (5μg/200μl). This was followed by gaseous 
induction of anaesthesia. Paw swelling was then induced by recombinant murine 
TNF intra-plantar injection into the right hind paw as described above. 
Measurements of paw thickness were taken at sequential time points or in vivo optical 
imaging was performed at 2, 8 and 24 hours as per the protocol described in Section 
2.7. 
2.6 Histopathological Evaluation of Arthritis 
2.6.1 Haematoxylin and Eosin (H&E) Specimen Preparation 
At the end of an experiment, paws were dissected post-mortem and fixed overnight at 
4ºC in 1% phosphate buffered PFA. Paws were then decalcified in a 0.3M EDTA 
solution for 12-14 days. Placing the slides in standard histology cassettes and an 
excess of EDTA ensured an adequate volume and circulation of the decalcificant. 
Decalcificant was intermittently manually agitated and changed on two occasions. In 
order to further facilitate the decalcification process, paws were sagitally divided to 
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the proximal metatarsal joint. X-ray analysis performed between days 7 and 14 to 
monitor the progress of decalcification was performed to ensure that decalcification 
was complete so that cutting can be optimized as shown in Figure 2-5. Decalcification 
of the inflamed mouse paws is necessary for subsequent cutting of the specimens. If 
calcified bone remains in the tissue it will splinter and fracture when cut on the 
microtome. Tissue blocks were sectioned to 4 μm thicknesses using a microtome. The 
tissue sections were allowed to adhere onto Snowcoat X-tra glass microscope slides 
(Surgipath, Peterborough, UK) and stained using Mayer’s modification of Harris 
haematoxylin and eosin method. Used with a mordant, haematoxylin stains nuclei 
blue. Eosin is used to counterstain other cellular components red-pink. For the 
staining, tissue sections were first deparaffinised in xylene and re-hydrated in absolute 
alcohol. After washing in distilled water, sections were stained in Harris haematoxylin 
solution for 3 minutes. Excess stain was washed away with water, and the staining 
differentiated in 1% acid alcohol for 30 seconds. Following washing in water, sections 
were dipped into 0.2% ammonia water for 30 seconds for blueing the haematoxylin 
dye. Sections were washed in water and counterstained in eosin solution for 30 
seconds. Slides were washed with water, dehydrated through 95% and absolute 
alcohol. Before the tissue sections were mounted with xylene based mounting 
medium, they were cleared with xylene. The stained sections were assessed 
microscopically to evaluate arthritic changes in the tibia tarsus joint (TTJ), 
metatarsophalangeal joint, proximal phalangeal joint (PPJ) and the distal phalangeal 
joint (DPJ). Images were captured with a digital camera (ProgRes CF Scan, Jenoptik, 
Jena, Germany) connected to an Olympus BH-2 microscope (Olympus, Tokyo, Japan) 
and analysed using (ProgRes Capture Pro camera control software, version 2.11 
Jenoptik, Germany).  
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Figure 2-5 Decalcification of mouse paws 
X-ray analysis of mouse paws at days 7, 9 and 14 (panels a,b,c) to monitor the progress of 
decalcification. X-ray analysis at 7 days shows significant areas of calcification (arrow) within the 
tarsal bones of the mouse paw that had resolved by day 14 (c). 
 
2.6.2 Immunohistochemistry for Vascular Markers of Inflammation 
In preliminary studies, arthritic mouse paw sections were utilized to examine the 
expression of E-selectin. These were used to determine an optimum protocol for i) 
fixation, and ii) decalcification to optimize antigen preservation. Prior experience with 
these techniques has shown that preservation of antigenicity has been very difficult to 
maintain during the fixation and decalcification process. My work in this area has 
enabled the formulation of a novel and reproducible protocol for subsequent time-
course experiments facilitating reproducible immunohistochemistry for analysis of 
paw sections in the CIA model. The following conclusions were reached regarding 
fixation: Frozen, unfixed specimens demonstrated positive staining with anti-E-
selectin antibody compared to a negative control (no primary antibody), but there was 
poor overall preservation of tissue architecture. Fixation with formaldehyde did not 
preserve of antigenicity. Antigenicity was preserved with the use of 1% PFA in frozen 
sections. Antigenicity was not preserved in paraffin embedded sections.  
Following decalcification as described above, tissue blocks were mounted onto a cork 
disc embedded in an optimum cutting temperature glycol resin, snap frozen in 
isopentane suspended in a bath of liquid nitrogen, cut to a width of 4µm on a cryostat 
a) b) c)
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(Leica CM 1900) with a tungsten carbide blade, picked up onto glass microscope 
slides (Menzel-glaser superfrost plus) and finally specimens were bonded onto the 
slides by heating in an oven for 2 hours at 37°C. (Initial specimens demonstrated poor 
adherence to the slide, but fixed specimens which were heat bonded onto specialised 
slides for frozen sections showed improved adherence). The complete protocol for 
preparation of specimens is shown in Appendix 2.1. Briefly, slides were blocked with 
10% normal rat serum (Vector, Peterborough, UK) before addition of anti-E-selectin 
or anti-DNP antibodies (10µg/ml) or anti- CD31 (MEC 13.3; BD Pharmingen, 
Oxford, UK) (diluted 1:400), followed by 0.5g/ml biotinylated rabbit anti-rat 
antibody (Vector, Peterborough, UK), avidin-biotin-peroxidase complexes and 3,3'-
diaminobenzidine (Vector, Peterborough, UK) solution. Finally slides were 
counterstained with Harris Haematoxylin (Sigma-Aldrich, Poole, UK).  
2.6.3 Detection Of In Vivo Injected E-Selectin Antibody by 
Immunohistochemistry In Ex Vivo Specimens 
In order to determine whether i.v. injected E-selectin tracks to the inflamed synovium 
of the arthritic joint where E-selectin expression has been demonstrated histologically, 
mice with severe arthritis (>day 10) were injected with 50ug of either anti-E-selectin 
or anti-DNP antibody (n=3) per group at time points of 1,4 and 24 hours. Following 
injection the mice were sacrificed and paws were then fixed and prepared (as 
described in Section 2.6.2 in paraformaldehyde, decalcified in EDTA and snap frozen 
in the same way as for previous optimized specimen preparation. For the staining 
protocol slides were blocked with 10% normal rat serum (Vector, Peterborough, UK) 
followed by 0.5g/ml biotinylated rabbit anti-rat antibody (Vector, Peterborough, 
UK), avidin-biotin-peroxidase complexes and 3,3'-diaminobenzidine (Vector, 
Peterborough, UK) solution. Finally slides were counterstained with Harris 
Haematoxylin (Sigma-Aldrich, Poole, UK).  
2.7 In Vivo Optical Imaging 
The following relates to general details regarding preparation of mice for in vivo 
imaging and principles of image capture. An appropriate anaesthetic regime using 
isofluorane has been utilized to ensure mice can be imaged in vivo for multiple time 
points and prolonged periods. The anaesthetic circuit for the Kodak imager has been 
redesigned for effective and safe anaesthetic use. It was necessary to design and build 
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an oxygen/gas delivery circuit that effectively balances administration of anaesthetic 
gases as well as safely scavenged used or excess anaesthetic gas. The circuit is housed 
within the pre-existing imaging box and is capable of regulating the supply of 
anaesthetic gas for up to three animals. It is also capable of providing a warm air 
supply for prolonged anaesthesia as demonstrated in the following Figure 2-6. 
  
 
Figure 2-6 Anaesthetic device for small animal imaging 
Images of prototype design for (a) anaesthetic housing and (b) animals anesthetised prior to fluorescent 
imaging. Isofluorane and Oxygen is delivered and scavenged via nose cones (as indicated by arrows). 
Multiple animals (n=3) animals can be imaged at any one time point and positioning of animals can be 
reproduced for sequential imaging studies. 
 
Mice were injected with either control or anti-E-selectin antibody conjugated with 
Thermofisher DyLight 750 NIR dye (5-50 µg) via the tail vein. For imaging they were 
then anaesthetised with a mixture of isofluorane (2-3%) and Oxygen (2-4l/min). 
Optical imaging was performed using the Kodak Multispectral FX Pro fluorescence 
reflectance imaging device (Carestream Molecular Imaging, Rochester, USA) as 
described above. Filters for excitation and emission were set to 730nm and 770nm 
a)
b)
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respectively. An identical imaging protocol (exposure time: 60 seconds, 4x binning, f-
stop: 2.51, field of view: 158.5, focal plane: 9.4mm) was maintained for all images. 
When required comparative X-ray images were taken using the following image 
settings: (exposure time: 20 seconds, 4xbinning, f-stop: 2.51 field of view: 158.5, 
focal plane 9.4mm) 
Images were analysed using the Kodak Molecular Imaging software program 
(Version 5.0, Carestream Molecular Imaging, Rochester, USA). A region of interest 
(ROI) created by an automated tool was determined around the inflamed or control 
paw. Mean ROI signal intensities are expressed as arbitrary fluorescent signal 
intensity units. Fluorescence gray scale images were artificially coloured for depiction 
purposes according to a colour scale set to the highest and lowest levels of mean 
fluorescence intensity (red and purple indicate maximum and minimum light intensity 
respectively). The fluorescence images were co-registered onto X-ray images taken 
concurrently, when anatomical localisation was required. 
2.7.1 Determination of Optimum Excitation/Emission Wavelength of 
Fluorescent Dye for Excitation for In Vivo Imaging by Measurement of 
Autofluorescence 
To determine the peak levels of autofluorescence a live DBA/1 mouse was 
anaesthetised and imaged according to protocols described in Section 2.7. Images 
were taken at sequential excitation wavelengths between 390-770nm, and the 
resulting Autofluorescence emitted read between 535-830nm, using the Kodak In 
Vivo FX Pro imaging system. 
2.8 Statistical Analysis 
Results were expressed as mean ± SEM. Data were analysed using, 1- and 2-way 
analysis of variance (ANOVA) with Bonferroni post-hoc analysis, or Students t-test. 
P-values of less than 0.05 were considered to be statistically significant. Data were 
analysed using GraphPad Prism 5.0 (Graph Pad Software, CA, USA). 
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Appendices 
Appendix 2.1 Staining protocol for E-selectin, CD-31, and DNP antibodies 
1. Slides placed in 37°C oven for two hours to optimize adhesion to the slide 
2. Fix in acetone for 5 minutes 
3. Air dry slides for ½ min. DO NOT LET SLIDES DRY AFTER THIS STEP. 
4. Wash in PBS/TBS gently tip off and discard (subsequently referred to as 
‘wash’) 
5. Block with 10% normal serum/PBS/TBS for 60 minutes at room temperature 
(RT). Normal serum is the serum of the species that the secondary biotinylated 
antibody is raised in. Use heat-inactivated serum, in this case rabbit serum. 
6. Wash 
7. Block with Avidin solution undiluted for 15 minutes at RT in moist chamber 
(Vector Blocking Kit- Catalog No. SP2001). 
8. Wash 
9. Block with biotin solution undiluted for 15 minutes at RT in moist chamber 
(Vector Blocking Kit). 
10. Wash 
11. Add primary antibody (200µl per slide) (working antibody concentration of 
10µg/ml) Incubate for 45 minutes at RT in moist chamber. 
12. Wash in PBS for 5 min. 
13. Incubate with secondary antibody (rabbit-anti rat) biotinylated for 40 minutes 
at RT in a moist chamber. Dilute this antibody 1:100 with PBS/TBS to which 
normal serum from the species that the tissue is from has been added at 2%. 
14. (When working with mouse tissue, make sure that the secondary antibody is 
not absorbed against rabbit because you get more unspecific staining for 
unknown reasons). 
15. Prepare the ABC complexes at this stage. Use Vector’s ABC-Elite-Standard 
Kit for Peroxidase (Vector Catal. No. PK6100). To 100l of PBS add 1 l 
solution A (Avidin) from the kit and mix well. Then quickly add 1l of 
solution B (Biotin-Peroxidase) from the kit and mix well. Let stand 30 minutes 
for the complexes to form and it is ready to be used. If it stands a little longer 
it is OK but not less than ½ hour. MAKE SURE TO USE DIFFERENT 
PIPETTE TIPS FOR SOLUTION A and SOLUTION B. 
16. Wash 
17. Inactivate slides for endogenous peroxidase by incubating them for 15 minutes 
in 0.3% hydrogen peroxide/PBS/TBS at RT. 
18. Wash 
19. Incubate with the ABC complexes prepared for 40 minutes at RT in a moist 
chamber. 
20. Prepare Vector DAB: As per kit (4 drops buffer, 8 drops DAB, 4 drops 
hydrogen peroxide substrate in 10mls distilled water) 
21. Wash 
22. Incubate in DAB solution for 4 minutes 
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23. Wash in PBS for 5 min. 
24. Counterstain with Harris Haematoxylin for 1minute, differentiate in i) 0.5% 
acid/alcohol ii)wash tap water until nuclei blue 
25. Dehydrate in graded alcohol baths (automated) – 70%/90%/absolute/absolute 
26. Clear with 3 baths of xylene 
27. Slides mounted with surgipath coverslips and pertex xylene based mountant 
on Leica CV5000 automated coverslipper 
28. Personal protective clothing and safety equipment to be used throughout all 
procedures. 
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Appendix 2.2 Procedure for Labelling Proteins with DyLight Fluorophores 
(Thermofisher technologies) 
 
A. Protein Preparation  
Note: When labelling with the DyLight 594 Kit, prepare the protein in PBS. If the 
Borate Buffer has precipitated during storage, solubilize it by warming and vortexing 
the vial.  
 
1. The optimal labelling buffer is 50 mM sodium borate, pH 8.5 (please see note 
above). For best results use 1 mg of protein at ~2 mg/ml. Prepare the protein as 
follows:  
Proteins Lyophilized in PBS: Just before use, prepare the labelling buffer by diluting 
the Borate Buffer (0.67 M) to 0.05 M in PBS or ultrapure water. Prepare only enough 
labelling buffer required for the reaction (for example, to prepare 1 ml, add 75 μl of 
Borate Buffer (0.67 M) to 925 μl of ultrapure water or PBS). Reconstitute 1 mg of 
protein with 0.5 ml of labelling buffer.  
Proteins in PBS Solution: Add 40 μl of the Borate Buffer (0.67 M) to 0.5 ml of 2 
mg/ml protein in PBS. If the protein is > 2 mg/ml, adjust the concentration to 2 mg/ml 
with labelling buffer (for example, 0.05 M sodium borate − see the above bullet point: 
Proteins Lyophilized in PBS).  
Proteins in Other Buffers: Protein must not be in a buffer containing ammonium 
ions or primary amines (for example, Tris or glycine). If necessary, replace buffer 
with 50 mM sodium borate (Product No. 28384), pH 8.5 by dialysis or buffer 
exchange.  
 
B. Protein Labelling  
1. Tap the bottom of the DyLight Reagent vial against a hard surface to ensure the 
dye is in the bottom of the tube. Add 0.5 mls of the prepared protein to the vial of 
DyLight Reagent and vortex gently or invert 10 times.  
2. Briefly centrifuge the vial to collect the sample in the bottom of the tube.  
3. Incubate the reaction mixture for 60 minutes at room temperature protected from 
light.  
 
C. Protein Purification  
1. Place two spin columns in two microcentrifuge collection tubes.  
2. Mix the Purification Resin to ensure uniform suspension and add 400 μl of the 
suspension into both spin columns. Centrifuge for 45 seconds at ~1,000 × g to 
remove the storage solution. Discard the used collection tubes and place the 
columns in new collection tubes.  
3. Add 250-270 μl of the labelling reaction to each spin column and mix the sample 
with the resin by pipetting up and down or briefly vortexing.  
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4. Centrifuge columns for 45 seconds at ~1,000 × g to collect the purified proteins. 
Combine the samples from both columns (~0.5 mls total). Discard the used 
columns.  
5. Store the labeled protein protected from light at 4°C for up to one month. 
Alternatively, store labeled protein in single-use aliquots at -20°C. Avoid repeated 
freeze/thaw cycles. If the final concentration of conjugate is < 1 mg/ml, add a 
stabilizing agent, such as bovine serum albumin at 1-10 mg/ml.  
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3 ANTIBODY CHARACTERISATION AND LABELLING 
3.1 Introduction 
A potential molecular target for fluorescent labelling and subsequent imaging in in 
vivo models of inflammation is E-selectin (ELAM-1). It is a 115kDa glycoprotein 
induced on EC in response to pro-inflammatory cytokines involved in RA such as IL-
1 and TNF (Pober, Gimbrone et al. 1986; Wellicome, Thornhill et al. 1990). As 
part of a complex multistep process, selectins promote the initial attachment 
(tethering) and subsequent moving (rolling) of leukocytes on endothelium, where they 
become activated as a result of locally produced chemokines (Springer 1994). Locally 
produced inflammatory mediators and the subsequent up-regulation of adhesion 
molecules at sites of inflammation are key factors in RA pathogenesis (Tak, Taylor et 
al. 1996). The vascular endothelium acts as an interface for the interaction between 
cytokines and cell surface receptors, promoting the recruitment of circulating 
leucocytes to sites of inflammation. The endothelium in RA synovium has been 
demonstrated to express E-selectin (Corkill, Kirkham et al. 1991). Selectin:ligand 
interactions are one of the first to occur during recruitment of circulating leucocytes to 
sites of inflammation. E-selectin has previously been investigated as a molecule for 
tracking inflammation. Scintigraphy utilizing a radiolabelled anti-E-selectin antibody 
has also been used to successfully image synovitis in patients with RA, with a 99m 
Tc-anti-E-selectin-Fab demonstrating improved specificity compared to a 
conventional tracer for bone and joint inflammation, 99mTc-oxidronate (Chapman, 
Jamar et al. 1996; Jamar, Chapman et al. 1997; Jamar, Houssiau et al. 2002). This 
study also demonstrated particular specificity for targeting active joint inflammation 
(Jamar, Houssiau et al. 2002). Decreased endothelial expression and reduced serum 
levels of E-selectin have also been demonstrated in patients with RA treated with anti-
TNF therapy (Paleolog, Hunt et al. 1996; Tak, Taylor et al. 1996). 
Production of functional, uniform E-selectin antibody was a key objective of the early 
work of this project. The work in this chapter aimed to ensure that E-selectin antibody 
which was produced from cell culture could bind to both E-selectin and to TNF-
stimulated EC, after labelling with fluorophore. Furthermore, selection of dye in the 
near infra red (NIR) range also has been demonstrated in other studies to be at an 
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optimal wavelength to delineate specific signal in the animal model. My objective 
was therefore to confirm this in the live animals to be used for both a model of acute 
inflammation, namely the TNF paw injection model, and for CIA, a chronic model 
of inflammatory arthritis. 
Determining and demonstrating that a reproducible labelling technique was also of 
paramount importance prior to commencing in vivo imaging experiments. Prior 
studies have clearly demonstrated that free dye can track to sites of inflammation due 
to increased vessel permeability and this is discussed in detail in introductory section 
1.2.4. Confirmation that free dye had been removed from labelled anti-E-selectin and 
isotype control preparations is therefore presented. 
Image acquisition and the parameters for digital imaging are also explored. Image 
acquisition has been developed in keeping with proprietary protocols for imaging 
fluorescent agents with differing emission and excitation spectra as per the 
manufacturers’ guidance.  
Recording a digital image involves determining an appropriate focal length for 
imaging at particular wavelengths as well as calibrating the camera for artefact due to 
lens refraction. Image capture time may be varied according to brightness of 
fluorescent emission and size of region of interest. Pixel binning may be required to 
increase the sensitivity of image capture. Pixel binning involves the summation of 
detected signal from more than one pixel to one central pixel effectively decreasing 
the resolution of the image. Changing the aperture (f-stop) of the camera is another 
way of either allowing more or less light through the lens and hence to the sensor. 
Allowing more light utilizes a larger surface of lens and hence there is likely to be 
more distortion of light from the lens edges, with the converse being true if the less 
light and the central portion of the lens is used. For in vivo imaging experiments a 
simple protocol has been developed so that both exposure time, pixel binning, focal 
length, aperture, and field of view are kept constant so that images can be compared 
accurately. The parameters of image processing are therefore examined, to ensure a 
reliable method of data collection is employed. A technique was developed to provide 
quantification of digital signal from fluorescent images. This was so that signal 
intensity between selected areas could be determined and longitudinal comparisons 
made of fluorescence signal over time. 
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3.2 Objectives 
i. To demonstrate the adequate production from cell culture of functional 
uniform, anti-E-selectin and matched isotype anti-DNP control antibodies 
ii. To ensure that anti-E-selectin antibody could bind to both E-selectin and to 
TNFstimulated EC before and after labelling with fluorophore 
iii. To determine a reproducible fluorescent dye labelling technique with 
satisfactory dye:protein ratios and with exclusion of free dye from the sample 
iv. To demonstrate that imaging in the NIR spectrum optimises target fluorescent 
signal intensity 
v. To delineate the parameters of image quantification from the digital imaging 
device 
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3.3 Results 
3.3.1 Determining Purity of Antibody By SDS PAGE Prior to Labelling 
The purity of anti-E-selectin and anti-DNP antibodies obtained from cell culture was 
determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS 
PAGE). This demonstrated that both anti-E-selectin antibody and control anti-DNP 
antibody show major bands at 100-150kDa (G9 and G10 respectively), and at 
approximately 50kDa (H5 and H6) and 25kDa (H9 and H10) as demonstrated in 
Figure 3-1a. These are most likely to correspond to immunoglobulin heavy and light 
chain fragments. Analysis of the bands was then performed by mass spectroscopy. 
This confirmed the identity of the major bands (Figure 3-2). The minor bands are 
likely to be albumin (F9 and F10), that had been carried over from the purification 
process. It is possible to generate other sizes of immunoglobulin fragments if cell 
culture conditions are not carefully regulated. This may in turn have implications for 
the efficiency of antibody labelling and hence ability of the labelled antibody to target 
E-selectin expression on activated EC in vivo. If for example there were significant 
amounts of albumin contaminating the sample, this could non-specifically track to 
sites of inflammation due to local permeability changes. 
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Figure 3-1 Purity of anti-E-selectin and anti-DNP antibodies produced from cell 
culture 
Purity of antibodies was confirmed by gel protein electrophoresis (NuPAGE Novex Bis-Tris Mini Gel, 
Invitrogen, Renfrew, UK) followed by Coomasie stain. The left hand section of the gel is a molecular 
weight standard (MW), with subsequent lanes for anti-E-selectin antibody and anti-DNP antibody 
respectively. The following Figure 3-2 demonstrates the corresponding mass spectometry readouts for 
the various gel bands. 
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Figure 3-2 Summary of immunoglobulin components identified by mass 
spectroscopy 
Sections of gel were cut out from gel protein electrophoresis (NuPAGE Novex Bis-Tris Mini Gel, 
Invitrogen, Renfrew, UK) The corresponding mass spectrometry (Waters Micromass Xevo QTof, 
Milford, Massachusetts, USA) readouts for the various gel bands as shown in Figure 3-1 are displayed.  
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3.3.2 Imaging in the Near Infrared Spectrum Leads to Reduced Levels of 
Autofluorescence in A Live Mouse 
This preliminary investigation was performed to ensure that imaging in the NIR was 
optimal in order to decrease levels of autofluorescence in the live strain of mouse 
chosen for in vivo experiments. This would then maximise measurable signal from 
targeted fluorescence to sites of inflammation compared to background signal (i.e. 
increase signal specificity). A healthy DBA/1 mouse was anaesthetised and imaged at 
sequential emission and excitation wavelengths from 400-800nm. This confirmed that 
peak autofluorescence levels were measured at lower wavelengths (500-60nm) with 
minimal autofluorescence in the NIR range (700 to 800nm). A representative example 
of imaging at both low (below the NIR range) and higher wavelengths (within the 
NIR range) is demonstrated in Figure 3-3 (a) and (b) respectively. A graph of 
autofluorescence throughout the range of wavelengths from 400 to 800nm is shown in 
Figure 3-4. This confirmed that fluorophores working in the yellow hashed area 
would not be subject to the autofluorescence interference that is measured at lower 
wavelengths. The following sections detail the in vitro and in vivo characterisation of 
anti-E-selectin and control antibodies labelled with NIR fluorescent dye. 
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Figure 3-3 Visual representation of autofluorescence from a live DBA/1 mouse 
A live DBA/1 mouse was anaesthetised and images obtained of (a) autofluorescent emission (535nm) 
following light excitation at (390nm) and (b) autofluorescent emission within the autofluorescent range 
(730nm) following excitation (750nm), using the Kodak In Vivo FX Pro imaging system. 
 
Figure 3-4 Autofluorescence in a live DBA/1 mouse 
A live DBA/1 mouse was anaesthetised and images obtained of autofluorescent emission (535-830nm) 
following light excitation between 390-770 nm, and the resulting autofluorescence read between 535-
830 nm, using the Kodak In Vivo FX Pro imaging system. 
a) b)
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3.3.3 Dye/Protein Binding: Ratio of Absorbance At 280 And 750nm 
Following conjugation of antibodies to the Thermofisher Dylight 750nm 
fluorochrome as detailed in Section 2.4.5, it was necessary to firstly ensure that there 
was absorbance corresponding to the peak absorbance/fluorescence of the dye at 
750nm (i.e. within the NIR range required for in vivo imaging). Secondly, it was 
important to determine that the dye-protein ratio was within the range to allow 
adequate emission of the dye for in vivo imaging. Over-labelling of the dye can cause 
quenching of fluorescent signal because one fluorescent molecule will absorb light 
from an adjacent one, this is termed auto quenching. Thirdly, I aimed to test the 
reliability of consecutive labelling reactions to ensure that control and anti-E-selectin 
antibodies were comparably labelled. This was to ensure that there could be accurate 
quantification of fluorescent signal in relation to known antibody concentration for in 
vivo imaging experiments. Furthermore, this ensured there could be a comparison 
between experiments conducted with batches of antibody from labelling reactions 
performed at different time points. Following labelling it is recognised that over time 
there is a relative decrease in fluorophore intensity following excitation. The rate of 
this degradation was not measured in the present study, but rather fresh batches of 
antibody were made and tested for dye protein ratios and the efficacy of antibody 
binding quantified by ELISA as described below. Relative absorbance was measured 
at a range of wavelengths from 220nm to 800nm, as shown in Figure 3-5a to 
determine the A280 and Amax of the protein/dye conjugate at 750nm. Dye:protein 
ratios were 1.65 and 1.93 mols of dye per mol of protein for anti-E-selectin and anti-
DNP antibodies respectively as measured for three separate labelling reactions, based 
on the ratio between the absorbance at 750nm and 280nm (Figure 3-5b). I found some 
degree of variation in the use of absorbance calculations to measure either protein 
concentration (A280) or to measure the absorbance of fluorophores at higher 
wavelength following conjugation with antibody. In order to ensure that an accurate 
amount of antibody was both used for fluorophore labelling and then subsequently 
injected during in vivo experiments, a BCA protein assay was used to determine 
accurate protein concentration measurements prior to labelling. 
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Figure 3-5 Dye protein binding: ratio of absorbance at 280nm and 750nm 
Panel (a) shows typical absorbance spectra of both anti-E-selectin and anti-DNP Thermofisher Dylight 
750nm dye labelled antibodies at wavelengths from 200 to 800nm, showing comparable absorbance 
and relative ratio of absorbance at 280nm versus the peak of dye absorbance at 750nm. Panel (b) 
demonstrates that the absorbance ratios (ratio of absorbance at 750nm/280nm) have remained 
consistent over three labelling reactions. 
Further purification steps were also undertaken to ensure that the above measurements 
did not include absorbance from dye at 750nm that was unbound to antibody (i.e. that 
the labelling reaction had not been complete and there was free dye in the sample). 
This is especially important because it is recognised that free dye may track to sites of 
both acute and chronic inflammation due to changes in vascular permeability (as 
discussed in Section 1.2.4). Specimen samples were dialysed against PBS. Figure 3-6 
illustrates that pre- and post-dialysis samples exhibit comparable absorbance 
characteristics. This suggests that excess free dye was not contributing to the small 
difference in absorbance between DNP and E-selectin antibodies observed in Figure 
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3-5, and that there was not free dye in the samples. Further absorbance spectroscopy 
on the dialysate also confirmed no absorbance (i.e. no free dye had been dialysed 
from the sample). In a separate preliminary experiment both samples were also 
subjected to further centrifugation using a molecular weight cut-off spin column and 
this also confirmed that there was no fluorescence in the lysate, confirming that all 
dye in the sample was bound to antibody and could therefore not pass through the 
spin column (data not shown).  
 
 
 
 
 
 
 
 
 
Figure 3-6 Dye protein ratio following dialysis 
The absorbance of both anti-E-selectin and anti-DNP Thermofisher Dylight 750nm dye labelled 
antibodies were measured before and after dialysis. 
 
Taken together these experiments have demonstrated that using a commercially well 
validated labelling technique for antibody conjugation to a NIR fluorophore had taken 
place effectively with a satisfactory number of dye molecules per antibody and that 
free dye had been removed effectively from the sample. 
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3.3.4 Characterisation of Anti-E-Selectin Antibody Binding 
3.3.4.1 ELISA following fluorophore conjugation 
The specificity of dye labelled anti-E-selectin antibody binding to E-selectin coated 
ELISA plates was subsequently assessed. This was to ensure that fluorophore 
conjugation had not altered the binding properties of the anti-E-selectin antibody. This 
was compared to that of a commercially available anti-E-selectin antibody as 
demonstrated in Figure 3-7. There were slight increases in binding efficacy following 
conjugation. This might be due to small differences in the calculated concentration of 
the dye antibody conjugate following conjugation. Secondly, there may also be a 
small contribution from the fluorophore to the optical reading taken at the end of the 
ELISA, which was not corrected for during the calculation of binding efficacy for the 
dye antibody conjugate. The contribution from the fluorophore is likely to very small, 
as confirmed from the minimal relative absorbance at 450nm from the conjugate 
demonstrated in Figure 3-5. Furthermore this experiment confirmed that control anti-
DNP antibody failed to bind recombinant murine E-selectin. This process was also 
repeated on further batches of antibody to confirm similar levels of immunoreactivity 
of cultured antibodies prior to use for in vivo imaging experiments. This ensured that 
the antibody production technique had produced antibody of consistent efficacy and 
that there had not been any degradation of antibody efficacy following storage after 
production. 
 
 
 
 
 
Figure 3-7 Anti-E-selectin antibody binding before and after fluorophore labelling 
Anti-E-selectin or isotype control (anti-DNP) antibodies were added at a concentration of 2ng/ml to 
plates pre-coated with recombinant mouse E-selectin (3μg/ml). Binding was compared before and after 
labelling with Dylight 750 nm near infrared fluorophore, and quantified using a standard curve of 
commercial anti-mouse E-selectin antibody. Dashed line shows PBS (background control). 
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3.3.4.2 Binding to mouse PY4.1 endothelial cell line following TNF stimulation 
To confirm that anti-E-selectin antibody bound effectively to activated endothelium, 
as a pre-requisite to in vivo imaging studies in models of inflammation, murine PY4.1 
EC were incubated in the absence or presence of TNF. This experiment showed that 
anti-DNP antibody did not bind to activated PY4.1 cells, in contrast to anti-E-selectin 
antibody, which demonstrated significantly increased binding following TNF 
treatment of PY4.1 as shown in Figure 3-8 
 
 
 
 
 
 
 
 
Figure 3-8 Anti-E-selectin binding to endothelial cells following stimulation with 
TNF 
Mouse PY4.1 endothelial cells were stimulated in the absence or presence of recombinant murine 
TNF (10ng/ml for 5 hours). Cells were incubated with either anti-E-selectin or isotype control (anti-
DNP) antibodies (0.2μg/ml and 2μg/ml) and binding was quantified colourimetrically. Dashed line 
shows binding of secondary antibody only. Data are mean ± SD, and were analysed by 1-way ANOVA 
versus unstimulated PY4.1 cells: *** p<0.001, ns = not significant. 
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The effect of increasing the TNF dose on anti-E-selectin antibody binding to 
stimulated EC is shown in Figure 3-9. At the two doses used here there was no 
difference in the binding of anti-E-selectin. Other experiments with lower doses of 
TNF stimulation, for both the same and longer periods (5 and 24 hours) did not 
demonstrate increased binding of anti-E-selectin antibody (not shown) 
It is interesting to note that there was a degree of anti-E-selectin antibody binding to 
unstimulated cells. The cell culture is not serum starved and therefore increased levels 
of cytokine expression (which might stimulate E-selectin) maybe expected. Equally it 
is possible that PY4,1 cells express E-selectin ‘constitutively’.  
 
 
 
 
 
 
 
Figure 3-9 Comparison of E-selectin binding at different doses of TNF  
Mouse PY4.1 endothelial cells were stimulated in the presence of recombinant murine TNF (10ng/ml 
or 100ng/ml for 5 hours). Cells were incubated with either anti-E-selectin antibody (2μg/ml) and 
binding was quantified colourimetrically. Data are mean ± SD, and were analysed by 1-way ANOVA 
versus unstimulated PY4.1 cells: *** p<0.001, ns = not significant. 
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Images of EC following stimulation with TNF and binding of anti-E-selectin 
antibody were also taken. This was achieved by applying an Alexa Fluor® 488 
streptavidin conjugate following application of the biotinylated rabbit anti-rat 
secondary antibody. A DAPI nuclear counterstain was used to delineate individual 
cells as demonstrated in Figure 3-10. 
.  
Chapter 3 
104 
  
Anti-DNP 
 
Anti-E-Selectin 
 
 
Figure 3-10  Fluorescent imaging of endothelial cells expressing E-selectin 
Representative fluorescence images of either anti-DNP or anti-E-selectin stained PY4.1 cells incubated 
in the absence (a,c) or presence (b,d and c,e) of TNF followed by secondary detection with 
biotinylated rabbit anti-rat IgGa and then by streptavidin Alexa Fluor 488 with DAPI nuclear counter 
stain. Magnified images of anti-DNP (c) and anti-selectin (f) antibody stained cells as demonstrated by 
hashed boxes. 
(a)
(b)
(c)
(d)
(e)
(f)
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3.3.5 Visualisation and quantification of Fluorescent Signal Using Fluorescent 
Reflectance Imaging 
Preliminary experiments were performed using the Kodak fluorescence reflectance 
imaging device. This was firstly to understand clearly the visual representation of 
fluorescent signal following acquisition of a digital image and, secondly, ensure 
accurate quantification of fluorescent emission from the dye antibody conjugate to 
enable meaningful analysis of in vivo fluorescence imaging. This would also 
determine the detection limits of the device for differentiating between control and 
targeted fluorescent antibody signal. This was undertaken by imaging a 96 well plate 
with serial dilutions of both dye labelled antibodies (unbound to any particular target 
antigen). Identical settings were used for imaging (exposure time: 60 seconds, 4x 
binning, f-stop: 2.51, field of view: 158.5mm, focal plane: 9.4mm). Visual 
representation of the image is demonstrated in Figure 3-11. 
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Figure 3-11 Visualisation of fluorescent signal using fluorescent reflectance 
imaging 
Figure demonstrates the fluorescent image obtained after placing a 96 well plate containing dye 
labelled E-selectin (wells A-C) or DNP (wells D-F) antibody conjugate in 1:2 serial dilutions with a 
highest concentration of 12.5μg/ml and lowest of 0.2μg/ml (1-6). The same plate is shown in panels (i-
iii) but the image settings have been changed. Panel i) is a grayscale image, ii) following application of 
a colour wheel and iii) demonstrating the effect of narrowing the range of colour used to depict 
different fluorescence intensities. The following imaging protocol was used: (exposure time: 60 
seconds, 4x binning, f-stop: 2.51, field of view: 158.5, focal plane: 9.4mm). Fluorescence gray scale 
images were artificially coloured for depiction purposes according to a colour scale set to the highest 
and lowest levels of mean fluorescence intensity (red and purple indicate maximum and minimum light 
intensity respectively). MFI=Mean fluorescence intensity. 
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500 (MFI) 10000 (MFI)
A
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The fluorescence of the anti-E-selectin and DNP dye labelled conjugate relative to the 
concentration of antibody using the Kodak fluorescence reflectance imaging device 
was then determined by measuring the mean fluorescence intensity (MFI) of each 
well taken from the digital images depicted in Figure 3-11. It is important to note that 
the underlying measurement of MFI expressed as arbitrary units will remain constant. 
This is irrespective of whether the image had been adjusted for either grayscale or 
colour, or whether the colour wheel has been changed to represent a narrower range 
of mean fluorescence intensity as depicted in Figure 3-11(iii). 
 
 
 
 
 
 
 
Figure 3-12 Quantification of fluorescent signal using fluorescent reflectance 
imaging 
Figure demonstrates results of quantifying fluorescent images obtained after placing a 96 well plate 
containing dye labelled anti-E-selectin or control antibody diluted in serial 1:2 dilutions with a highest 
concentration of 12.5μg/ml and lowest of 0.2μg/ml. This shows a linear relationship for both samples 
taken under the following settings: (Exposure time: 60 seconds, 4x binning, f-stop: 2.51, field of view: 
158.5, focal plane: 9.4mm). Regions of fluorescence were quantified by taking a mean fluorescence 
signal level from a circular area around each well. 
 
The above figure demonstrates that the concentration of dye antibody conjugate 
versus MFI was identical for both anti-DNP and E-selectin antibodies and that there 
was a linear relationship between the concentration of either dye antibody conjugate 
and emitted MFI following excitation at 730nm and measured emission at 770nm. 
This data also delineates a threshold for detection of fluorophore dye/antibody 
conjugate with the current image settings. The minimal concentration of 
antibody/fluorescence conjugate used is 19.53ng/ml and this returned a MFI signal of 
148.1 arbitrary units (au). This is well within the range of error for mapping 
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fluorescent images, particularly in the inflamed mouse paw as discussed in Section 
3.3.6. Care was therefore taken to ensure that the parameters for imaging were kept 
constant for future experiments in vivo imaging experiments for accurate comparison 
of datasets.  
 
3.3.6 Mapping Fluorescence Levels in Paw Inflammation: Using A ROI Tool to 
Accurately Quantify Signal 
Following the in vitro studies described above, a technique was required that could 
reliably sample and quantify the degree of fluorescent signal within mouse paws in 
vivo. Selecting a circular region of interest is an appropriate technique for quantifying 
signal from a fixed, uniform source of emission such as from an ELISA plate as 
depicted in Figure 3-12. Signal from an irregular, variably sized paw where signal 
may be homogenous may require a different technique. Placement of a circular region 
of interest (ROI) could either under or over estimate fluorescence signal intensity 
depending on positioning and may also be affected by bias. Sequential circular, fixed 
regions of interest were compared to applying regions of interest using a mapping tool 
(Figure 3-13(i)). The latter technique maps a line to the point of maximal difference 
between an area of increased signal intensity and lower levels as depicted in Figure 
3-13(ii), in mice injected with TNF into the right paw. When quantifying signal the 
intensity of light emission from each pixel can either be expressed as a mean or net 
amount (with background levels of fluorescence subtracted). Figure 3-13(iii) 
demonstrates that both mean and net scores return a similar distribution of signal 
when taking a region of interest of the whole paw for analysis. While there may be, a 
degree of variable signal throughout a mouse paw due to increases in signal from 
isolated areas of E-selectin expression due vascular activation the overall value for 
each paw has been used. The resolution of fluorescent imaging device may not be 
sufficient to delineate changes in specific areas of the mouse joint such as individual 
metatarsal joints which measure ~0.1mm. In addition since there is no method to 
determine the depth of tissue from which fluorescent signal is emitted from accurate 
comparisons between groups would be problematic. 
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Figure 3-13 Techniques for mapping fluorescent intensity levels in paw 
inflammation 
Representative images taken following injection of anti-E-selectin antibodies labelled with Dylight 750 
nm Near Infra Red fluorophore (50μg i.v.). Paw swelling was induced by the intraplantar injection of 
murine TNF (50ng) into the right paw. Panel (i) depicts images of measuring pixel intensity by a 
fixed circular ROI (a) and using an automated mapping tool (b). All readings were taken from a single 
inflamed paw. Panel (ii) shows the quantification of mean fluorescence intensity by using either the 
ROI tool or by using a fixed ROI. (iii) Mean and Net scores are represented from 5 mice with inflamed 
paws at 8 hours following injection of TNF into the footpad. The mean score is calculated by taking 
the mean of the fluorescent signal returned from all pixels within the ROI. The net score is the total of 
the fluorescent signal returned from all pixels intensity signal with a mean of the ROI perimeter 
subtracted. Mean ± SEM are indicated. 
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3.4 Discussion 
My objectives in this chapter were to demonstrate that both anti-E-selectin and DNP 
isotype control antibodies can be reproducibly produced from cell culture. My second 
objective was ensure that that labelling with a NIR dye had resulted in satisfactory 
dye to target ratios and that free dye has been removed from the resulting conjugate. I 
have ascertained that anti-E-selectin antibody can bind to both E-selectin and to 
TNF stimulated EC. Finally the parameters and potential method of quantifying 
fluorescent images have been explored. NIR imaging at wavelengths of 700-800nm in 
a DBA/1 mouse model is optimal to ensure auto fluorescent signal returned from 
tissue is minimised. The increase in signal seen at lower wavelengths is due to 
fluorescent emission from primarily deoxygenated and oxygenated haemoglobin 
(Weissleder and Ntziachristos 2003). This observation has important implications for 
assessing the overall sensitivity of FRI to delineate a specific molecular target. Higher 
background autofluorescence levels would significantly decrease the sensitivity of the 
system (i.e. the ability to detect a minimal amount of fluorescence signal returned 
from a specific molecular target). 
I have confirmed that a NIR fluorophore can be bound to both anti-DNP and E-
selectin antibodies reproducibly and that an appropriate ratio of fluorophore to 
antibody can be achieved. This is vital to ensure that the bound fluorescently labelled 
antibody will return adequate brightness following illumination for it to emit signal 
that can be detected externally by the fluorescent reflectance imaging device. Over-
labelling of the antibody can cause auto quenching of the conjugate and hence 
decrease fluorescence levels. While it is clearly paramount that the optical conjugate 
is as bright as possible it is also interesting to note that it appears from the images of 
EC that anti-E-selectin antibody is rapidly internalised and can be visualised within 
the cells as discrete areas of increased fluorescence. If for example the conjugate was 
internalised and then the fluorophore could be engineered to dissociate from the target 
molecule the fluorescent signal would then increase and this could be an effective 
way of localising the fluorophore to its intended location. This has been explored by 
labelling a monoclonal antibody target with up to 7 fluorophores that were then found 
to dissociate following binding, thereby increasing fluorescence at the intended target 
(Ogawa, Regino et al. 2009). Anti-E-selectin labelled fluorescence labelling does not 
affect epitope recognition. 
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It was then necessary to ensure that the conjugation process had not affected the 
binding of antibody for its intended molecular target. This was confirmed by both 
ELISA and a cell based assay of EC that had been stimulated with TNF. This system 
also helped to confirm the time course of E-selectin expression following stimulation 
with TNF. This is of relevance particularly when investigating the parameters of E-
selectin expression following injection of TNF into the mouse footpad. The time 
course of E-selectin expression also reflects that seen by previous investigators when 
E-selectin is induced on EC in response to pro-inflammatory cytokines involved in 
RA such as interleukin (IL)-1 and TNF(Pober, Gimbrone et al. 1986; Wellicome, 
Thornhill et al. 1990). The analysis of pixel intensities returned from digitised images 
and from labelled E-selectin and DNP antibodies demonstrates a linear relationship 
between antibody/fluorophore concentration and Mean fluorescence intensity. The 
ability to understand clearly both the composition of a digital image and how it may 
be quantified, with a reproducible measuring technique was clearly vital for 
performing quantification when undertaking in vivo imaging experiments. 
The following chapter details how an acute model of inflammation may be used to 
determine the parameters of targeted in vivo fluorescent imaging. The effects of 
TNF injection into the paw are investigated. Increased E-selectin expression is 
demonstrated by immunohistochemistry, and the use of in vivo fluorescent imaging to 
detect specific E-selectin targeted signal is investigated. 
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4 RESULTS: ESTABLISHING AN ACUTE MODEL OF 
INFLAMMATION FOR IN VIVO FLUORESCENCE 
IMAGING 
4.1 Introduction 
In the previous chapter I demonstrated that E-selectin could be targeted by anti-E-
selectin antibody following its conjugation to a NIR fluorophore. Following the ex 
vivo fluorescence imaging described in Section 3.3.5, my subsequent aim was to use 
this conjugate to quantify E-selectin expression by detecting NIR fluorescence in vivo. 
Fluorescence imaging has been used previously to detect arthritis and the ability of 
fluorescence imaging to detect both non-specific uptake of dye to sites of 
inflammation (Hansch, Frey et al. 2004) and also detect antigen targeted dye 
deposition (Hansch, Frey et al. 2004; Chen, Mahmood et al. 2005) is discussed in 
Section 3.3.6. These studies have unpinned the potential use of fluorochrome imaging 
in the NIR for the detection of inflammatory changes in experimental arthritis.  
An acute model of inflammation was required for in vivo imaging studies to 
determine whether E-selectin could be detected early in the inflammatory response, 
prior to exploring the parameters of fluorescence imaging in murine CIA, which is a 
complex model of arthritis characterised by significant heterogeneity in time of onset, 
incidence and disease severity. Therefore, while setting up novel imaging equipment 
and determining the parameters of imaging in vivo, an acute model of inflammation 
would best serve this purpose. This would also ensure that appropriate numbers of 
animals could be used for controls, experiments could be performed quickly and 
efficiently, whilst also minimising animal redundancy because incidence would be 
100%. In my preliminary work (not described in this thesis), I investigated the effect 
of zymosan injections into the mouse paw. This technique is recognised to produce an 
acute, intense inflammatory reaction with severe joint swelling. Prior work by Gado 
and Gigler has investigated this model to explore the parameters of pain pathways. 
The development of these models is discussed in Section 1.4.2. In their experiment, 
the rat paw was injected with 0.1ml of a 2% suspension of zymosan and this caused a 
90% increase in paw volume (Gado and Gigler 1991). My preliminary qualitative 
findings also confirmed that animals develop an intense degree of paw oedema. I 
therefore considered that the modulation of an inflammatory model by a single 
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cytokine may generate a less complex inflammatory process that did not lead to such 
significant levels of oedema. Since TNF is a central regulator in CIA as well as in 
RA, I explored whether this cytokine could be used to develop an acute inflammatory 
response. The role of TNF in CIA was primarily demonstrated by investigating the 
effect of TNF blockade. The abrogation of arthritis in this animal model provided 
the pre-clinical data demonstrating that blockade of TNF was a viable therapeutic 
target for patients with RA (Williams, Inglis et al. 2005). TNF injections into the 
footpad have also been used to investigate mechanisms of hyperalgesia. Prior work on 
this model is discussed in the introductory Section 1.4.2.  
TNF, IL-1 and bacterial lipopolysaccharide all transcriptionally induce the 
expression of E-selectin, an adhesion molecule expressed in RA and the target of the 
antibody characterised in Chapter 3. Work on human endothelioma cell lines has 
shown expression of the protein to reach maximal levels 4-6 hours after stimulation 
with TNF with a decline to basal levels at 12-16 hours (Pober, Lapierre et al. 1987; 
Wellicome, Thornhill et al. 1990). Similar expression kinetics were also shown on 
mouse endothelioma cell lines, with maximal cell surface expression at 4 hours when 
stimulated with TNF (Weller, Isenmann et al. 1992; Hahne, Jager et al. 1993). 
Furthermore, my own results described in Chapter 3 have shown that TNF 
upregulates E-selectin expression in mouse PY4.1 endothelial cells. This therefore 
confirms that the expression kinetics of E-selectin are well suited to investigation with 
an acute inflammatory model. 
A well validated target antibody, labelled to a NIR fluorophore with confirmed 
binding to recombinant E-selectin and to E-selectin expressed on TNF-stimulated 
EC, as well an isotype control antibody, were both now ready. These could be tested 
in an acute model of inflammation to explore the parameters of in vivo imaging, as 
described in Chapter 3. My objective was therefore to investigate the specificity of 
localised antibody binding versus non-specific trafficking to sites of inflammation. By 
utilising the above target and control antibody I aimed to delineate the sensitivity of 
the system (differences between background autofluorescence and dye-labelled 
antibody generated signal intensity); and the specificity of binding (differences 
between anti-E-selectin versus anti-DNP generated fluorescent signal intensity).  
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Finally, a number of different anti-TNF MoAbs have now been shown in clinical 
trials to be effective in patients with severe RA. This mode of therapy for RA is 
discussed in Section 1.1.2. In addition to chimeric or humanised monoclonal 
antibodies that are in clinical use for TNF blockade in RA, various TNF receptor 
based biologics have also been tested and shown to be effective. The most significant 
of these in current clinical use is etanercept, a dimeric TNF receptor type II-Fc fusion 
protein (Moreland, Baumgartner et al. 1997). I have investigated the use of this drug 
to prevent TNF-induced paw swelling and have shown that this can also be detected 
by E-selectin targeted in vivo fluorescent imaging, thereby validating this as an in vivo 
molecular imaging technique. 
4.2 Objectives 
i. To develop a cytokine-mediated acute model of inflammation that has a 100% 
incidence, an acute time course, is dose dependent and reproducible 
ii. To demonstrate that TNF injection into the paw causes increased E-selectin 
expression that can be detected by immunohistochemistry 
iii. To investigate whether TNF injection into the paw causes increased E-
selectin expression that can be detected in vivo by fluorescently labelled anti-
E-selectin antibody 
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4.3 Results 
4.3.1 The TNFInduced Model of Acute Paw Inflammation 
Acute paw swelling caused by local injection of TNF was developed as a 
reproducible acute model of paw inflammation in vivo. This was a prelude to 
exploring the parameters of in vivo fluorescence imaging. While this model has been 
used to investigate the mechanism of pain, and while paw swelling has been 
recognised to be caused by TNF (Cunha, Poole et al. 1992; Woolf, Allchorne et al. 
1997; Campos, Souza et al. 1998), further delineation of the TNF-induced response 
was required to ensure that it was an acute, reproducible, dose dependent model of 
inflammation where increased E-selectin expression could be demonstrated. A 
representative example of paw swelling induced by the intraplantar injection of TNF 
is demonstrated in Figure 4-1. 
 
 
Figure 4-1 Representative example of paw swelling following the intraplantar 
injection of TNF 
Paw swelling was induced by intraplantar injection of murine TNF 50ng into the right mouse paw in 
C57/BL6 mice. A representative image of the right mouse paw at peak paw swelling (4-6 hours) is 
demonstrated. The uninflamed, contralateral, left, uninjected paw is also shown.  
 
This figure demonstrates that following TNF injection the paw is uniformly 
oedematous. Paw swelling was evident on both dorsal and plantar surfaces. Following 
a 50ng injection of TNF, at the 4 hour time-point the mean paw thickness would be 
expected to increase by a mean of 0.4mm from 2.1mm to 2.5mm – an increase of 
19.1% (n=5 animals).  
Left
Right
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4.3.1.1 Measurement of acute paw swelling induced by TNF: a dose dependent 
transient increase in paw thickness 
Injection of between 5 and 100ng of TNF into the mouse right foot-pad produced a 
transient dose-dependent right paw swelling that peaked at 4-6 hours post-injection 
and resolved within 24 hours, with a 100% incidence, thereby reducing animal 
redundancy. Paw swelling was assessed by measuring the maximal thickness between 
the dorsal and planter surfaces of the paw using microcalipers and calculating the 
change in thickness for each inflamed paw as demonstrated in Figure 4-2. This 
experiment confirmed that injection of an identical quantity (10μl) of vehicle (PBS 
with 1% mouse serum) did not produce any swelling of the mouse paw. Following 
injection of TNF (50ng), there was also no evidence of swelling in the contralateral 
left paw (LP); this is investigated in more detail in Figure 4-3. By 24 hours following 
injection of TNF, visible paw swelling had resolved and there was no difference in 
paw thickness compared to time 0. In separate experiments I have also confirmed that 
there were no secondary or biphasic increases in paw swelling at later time-points (not 
shown). 
 
 
 
 
 
 
 
Figure 4-2 TNF induced paw model: paw swelling is dependent on the dose of 
TNF 
Transient paw oedema was induced by intraplantar injection of mouse TNF (5-100ng) into the right 
paw of C57/BL6 mice (n=4-5 per group). Vehicle (PBS) injected-mice were used as a control. Paw 
thickness of the contralateral left paws (LP) of animals injected with TNF (50ng) are also shown. 
Data were analysed by 2-way ANOVA versus vehicle: ** p<0.01, *** p<0.001, ns=not significant. 
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I also investigated whether there were any systemic effects following injection of 
TNF into the right paw, by determining whether there was any contralateral paw 
swelling. At doses of up to 50ng of TNF, no swelling of the left uninjected 
(contralateral) paw occurred (also shown in the experiment illustrated in Figure 4-2), 
although there was transient contralateral paw swelling when 100ng of TNF was 
injected. However, this effect was not statistically significant when compared to 
vehicle-injected mice. This is demonstrated in Figure 4-3, and suggests that this 
concentration of locally injected TNF was having a systemic effect. For future 
experiments it was important to select a dose of TNF that did not produce changes in 
contralateral paw thickness since this paw serves as an internal control for measuring 
mean fluorescence signal as described in the following sections. Subsequent studies 
for in vivo imaging therefore all utilised 50ng TNF to induce paw swelling. 
 
 
 
 
 
 
 
 
Figure 4-3 Demonstration of systemic action of TNF following injection  
Transient paw oedema was induced by intraplantar injection of mouse TNF (5-100ng) into the right 
paw of C57/BL6 mice (n=5 per group). Vehicle (PBS) injected-mice were used as a control. Paw 
thickness of the contralateral left paws (LP) of animals is shown. Data were analysed by 2 way 
ANOVA versus vehicle: ns=not significant. 
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To confirm that anti-E-selectin antibody did not have any effect on paw swelling 
following the injection of TNF (as a pre-requisite to imaging studies), animals were 
pre-injected intra-venously (i.v.) with different quantities of either anti-E-selectin or 
DNP antibodies. The data in Figure 4-4a demonstrate that anti-E-selectin antibody 
does not have a measurable effect on paw thickness at doses of either 5 or 50g, given 
by i.v. injection 1 hour prior to the subsequent intraplantar injection of TNF. Similar 
data were obtained for anti-DNP antibody (Figure 4-4b). 
(a) 
 
 
 
 
 
 
(b) 
 
 
 
 
 
Figure 4-4 Effect of pre-injection of anti-E-selectin on TNF induced paw 
swelling 
Paw swelling was induced by the intraplantar injection of murine TNF 50ng into C57/BL6 mice 
(n=4-5 per group). Mice had been pre-injected with anti-E-selectin antibody (a) or anti-DNP antibody 
(b) at doses of 5 or 50μg (i.v.) 1 hour prior to the induction of paw swelling using TNF. Graph 
demonstrates mean change in paw thickness over time. Data were analysed by 2-way ANOVA versus 
animals not injected with antibody: ns=not significant. 
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4.3.2 Histological Changes in TNF-Induced Paw Inflammation Model 
Histological specimens were also taken at various time-points following the induction 
of inflammation by injection of TNF into the footpad, to study the time-course of 
inflammation and potentially E-selectin expression. Figure 4-5 shows that 4 hours 
after TNF injection, there is a marked inflammatory infiltrate in the footpad, but this 
had resolved by 24 hours. 
 
Figure 4-5 Comparison of paw inflammation in TNF injected and PBS injected 
mouse paws following injection 
C57/BL6 mice were injected with 50ng TNF into the right paw d,e) or uninjected left paw a,b). Paw 
sections were stained using haematoxylin and eosin. Images were taken at x20 magnification. These 
representative images demonstrate that there is no paw inflammation or cellular infiltrate at the base of 
the footpad at 4 hours in the left paw (a,b), whereas TNF induced an inflammatory infiltrate in the 
right paw, as indicated with arrow (d,e). No inflammation was detected in the right paw at 24 hours 
following TNF injection (c,f). 
a)
b)
c)
d)
e)
f)
Chapter 4 
121 
Further specimens were taken at early (2 hours), mid (6 hours) and late 72 (hours) 
time-points to confirm that there was both an influx of inflammatory cells and that 
there was subsequent resolution (data not shown). 
E-selectin expression in the paw oedema model was then explored. This is shown in 
Figure 4-6. This demonstrates that increased binding of anti-E-selectin antibody can 
be detected at 4 hours following injection of TNF into the footpad. Increased 
antibody binding is localised to areas where there has been substantial inflammatory 
infiltrate. This is likely to represent increased E-selectin antibody binding to sites of 
increased E-selectin expression in microvessels where the endothelium is activated 
due to the local injection of TNF. 
 
Figure 4-6 E-selectin expression in the TNF-induced paw oedema model 
Representative histological images of paws harvested 4 hours following induction of paw oedema by 
intraplantar injection of TNF (50ng) in C57/BL6 mice. Serial sections were stained with either anti-E-
selectin antibody or isotype control antibody (anti-DNP). Immunostained sections were counter-stained 
with haematoxylin. Images show the metatarsal joints of mouse paws. (a) Original magnification x 40, 
with further magnification depicted in (b). Increased staining at sites of inflammation is shown by 
arrows. 
Isotype control (anti-DNP) Anti-E-selectin
(b)
(a)
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4.3.3  E-Selectin Targeted Fluorescence Imaging In Vivo: Quantifying 
Endothelial Activation In Vivo In TNF-Induced Paw Oedema 
Having established TNF-induced paw swelling as a reliable and reproducible model 
of paw inflammation, characterised by expression of E-selectin and by neutrophil 
infiltration, my study then aimed to investigate anti-E-selectin antibody trafficking in 
vivo. To study NIR fluorescently labelled anti-E-selectin antibody trafficking in vivo, 
images were obtained at different times following injection of NIR fluorophore 
labelled anti E-selectin antibody followed by induction of paw swelling with 50ng 
TNF and compared with the signal obtained from isotype control anti-DNP 
antibody. Visual representation of the changes in fluorescence signal intensity was 
obtained by applying a colour wheel graded to signal intensity (Figure 4-7). These 
images suggest that E-selectin antibody localised selectively to the TNF-injected 
right paw to a greater extent than control antibody, particularly at early time-points 
after TNF injection. 
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Figure 4-7 TNF-induced paw swelling can be detected by E-selectin targeted 
NIR fluorescent imaging 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm Near 
Infra Red (NIR) fluorophore (50μg, i.v.), paw swelling was induced by intraplantar injection of murine 
TNF (50ng) into the right paw (indicated by arrow) of C57/BL6 mice. Fluorescence images were 
obtained at different time-points post-injection of TNF and are shown from representative anti-E-
selectin and anti-DNP-injected mice. 
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The following Figure 4-8 shows the fluorescent changes obtained from imaging at the 
8 hour time-point. This is to demonstrate in closer detail the fluorescent image 
obtained from a mouse injected with either NIR fluorophore labelled anti-DNP 
antibody or anti-E-selectin targeted antibody. Figure 4-8b also shows the method for 
demarcating a region of interest around the mouse paw. The Mean Fluorescence 
Intensity (MFI) could then be calculated. The technique for this is detailed in Section 
3.3.6. Animals were then kept in the same batches and placed in the same order for 
imaging throughout the time course of experiment, so that imaging time-points were 
kept as accurate as possible. 
 
Figure 4-8 Demonstration of fluorescence images at the 8 hour time-point 
following injection of TNF 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore (50μg, i.v.), paw swelling was induced by intraplantar injection of murine TNF (50ng) 
into the right paw (indicated by arrows) of C57/BL6 mice (a). Panel (b) demonstrates the regions of 
interest taken from a representative mouse paw to determine levels of fluorescence. 
DNP E-selectin
(a)
(b)
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Quantification of fluorescence intensity levels from regions of interest (ROI) of 
inflamed paws showed the dynamic changes of anti-E-selectin and anti DNP antibody 
signal in eight animals injected with either target or control dye-labelled antibody and 
then imaged in pairs. The signal in the right paws (RP) from both groups peaked 6-8 
hours after injection and had largely returned to baseline at 72 hours following 
injection of antibody (Figure 4-9). Fluorescence signal was higher for anti-E-selectin-
injected animals than for anti-DNP-injected mice. Furthermore, fluorescence signal 
was lower in the contralateral left paws (LP; not injected with TNF) than in the RP 
for both anti-E-selectin and anti-DNP antibody-injected mice.  
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Figure 4-9 Quantification of E-selectin targeted NIR fluorescence in the TNF-
induced paw swelling model  
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore (50μg, i.v.), paw swelling was induced by intraplantar injection of murine TNF (50ng) 
into the right paw (RP) of C57/BL6 mice. Fluorescence images were analysed at different time-points 
post-injection of TNF for pairs of anti-E-selectin and anti-DNP-injected mice. Mean Fluorescence 
Intensity (MFI) measurements in injected RP and contralateral left paws (LP) for 4 individual pairs of 
mice are shown in panels (a-d). 
The mean fluorescence signal from all mice was then analysed, this is shown in 
Figure 4-10. These data show that there were significant differences (p<0.001) 
between the anti-E-selectin and anti-DNP antibody injected animals in terms of the 
fluorescence signal in the TNF-injected right paws (Figure 4-10a). There were also 
significant differences between the anti-E-selectin and anti-DNP antibody injected 
animals in the contralateral left paws (LP; p<0.001), and in animals that were injected 
with dye-labelled antibody but did not receive any intraplantar injection of TNF 
(p<0.001; Figure 4-10b). Further analysis of the control groups for this experiment is 
outlined in the next paragraph. 
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Figure 4-10 Quantification of E-selectin targeted NIR fluorescent imaging over 
time 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore (50μg, i.v.), paw swelling was induced by the intraplantar injection of murine TNF 
(50ng) into the right paw of C57/BL6 mice. Panel (a) demonstrates right paw (RP) mean fluorescence 
intensity (MFI) at different time-points post-injection (n=5 per group). Panel (b) demonstrates the 
fluorescent signal returned from the contralateral left paws (LP) and also from paws of animals 
uninjected with TNF (n=5 per group). Data were analysed by 2-way ANOVA comparing anti-DNP 
versus anti-E-selectin-injected mice: *** p<0.001.  
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Because there were differences between anti-E-selectin and anti-DNP injected 
animals (Figure 4-10b), I therefore considered how to account for this in order to 
make meaningful comparisons between anti-E-selectin targeted signal and the signal 
in animals injected with anti-DNP control antibody. To resolve these differences, the 
MFI of the control uninjected left paw (LP) was subtracted from each inflamed right 
paw (RP). This is demonstrated in Figure 4-11. This shows that there is a significant 
increase in E-selectin targeted signal relative to anti-DNP injected animals. This also 
demonstrates that the mean fold difference in corrected signal intensity of E-selectin 
to DNP is 1.72 at the 8 hour time point. This was the maximal fold difference for this 
experiment: the fold difference at 2 and 24 hours was 1.15 and 1.51 respectively.  
 
Figure 4-11 Mean fluorescence intensity following subtraction of control paw 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore (50μg, i.v.), paw swelling was induced by the intraplantar injection of murine TNF 
(50ng) into the right paw (RP) of C57/BL6 mice (n=5 per group). The mean fluorescence intensity 
(MFI) of the left (uninflamed) paw (LP) has been subtracted from the MFI for each RP for each animal. 
Data were analysed by 2-way ANOVA: *** p<0.001. 
Other methods of correcting for the difference in signal were considered. These 
included using an alternative vascular site on the mouse such as the snout so that this 
could serve as an internal reference. A redesign of the anaesthetic equipment resulted 
in this being technically difficult because the snout was contained within the 
anaesthetic nose cone. Another method was also considered. This was to subtract the 
values of fluorescent signal from earlier time-points. However these points are subject 
to significant variability in signal intensity. This is because of the short time period 
between injection of antibody and imaging may be different between injected groups 
0 2 4 6 8 10
0
500
1000
1500
2000
24 48 72
Anti-DNP (RP-LP)
Anti-E-selectin (RP-LP) ***
Time post-TNF  injection (hours)
M
F
I 
(a
u
)
Chapter 4 
129 
and initial clearance of dye may be more variable between animals. The in vivo 
parameters of these very early time-points may be technically more challenging to 
investigate since animals would effectively need to be continuously anaesthetised for 
imaging. 
4.3.4 Reduction in Injected Antibody Dose Increases Signal Specificity 
Further experiments were then performed to determine in more detail the effect of 
injected antibody dose on specificity for E-selectin and to assess further the 
measurement of signal in animals uninjected with TNF. MFI was measured in both 
injected right paws and contralateral left paws of animals injected with different doses 
of antibodies (Figure 4-12a). Decreasing the dose of injected antibody from 50g to 
5g increased the ratio of anti-E-selectin:anti-DNP signal from 1.15-fold to 2.13-
fold(Figure 4-12b-c). Since injection of 5μg of antibody demonstrated optimal 
specificity for E-selectin targeted binding, this antibody dose was subsequently used 
for in vivo fluorescence imaging studies. 
Interestingly there were small differences between fluorescent signal from anti-E-
selectin and anti-DNP injected mice in the control (left) paws (Figure 4-12a) or 
between anti-E-selectin and anti-DNP fluorescent signal in animals not injected with 
TNF in this series of experiments (not shown). This may be because of small 
differences in the labelling reaction, or antibody concentrations used in the first 
experiment. This was despite the prior attempts to generate similarly labelled anti-E-
selectin and anti-DNP antibody concentrations and fluorophore ratios. In practice the 
calculation of dye/protein ratios by measuring absorbance at 280nm and at the peak 
absorbance of the fluorophore are subject to some variation and therefore may not 
compare to the degree of fluorescence following in vivo injection of the dye-labelled 
antibody conjugate. 
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Figure 4-12 Effect of antibody concentration on target specificity 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore at doses of 5μg to 50μg i.v., paw swelling was induced in C57/BL6 mice by the 
intraplantar injection of murine TNF. MFI has been quantified at the 8 hour time-point. (a) Data from 
right injected (RP) and left uninjected (LP) paws are shown (n=5-10 per group). Data are mean ± SEM, 
and were analysed by 2-way ANOVA versus anti-DNP injected animals: *** p<0.001. (b) 
Fluorescence levels from uninflamed paws (LP) were subtracted. Data are mean ± SEM, and were 
analysed by 2-way ANOVA versus anti-DNP injected animals: *** p<0.001. (c) Fold difference of E-
selectin antibody MFI compared to control anti DNP antibody. Bars indicate mean values, and data 
were analysed by 1-way ANOVA with Bonferroni post-hoc correction versus 50μg antibody: *** 
p<0.001. 
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These experiments therefore suggested that 5μg of dye labelled antibody was optimal 
and subsequent studies utilised this dose. Figure 4-13a represents the results of an 
experiment designed to look more closely at both E-selectin targeted and control 
groups following injection of 5μg of dye-labelled control or anti-E-selectin antibody. 
This figure demonstrates that there is increased signal returned from anti-E-selectin 
antibody-injected animals (relative to anti-DNP-injected animals) at 2, 8 and 24 hours 
in the TNF-injected right paws (RP) with only minor differences between control 
(left) paws (LP). Figure 4-13b demonstrates further detail of the signal at the 8 hour 
time-point from either left paws, or from animals that did not receive an injection of 
TNF or those injected with the same volume of PBS and 1% mouse plasma into the 
right paw. The mean fluorescent signal following injection of either anti DNP or E-
selectin antibody for control groups (either LP, no injection of TNF or injection of 
PBS vehicle) is demonstrated. This shows that are no significant differences between 
the MFI returned from these groups at this time-point. Other time-points showed 
similar findings with regard to background signal. I was therefore able to subtract a 
mean background level of fluorescence from the mean of the left paw signal intensity 
to leave the specific signal (minus background) from control antibody or anti-E-
selectin injected right paws at 8 hours following the intraplantar injection of TNF. 
This is demonstrated in Figure 4-13c. The small levels of residual signal for the left 
paws represent the minor degrees of variation between injected animals following 
subtraction of the mean background signal.  
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Figure 4-13 Mean fluorescence intensity: increased specificity at 5μg antibody 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore at a dose of 5μg i.v., paw swelling was induced by intraplantar injection of 50ng murine 
TNF in C57/BL6 mice (n=4-6). Mean fluorescence signal (MFI) was measured between 2 and 24 
hours (a). (b) Mean fluorescence signal (MFI) quantified at the 8 hour time-point is shown for right 
injected (RP) and uninjected (LP), as well as for uninjected (RP) controls (no TNF or PBS control) to 
highlight the relative contribution of both autofluorescence and background mean fluorescence 
intensity. (c) The mean background intensity from control and anti-E-selectin targeted animals was 
subtracted. Data are mean ± SEM, and were analysed by 1-way ANOVA with Bonferroni post-hoc 
correction versus control antibody: *** p<0.001, ns=not significant. 
Chapter 4 
133 
The following Figure 4-14 demonstrates the relationship between the digital 
fluorescence images obtained and the quantitation of MFI. Figure 4-14a demonstrates 
a close-up detail of the fluorescence obtained at t=8 hours following injection of dye-
labelled antibodies. The gradation in the colour wheel applied to signal intensity in the 
left hand figure is set over the range of mean fluorescence intensity as indicated in the 
right hand graph. Figure 4-14b shows how the mean background (mean left paw MFI 
for each group) fluorescence can be subtracted from the digital image by narrowing 
the range over which the gradation of colour represents MFI. In addition this image 
has also been overlaid onto a digital X-ray of the mouse taken at the same time point. 
In Figure 4-14c the MFI returned from control animals (injected with anti-DNP 
fluorescent labelled antibody) has also been subtracted. The threshold of the colour 
wheel has been set above calculated mean background MFI for injection of control 
antibody into TNF injected paws. This image therefore represents the specific signal 
from anti-E-selectin targeted binding at 8 hours following induction of inflammation 
by injection of TNF into the mouse paw. 
  
Chapter 4 
134 
 
 
Figure 4-14 Specific anti-E-selectin targeted fluorescent signal co-registered with 
X-ray imaging 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore at a dose of 5μg i.v., paw swelling was induced by intraplantar injection of murine TNF 
in C57/BL6 mice (n=4-6). Mean fluorescence signal (MFI) was measured between 2 and 24 hours (a). 
(b) Mean fluorescence signal (MFI) quantified at the 8 hour time-point is shown for different groups of 
mice. (c) The mean background intensity (mean MFI of LP data) from control and anti-E-selectin 
targeted animals was subtracted. In the left hand panel the corresponding fluorescent image overlaid 
onto a coregistered X-ray. The colour wheel to depict signal intensity has been adjusted to the range as 
shown on the graph (a,b,c). 
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4.3.5 E-Selectin Targeted Signal Can Be Abrogated By TNF Receptor Blockade 
The purpose of this part of the study was to determine the effect of etanercept on 
TNF-induced paw swelling, to further confirm the dependence of paw swelling on 
TNF activity. Etanercept is an engineered TNFRII dimer with a fully human amino 
acid sequence linked to the Fc portion of human IgG1. It has been effective in the 
abrogation of disease in CIA (Piguet, Grau et al. 1992; Wooley, Dutcher et al. 1993). 
It is in clinical use for the treatment of RA patients not responsive to conventional 
DMARDs (Moreland, Baumgartner et al. 1997; Moreland, Schiff et al. 1999). Firstly 
the effect of etanercept on TNF-induced paw swelling by measuring paw thickness 
was investigated; this is demonstrated in Figure 4-15. This figure shows that the pre-
treatment by etanercept (100μg, i.p.) 12 hours prior to induction of paw swelling with 
TNF significantly abrogated the measured change in paw thickness. Indeed the paw 
thickness in animals which received TNF plus etanercept was not significantly 
different from the left paw thickness of TNF-injected mice. Similar results were 
obtained when etanercept was administered 4 hours prior to intraplantar injection of 
TNF (not shown). 
 
 
 
 
 
 
 
Figure 4-15 Etanercept abrogates TNF-induced paw swelling 
Paw swelling was induced by the intraplantar injection of murine TNF (50ng) in C57/BL6 mice, 
which received a prior injection of soluble human TNFRII (100μg, i.p.) 12 hours before TNF 
injection. Change in paw thickness over time was measured. Data are mean ± SEM (n=5 per group) 
and were analysed by 2-way ANOVA versus the contralateral left paw (LP) thickness of animals 
treated with TNF alone: *** p<0.001, ns=not significant. 
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I therefore investigated whether E-selectin targeted fluorescent imaging was also 
capable of detecting this change. Animals were pre-treated with etanercept and then 
imaged at 2, 8 and 24 hours following induction of paw swelling by the intraplantar 
injection of TNF. This is demonstrated in Figure 4-16, which shows that there was a 
significant 61.1% reduction in E-selectin targeted signal compared to control antibody 
signal. This demonstrates the considerable efficacy of etanercept in abrogating TNF 
dependent inflammation. There was also a reduction in the MFI of animals injected 
with dye-labelled control antibody but this did not reach statistical significance. This 
suggests that the E-selectin specific component to the fluorescent signal is reduced to 
a greater degree than the reduction in non-specific targeting of antibody to sites of 
inflammation. Since there is a significant reduction in paw swelling it would be 
expected that non-specific antibody uptake would also decrease. It is well recognised 
there is also a reduction in the non-specific trafficking of antibody into the site of 
inflammation due to changes in vascular permeability that occur at sites of 
inflammation, as discussed in Section 1.2.4. 
 
 
 
 
 
 
 
Figure 4-16 Etanercept abrogates E-selectin specific signal in inflamed paws 
Following injection of either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm NIR 
fluorophore (5μg i.v.), paw swelling was induced by intraplantar injection of murine TNF (50ng) in 
C57/BL6 mice. The effect of treatment using soluble human TNFRII (100g, i.p.) 12 hours prior to 
TNF injection is demonstrated. Mean fluorescence intensity (MFI) was measured at 8 hours. Mean 
background fluorescence levels from uninflamed left paws (LP) were subtracted. Data are mean ± 
SEM, and were analysed by 1-way ANOVA with Bonferroni post-hoc test versus untreated animals: ** 
p<0.01, ns=not significant. 
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4.4 Discussion 
In this chapter my objectives were initially to develop an acute model of inflammation 
and to demonstrate E-selectin expression early in the time course of inflammation by 
immunohistochemistry. The model was then used to determine the parameters of E-
selectin targeted in vivo imaging and to quantify E-selectin expression over the time 
course of inflammation. Induction of acute paw inflammation by the intraplantar 
injection of TNF has been utilised successfully for this purpose. I have further been 
able to demonstrate that in vivo fluorescence imaging of E-selectin is a sensitive, 
specific and quantifiable method of detecting endothelial activation in an acute 
inflammatory model. The final objective was to determine the effect of a therapeutic 
intervention in abrogating paw swelling following injection of TNF. This too has 
been demonstrated and the effect of this on targeted imaging has been quantified. This 
demonstrated that there was a significant decrease in E-selectin targeted imaging 
following pre-treatment with the soluble TNF receptor antagonist etanercept. Acute 
paw swelling caused by local injection of TNF was initially investigated as a 
reproducible acute model of paw inflammation in vivo. The expression of E-selectin 
was then investigated by immunohistochemistry. In order to measure cytokines or 
other molecules in whole joints, sectioning of bone is required. This was technically 
difficult to perform on a cryostat as the small bones in a mouse paw will often splinter 
disrupting the architecture of histological specimens. Work was therefore undertaken 
to refine this technique. Some investigators have reported the detection of cytokines 
(IL-1β and RANKL) in paraffin fixed decalcified joint (Romas, Sims et al. 2002; 
Lubberts, Koenders et al. 2004) but the ability to detect many other cytokines will be 
lost following paraffin sectioning. Techniques have been developed at the Kennedy 
Institute for decalcifying tissue sections and then performing fresh frozen sectioning 
(Marinova-Mutafchieva, Williams et al. 1997; Gabay, Marinova-Mutafchieva et al. 
2001). I therefore needed to develop a protocol for immunohistochemistry that 
ensured whole paw specimens could be processed and E-selectin expression 
demonstrated in the TNF induced paw model. Measurements of paw thickness 
following TNF injection confirmed that the change in paw thickness over time is 
reproducibly dependent on the dose TNF. Immunohistochemistry demonstrated the 
expression of E-selectin following at early time points following the injection of 
TNF. The application of immunohistochemistry techniques developed in this model 
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could then also be used to investigate the in vivo expression of E-selectin in CIA. 
Application of antibodies labelled with NIR fluorophore in the TNF-induced paw 
model, allowed measurement of levels of signal from uninflamed paws to determine 
signal sensitivity (E-selectin antibody signal versus background), whereas comparing 
control antibody injected groups to those injected with anti-E-selectin antibody 
determined signal specificity (anti-E-selectin versus anti-DNP antibodies). 
Subtracting background signal (mean signal intensity of uninflamed left paws) from 
the signal obtained from inflamed right paws ensured variations due to injection 
differences were excluded. The time course of anti-E-selectin antibody binding over 
6-8 hours in this model is in keeping with previously found kinetics for E-selectin 
expression in vivo (Harari, McHale et al. 1999). Labelling anti-E-selectin antibody 
with a fluorophore in the NIR range was key to the success of in vivo imaging. This 
ensured specific signal from inflamed paws was not subject to the significant 
autofluorescence that occurs when imaging at lower wavelengths. So that following 
imaging the system was able to detect E-selectin specific signal in difference to the 
signal returned from control antibody. The optimum wavelength for imaging was 
determined when a DBA/1 mouse was imaged at different wavelengths below and 
within the NIR as demonstrated in Section 3.3.2. This has also been recognised by 
others to be a significant determinant for the ability of fluorescent imaging to 
delineate target signal (Fischer, Gemeinhardt et al. 2006; Weissleder and Pittet 2008). 
The facility to co-register images with digital X-ray imaging of the target region 
further helped delineate anatomical localisation of fluorescence signal.  
A reason for increased signal in the anti-E-selectin antibody-injected groups could be 
due to systemic E-selectin expression due to a generalised effect from the intraplantar 
injection of TNF. Particularly since there was a small effect on paw thickness at 
higher (100ng) doses of TNF and there may therefore be a low level of E-selectin 
expression at doses lower then 100ng. However in the control animals that received 
intravenous injection of dye-labelled antibodies but no intraplantar injection of TNF 
there were still differences between anti-E-selectin and DNP fluorescence signals. 
This may indicate that there are differences in the amount of injected antibody or that 
the degree of fluorophore labelling was different between the groups. Interestingly, 
this difference was not demonstrated when making a comparison between 
fluorescence intensity by measuring the fluorescence from serial dilutions of dye-
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labelled antibodies in vitro as shown in Section 3.3.5. Another possibility is that there 
was a small degree of constitutive E-selectin expression accounting for the increased 
anti-E-selectin targeted signal. E-selectin expression in vivo has been characterised in 
the pig following injection of either IL-1 or TNF and constitutive expression of E-
selectin in the skin demonstrated by immunohistochemistry in this model (Keelan, 
Licence et al. 1994). In initial experiments one significant limiting technical factor 
was performing multiple i.v. injections within a short time period so that animals were 
grouped for accurate analysis at both early, mid and late time-points. Although it may 
be possible to stagger the imaging time points this would also be technically 
challenging. Hence a significant additional component to this early work was 
establishing efficient procedures for preparation, injection and imaging of animals. 
In this study I also explored the possibility of whether E-selectin antibody had any 
therapeutic effect in the TNF-induced paw inflammation model. Pre-injection of anti 
E-selectin antibody at varying doses did not have any effect on TNF-induced paw 
swelling. Targeting E-selectin may expected to inhibit the interactions between 
leukocytes, platelets and EC within the vascular compartment, leaving tissue 
leukocyte interactions intact. Some studies using E-selectin antagonists in humans 
examining the effect of targeted selectin therapy on reperfusion injury have been 
promising (Lefer 2000). However a carbohydrate based on Sialyl-Lewis X had no 
effect in patients undergoing angioplasty for ischaemia reperfusion injury (Harari, 
Marshall et al. 2001; Marshall and Haskard 2002). Intravenous administration of the 
CDP850 humanised anti-E-selectin antibody reduced levels of soluble E-selectin in 
plasma and of E-selectin in psoriatic plaques of patients of patients with psoriasis, but 
did not affect overall clinical outcomes (Bhushan, Bleiker et al. 2002). This may be 
explained in part by a degree of redundancy with regard to circulating leukocyte 
attachment to the activated endothelium in humans and animal models. Furthermore 
as both E- and P-selectin recognise PSGL-1 there may also be redundancy in ligand 
recognition (Moore 1998). It remains possible that inhibitors of selectin function may 
emerge that have higher affinity for selectins than sialyl-Lewis X analogues. For 
example a recombinant soluble antagonist of PSGL-1, rPSGL-Ig has shown promise 
as a cardioprotective agent by improving postischaemic flow following ischaemia 
reperfusion injury in pigs (Hansen, Kumar et al. 2004). The therapeutic potential of 
the rPSGL-1 was also demonstrated in established CIA in DBA/1 mice (Sumariwalla, 
Malfait et al. 2004).  
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The following chapter aimed to translate the refined techniques and observations from 
the TNF-induced paw oedema model into the CIA model, where paw swelling and 
clinical score is known to be heterogeneous and subjective. Murine heterologous CIA 
has several similarities with RA, including synovitis, pannus formation, erosion of 
cartilage and bone, fibrosis and joint rigidity (Holmdahl, Jansson et al. 1986; 
Holmdahl, Andersson et al. 1989). Therefore a clear understanding of specific versus 
non-specific fluorescent signal was required to delineate the relative effects of each in 
CIA. 
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5 RESULTS: QUANTITATIVE E-SELECTIN TARGETED 
FLUORESCENT IMAGING OF CIA 
5.1 Introduction 
The work described in the previous chapters generated important information about 
how to optimise in vivo optical imaging so that E-selectin targeted fluorescent 
signalling could be utilised in a mouse model of acute inflammation in vivo. In this 
chapter, I aimed to translate the studies in the TNF-induced paw swelling model into 
an effective method of imaging activated endothelium in CIA by targeting E-selectin 
expression. I also aimed to demonstrate how it can be used as a molecular imaging 
technique to delineate the effects of therapy in CIA. Taken together with my findings 
in the previous chapter this would validate in vivo visualisation of a fluorescently 
labelled MoAb detecting endothelial activation as a precise, quantifiable pre-clinical 
molecular imaging technique for murine arthritis. 
5.1.1 Collagen Induced Arthritis 
CIA is a clinically heterogeneous disease induced in genetically susceptible mice by 
the intradermal injection of type II bovine collagen (CII). This is discussed in Section 
1.4.1. In the present chapter the histological hallmarks of CIA and their relationship to 
E-selectin expression ex vivo are investigated. The histological features of CIA are not 
dissimilar from RA. In CIA there is infiltration of subsynovial tissue by inflammatory 
cells, synovial hyperplasia, angiogenesis and erosion of cartilage by bone, all of 
which occur in RA (Trentham, Townes et al. 1977; Wooley, Luthera et al. 1981; Lee 
and Weinblatt 2001). B- and T-lymphocytes are both involved in the pathogenesis of 
CIA with a peak T-cell response occurring around the time of disease onset. Although 
T-cells play a role in the autoimmune response in CIA, B-cells and auto-antibodies 
against CII appear to be the primary effector mechanism in this model. The 
requirement for T-cells in this model is further supported by the fact that only mice 
with a certain MHC class II molecule are susceptible to CIA. CD4+
 
T-cells can be 
detected in the synovial tissue of CIA mice (Marinova-Mutafchieva, Williams et al. 
2000). However, transferring CIA with CD4+ T-cells has proven to be difficult 
(Taurog, Kerwar et al. 1985) and anti-CD4 treatment T-cell directed therapy of 
established CIA has relatively little impact on inflammatory processes in the joint 
(Marinova-Mutafchieva, Williams et al. 2000). The onset of CIA is characterised by 
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high titres of anti-CII antibodies, which bind to the joint cartilage and activate the 
complement cascade (Williams, Jones et al. 1998). In contrast to the transfer of CII-
reactive T-cells, passively transferred IgG anti-CII antibodies induces a severe 
arthritis in naïve mice (Holmdahl, Jansson et al. 1990). The importance of B-cells has 
further been shown by the fact that B-cell deficient mice are protected from CIA 
(Svensson, Jirholt et al. 1998). 
Pro-inflammatory cytokines such as TNF are crucial in the regulation of joint 
inflammation and tissue destruction in arthritis. The administration of TNF has been 
shown to accelerate severity of CIA in rats (Brahn, Peacock et al. 1992). In contrast, 
disease is inhibited when mice are treated with anti-TNF antibody (Williams, 
Feldmann et al. 1992). The expression of EC surface markers, however, has not been 
extensively studied in CIA. One study has made a comparison of the E-selectin 
expression at the mRNA and protein level in different murine models of 
inflammation. E-selectin expression was determined both at the mRNA level using 
RT-PCR and at the protein level using immunohistochemistry (Everts, Asgeirsdottir 
et al. 2003). CIA was induced by injection of bovine collagen intradermally and mice 
were given a booster of collagen at day 21. Signs of arthritis were not detected until 
day 28. Mice were then sacrificed at either day 28, day 30, day 35 or day 43 to 
generate knee specimens with either no, mild, moderate or severe arthritis 
respectively. Hence this model differs from the CIA experiments I have described in 
this chapter, being more chronic in nature. These workers did find that E-selectin 
mRNA levels in synovial biopsies from the knee specimens were increased in mild, 
moderate and severely diseased animals compared to those without any macroscopic 
signs of inflammation. Interestingly, these workers were less successful in 
demonstrating positive staining of E-selectin by immunohistochemistry in inflamed 
tissue. They noted occasional E-selectin expression detectable by 
immunohistochemistry in severe inflamed tissue at day 43 post immunisation but not 
at other times in mild and moderate disease. 
A number of prior studies have investigated fluorescent imaging in animal models of 
arthritis to detect both targeted and non-specific signal change in arthritis. A Cy5.5-
labeled antibody against macrophages was used successfully to label inflammatory 
changes in experimental arthritis. Between 2 and 72 hours, arthritic knee joints 
showed significantly higher fluorescence levels compared with contralateral joints. In 
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this study it appeared that following injection Cy5.5 bound mainly to albumin with 
microscopy confirming Cy5.5 deposition in the synovial membrane it also appeared 
that macrophages actively phagocytosed Cy5.5 following uptake to inflamed areas 
that had occurred most likely as a result of non-specific trafficking due to enhanced 
vascular permeability (Hansch, Frey et al. 2004). The same investigators targeted the 
F4/80 antigen on macrophages by conjugating the Cy5.5 fluorochrome to anti-F4/80 
antibody and demonstrated that signal in inflamed joints was significantly higher than 
that generated by the isotype control labelled antibody. Simon et al evaluated whether 
optical imaging of reinjected leukocytes labelled ex vivo with an NIR dye could detect 
antigen induced arthritis (Simon, Daldrup-Link et al. 2006). This study showed that at 
4 and 24 hours there was some significant accumulation in arthritic versus control 
knees. The targeting of arthritis by other mechanisms is also discussed in the 
introductory Section 1.3.3.2. No investigators thus far, however, have examined 
whether E-selectin can be utilised as a marker of endothelial activation in CIA and 
detected in vivo by utilising optical imaging of fluorescently labelled anti-E-selectin 
antibody, and this is addressed in the first part of this chapter. 
The following Section gives background information about a novel therapeutic 
approach for CIA and how this may be tested in the CIA model using in vivo E-
selectin targeted imaging, which forms the basis for the second part of this chapter. 
5.1.2 RB200: A Novel EGFR Antagonist 
In addition to utilising anti-E-selectin as technique to follow arthritis in vivo, it would 
be of interest to determine whether in vivo imaging can also be applied to study the 
effects of therapy in CIA. An antagonist (RB200) has been developed that targets all 
four members of the epidermal growth factor (EGF) receptor family. This is discussed 
further in section 1.2.3. Despite the success of conventional monoclonal antibody 
technology that usually targets a single molecule or receptor, there is often intricate 
cooperation amongst multiple signalling pathways or a number of closely related cell 
surface receptors that can lead to reduced efficacy. To circumvent this problem, a bi-
specific ligand trap, RB200, composed of the full length extracellular domain of 
HER-1/ErbB1 and HER-3/ErbB3 fused with the Fc domain of human IgG1 has been 
designed (Sarup, Jin et al. 2008; Jin, Zhang et al. 2009). RB200 may therefore be 
expected to down-regulate responses mediated via all four HER subfamily members 
due to its broad pan-HER efficacy. RB200 has been shown to bind to both HER-
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1/ErbB1 ligands (TGF-, HB-EGF) and to HER-3/ErbB3 ligands (NRG1- and 
NRG1-3). Moreover, RB200 inhibited EGF- and NRG1-1stimulated tyrosine 
phosphorylation of HER family proteins (HER-1, HER-2 and HER-3), and also 
showed potency in a variety of cell proliferation assays (Sarup, Jin et al. 2008). In 
addition RB200 has been shown to inhibit tumour growth in vivo in two human 
tumour xenograft (epidermoid carcinoma and non-small cell lung cancer) nude mouse 
models (Sarup, Jin et al. 2008). A representation of the structure of RB200 is 
demonstrated in the following Figure 5-1. 
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Figure 5-1 Representative structure and principle binding affinity of RB200 
Figure demonstrates that RB200 is an Fc mediated heterodimer of native HER1 and HER3 ligand 
binding domains, retaining the specificity of both HER1 and HER3. (EGF = epidermal growth factor, 
TGF-= transforming growth factor-, HB-EGF = heparin-binding EGF like growth factor, AR = 
amphiregulin, BTC = betacellulin, EPR = epiregulin, EPG = epigen; HER-3/ErbB3 ligands: NRG-1 = 
neuregulin-1, NRG-3 = neuregulin-3.) 
 
It was shown at the Kennedy Institute that adenoviral delivery of the human EGFR 
family inhibitor, Herstatin, significantly abrogated murine CIA (Sumariwalla, Jin et 
al. 2008). Herstatin is an N-terminally modified alternative splice variant of HER-
2/ErbB2, retaining intron 8, resulting in the formation of an approximately 68kDa 
protein, which disrupts dimerisation and thus serves as a natural inhibitor of native 
HER-2/ErbB2, as well as HER-1/ErbB1and HER-3/ErbB3 (Doherty, Bond et al. 
1999). Investigation of the role of IL-18 in upregulating angiogenic factors in RA 
tissue fibroblasts has demonstrated that downstream signalling pathways from 
phosphorylated tyrosine kinase domains of ErbB receptors induce angiogenic factors 
including VEGF via distinct mechanisms (Amin, Mansfield et al. 2007). This suggests 
that RTKs blockade may have significant effects on angiogenesis in RA. Engagement 
of HER receptors has been shown to increase the release of VEGF in malignancy 
(Petit, Rak et al. 1997; Konecny, Meng et al. 2004). Since homodimerisation and 
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heterodimerisation among members of the the ErbB family of receptors are known to 
occur agents that target multiple receptors are desirable. The dual kinase receptor 
lapatinib targets both EGFR and HER-2, and thus has been found to be more effective 
in the treatment of angiogenic proliferation in metastatic cancer (Diaz, Nguewa et al. ; 
Nahta, Yuan et al. 2007).  
The efficacy of RB200 has been investigated previously. RB200 inhibited EGF- and 
NRG1-1stimulated tyrosine phosphorylation of HER family proteins (HER-1, HER-
2 and HER-3), and also showed potency in cell proliferation assays (Sarup, Jin et al. 
2008). In addition RB200 has been shown to inhibit tumour growth in vivo in two 
human tumour xenograft (epidermoid carcinoma and non-small cell lung cancer) nude 
mouse models (Sarup, Jin et al. 2008). Prior work at the Kennedy institute has 
demonstrated the therapeutic efficacy of RB200 in abrogating CIA, demonstrating a 
significant effect on paw swelling, and clinical score. Immunohistochemical analysis 
also demonstrated reduced vascularity following analysis for CD31 staining 
(unpublished observations). In addition behavioural responses such as feeding, 
grooming, climbing were measured by an automated activity monitor. This 
demonstrated significant improvements following treatment with RB200 and there 
was also no evidence of adverse outcomes following treatment. Further experiments 
were therefore undertaken to determine whether there may be a synergistic effect 
between low dose RB200 and the TNF receptor blocker etanercept. This presented an 
opportunity to determine whether RB200 and etanercept either alone or in 
combination had significant effects on in vivo E-selectin targeted imaging in CIA. 
5.2 Objectives 
i. To determine the characteristics of CIA as a model of arthritis for in vivo 
fluorescence imaging 
ii. To demonstrate that increased E-selectin expression can be detected by 
immunohistochemistry 
iii. To investigate whether increased E-selectin expression can be detected in vivo 
by fluorescently labelled anti-E-selectin antibody 
iv. To determine the effect of a novel therapeutic compound, RB200, on in vivo 
E-selectin targeted fluorescent imaging. 
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5.3 Results 
5.3.1 Collagen Induced Arthritis 
5.3.1.1 CIA in DBA/1 mice – clinical course of the disease 
Immunisation of male DBA/1 mice with bovine type II collagen in complete Freund’s 
adjuvant resulted in development of inflammatory arthritis. Disease onset and 
progression was monitored daily from 10 days after immunisation. This was to 
determine the time of onset of arthritis and to quantify the extent of oedema, erythema 
and deformity. Figure 5-2 is a representative graph of disease development. The first 
clinical signs of arthritis generally appeared at day 14 after collagen injection, with a 
mean onset of 25 days post primary immunisation. The severity of arthritis was 
represented as an arthritic index on a 0-3 scale. Each paw was graded and the sum of 
the scores obtained from all four paws was used as the arthritis score, resulting in a 
maximal possible score of 12 per mouse. In conjunction with the clinical score, hind 
paw swelling was measured. In my experiments, the incidence of arthritis varied 
between 50-80%. The reasons for variability in incidence are not known. Theories 
have included that mice have originated from different housing facilities, or they were 
kept in different cages or that the collagen preparations have variable efficacy 
depending on their purity. For imaging experiments the combined clinical score of the 
hind paws was used. Front paws were not assessed by fluorescence imaging. This is 
because of their small size, difficulty positioning for clear recording of signal and 
difficulty interpreting histological sections. 
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Figure 5-2 Incidence of arthritis following immunisation with bovine type II 
collagen 
Graph demonstrates the typical incidence of a CIA experiment over time following immunisation of 
DBA/1 mice with bovine collagen. Mice were monitored daily to assess for disease onset. 
 
The clinical onset of CIA was marked by rapidly increasing oedema and erythema of 
the paws and ankles/wrists of both hind and forelimbs, usually commencing in one 
limb and then often spreading into the other limbs. Later clinical characteristics of the 
disease (beyond day 8 of arthritis) included reduced oedema, as a result of gross joint 
deformation and total loss of joint mobility. As well as the incidence, the severity of 
the disease was extremely variable between experiments. A clinical score of 12 was 
rarely reached; more common was a clinical score of 2.5-6, with the disease involving 
one or two paws of the animal. A representative time course of arthritis progression 
determined by measuring clinical score and paw thickness is demonstrated in Figure 
5-3. While there was progression and worsening of arthritis in the majority of animals 
over time, there was significant heterogeneity between animals at any particular time-
point of arthritis. This is best highlighted in Figure 5-3b. Unlike the typical clinical 
course of RA, disease progression in CIA is often characterised by an asymmetrical 
rapidly progressive arthritis that leaves some paws apparently unaffected. 
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Figure 5-3 CIA: Time course of progression in DBA/1 mice 
Graphs illustrate an example of a typical CIA experiment run in this study to demonstrate the disease 
course. Immunisation of DBA/1 mice with bovine CII induced joint inflammation with characteristic 
oedema and erythema. Mice with visual appearance of arthritis (redness and/or swelling of a paw) were 
monitored daily to observe disease progression. The inflammatory response was represented as paw 
thickness in mm and clinical score. Clinical score panel (a) correlated well with paw thickness panel 
(b). Data are expressed as means ± SEM (n = 11). 
 
 
 
Figure 5-4 Representative clinical scores of mice with CIA 
Panel (a) Normal hind paw (clinical score 0). (b) Hind paw with mild swelling (clinical score 1). (c) 
Hind paw with pronounced oedematous swelling (clinical score 2). (d) Hind paw with ankylosis (joint 
fusion) (clinical score 3). 
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Figure 5-4 demonstrates representative examples of clinical scoring for mice with 
CIA. The clinical score is based on a visual assessment of the overall appearance of 
the mouse paw. Since this scoring is subjective there can be differences between 
observers when making an assessment of the clinical score in CIA. This is especially 
the case with minimal mild (grade 1) paw swelling. This is further complicated by the 
occasional transient swelling of paws that can occur over 12-24 hours which has the 
appearance of early arthritis but then spontaneously resolves. 
5.3.1.2 Histological analysis of CIA 
Histological analysis was used to confirm the clinical assessments. Paws were 
harvested at various time-points and processed for histological evaluation. No clinical 
or histological evidence of arthritis was seen in control animals receiving CFA alone. 
Sections of healthy joints revealed well defined joint spaces, with the articular surface 
of bones covered with cartilage of uniform thickness and smooth surface. The 
histological examination of paws with collagen induced arthritis revealed a good 
correlation between the clinical and the histological findings. In paws judged to have 
mild arthritis, on histological analysis these demonstrated limited inflammatory cell 
infiltration in the superficial layers of the synovium. Sections of severely arthritic 
paws, however, exhibited widespread infiltration of inflammatory cells throughout the 
joint tissue, extensive proliferation and vascularisation of the synovium, as well as 
invasion and erosion of cartilage and subchondral bone by inflamed synovium, 
leading to complete disorganisation of the joint architecture and in some areas to the 
development of fibrous or bony ankylosis. Figure 5-5 demonstrates the typical 
histopathological features of a severely arthritic paw compared to a healthy paw. 
Areas where new vessel formation is suggested correspond to similar areas on 
specimens stained for CD31. 
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Figure 5-5 Histological characteristics of CIA 
Representative sections of first metatarsal joints from a), healthy and b), arthritic mice stained with 
haematoxylin and eosin. Tissue was obtained on day 10 of arthritis. The healthy section demonstrates 
normal joint architecture without signs of inflammation or bone destruction. Synovial hyperplasia, 
inflammatory cell infiltration, loss of cartilage and bone are evident in the arthritic joint. (s) inflamed 
synovium, (*) inflamed synovium invasion into bone, arrows show synovial blood vessels; (b) bone; 
(c) cartilage; (s) synovium; (js) joint space, (original magnification x 40). 
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5.3.1.3 Immunohistochemistry to assess E-selectin expression and synovial 
vascularisation in CIA 
To determine whether E-selectin is expressed in the inflamed synovium of mice with 
CIA, immunohistochemistry was performed. The technique used to preserve 
antigenicity was identical to that used to prepare specimens when examining E-
selectin expression in the TNF-induced paw inflammation model as presented in 
Section 4.3.2. Joint sections were obtained from the hind paw of an animal on day 5 
following the onset of hind paw arthritis. Representative images are shown in Figure 
5-6. These demonstrate that there was significant histological evidence of arthritis 
within the joint (Figure 5-6a,b) and that within areas of inflamed synovium there was 
positive staining for E-selectin as marked by the arrows (Figure 5-6d), but that there 
was no equivalent staining for microvessels in specimens stained with the isotype 
control antibody DNP (Figure 5-6c). 
 
Figure 5-6 E-selectin is expressed in the inflamed synovium of mice with CIA 
(a-c) Serial sections from a mouse paw with CIA (day 5) were stained using haematoxylin and eosin 
(a,b), or with either (c) isotype control antibody or (d) anti-E-selectin antibody (magnified from area in 
(b)). Arrows indicate brown precipitates demonstrating the presence of positive E-selectin binding in 
inflamed microvessels. (S=synovium, B=bone, C=cartilage, *=invading synovium). (scale bar 500μm) 
(b)
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Anti-E-selectin antibody binding to activated endothelium in inflamed synovium was 
compared to the staining pattern obtained by using an antibody directed to Platelet 
Endothelial Cell Adhesion Molecule 1 (PECAM-1/CD31). The staining process for 
CD31 also involved preparing cryosections following decalcification to preserve 
antigenicity as detailed in Section 2.6. The expression of CD31 by EC is well 
recognized for its use in detecting EC in tissue sections. CD31 is an immunoglobulin 
(Ig) superfamily member expressed on the surface of platelets and leukocytes, and is 
also concentrated at the lateral junctions of EC (van Mourik, Leeksma et al. 1985; 
Muller, Ratti et al. 1989; Albelda, Oliver et al. 1990). CD31 is composed of six 
extracellular Ig-domains, a transmembrane domain and a cytoplasmic domain. Its 
ligands include itself by homophilic interaction involving Ig-domain 1, and also vβ3 
integrin and cyclic ADP ribose hydrolase (CD38) by heterophilic interaction 
involving Ig-domains 1–3. Since its original cloning, much has been learned about the 
role of CD31 in mediating various cellular interactions. It has been implicated in 
various biological functions such as leukocyte transmigration, cell migration, 
angiogenesis, cell signalling and cell adhesion (Woodfin, Voisin et al. 2007). 
The staining patterns for anti-E-selectin antibody and anti-CD31 antibody are shown 
in Figure 5-7. This figure demonstrates that both are targeted to the inflamed 
synovium where there is likely to be new vessel formation. Anti-E-selectin antibody 
bound specifically to smaller vessels within the inflamed synovium, whereas anti-
CD31 antibody bound to both large and small vessels throughout the paw in both 
inflamed and uninflamed areas. The differential binding patterns for anti-E-selectin 
and anti-CD31 antibody are also demonstrated in Figure 5-9. 
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Figure 5-7 E-selectin expression in inflamed mouse synovium: comparison with 
CD31 
Haematoxylin and eosin section of inflamed mouse metatarsal joint, taken from DBA/1 mouse with 
severe arthritis (a). Further serial sections were immunostained with anti-CD31 antibody (b, d, f) or 
anti-E-selectin antibody (c, e, g), and are shown at 50x (b, c), 100x (d, e) and 200x (f, g) magnification. 
g)
a)
b) c)
d) e)
f) g)
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The following figure (Figure 5-8) demonstrates that in a mouse joint unaffected by 
arthritis (in immunised but non-arthritic animals) there was no histological evidence 
of arthritis. Haematoxylin and eosin stained tissue sections from this clinically healthy 
mouse displayed normal joint architecture without synovial hyperplasia or infiltrating 
leukocytes as well as intact cartilage and bone. There was no evidence of positive 
anti-E-selectin antibody staining. There was however evidence of CD31 positive 
staining in some of the vessels in the paw. These are histologically normal blood 
vessels that have a distinct lumen and larger diameter. 
 
Figure 5-8 Comparison of anti-E-selectin and CD31 staining in non-arthritic 
mouse paw 
Representative histological sections of paw tissue from a clinically healthy mouse that had been 
immunised with type II bovine collagen but did not develop arthritis. Images show the metatarsal joints 
of mouse paws. (a) Haematoxylin and eosin section (b) anti-E-selectin antibody-stained section. Brown 
precipitates indicate the presence of CD31 positive staining and are marked by the arrows in (c). 
(magnification x40). 
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Figure 5-9 Differential binding of anti-E-selectin and anti-CD31 antibody 
Representative figure of anti-CD31 (a) and anti-E-selectin antibody binding (b) from a DBA/1 mouse 
with severe (day 10) arthritis following immunisation with type II bovine collagen. Differential binding 
pattern in both figures is indicated by arrows. (S=synovium, B=bone, C=cartilage, V=vessel). x100 
magnification. 
Figure 5-9 represents the differential binding of anti-E-selectin and anti-CD31 
antibody. This shows that anti-CD31 shows positive staining to both large and small 
vessels in the mouse paw, but that anti-E-selectin positive staining has a greater 
intensity of staining in small calibre vessels with areas of inflamed synovium. 
E-selectin expression was further qualitatively assessed at early, mid and late time-
points of arthritis. This is demonstrated in Figure 5-10. This confirms that there was 
E-selectin expression evident at days 1, 5 and 10 following the onset of arthritis. 
Qualitative comparisons of anti-E-selectin binding have been made at different time-
points in arthritis, with the conclusion that there may be relatively more expression at 
earlier time-points (days 1-5 following onset of arthritis) compared to anti-CD31 but 
at later time-points (days 5-10 following onset of arthritis) there was relatively less 
anti-E selectin binding compared to CD31. Meaningful further quantification was not 
possible because of the limited number of available specimens with sufficiently 
preserved architecture. There was often considerable loss of tissue integrity and 
architecture following cryosectioning. This is one significant disadvantage of this 
technique. Frozen sections of demineralised bone are very brittle and quite often 
tissue damage occurred during preparation. Morphological analysis of demineralised 
cryosectioned bone tissue is not recommended due to difficulties in avoiding tissue 
artefacts at the sectioning procedure. For this reason only a few paw sections were 
available to compare from individual experiments. 
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Figure 5-10 E-selectin is expressed at early, mid and late time-points in CIA 
Serial sections at original x10 magnification showing anti-CD31 antibody staining (a,c,e) and anti-E-
selectin antibody staining (b, d, f) at days 1 (a, b), 5 (c, d) and 10 (e, f) of arthritis. Scale bars on images 
a, c and e are shown at 200μm. 
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Increased binding of anti-E-selectin antibody had therefore been demonstrated in ex 
vivo mouse paws with arthritis following the onset of CIA. I next sought to determine 
whether following i.v. injection of anti-E-selectin antibody, in vivo binding to 
activated endothelium could be detected in ex vivo specimens by secondary antibody 
directed against the E-selectin antibody (anti-rat antibody). This is demonstrated in 
Figure 5-11. 
 
Figure 5-11 Anti-E-selectin antibody can be detected following i.v. injection in 
CIA 
Sections of inflamed mouse metatarsal joint, taken from DBA/1 mouse with severe arthritis (>day 10 
from onset). Mice were injected with E-selectin (a, c, e) or isotype control anti–DNP (b, d, e) and 
sacrificed after 4 hours. Scale bars show length of 500m. Image (e) demonstrates small vessel staining 
with no similar staining shown in mouse injected with control antibody (f). Magnification scale bar in 
a) and b) 500μm.  
a) b)
c) d)
e) f)
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The above figure shows that E-selectin antibody can be detected at sites of 
inflammation in specimens that have received an injection of antibody in vivo. There 
was no positive staining for the control DNP antibody. Anti- E-selectin antibody was 
detected at 4 hours following i.v. injection of antibody but not at 12 or 24 hours not 
shown). The absence of antibody detection at the other time-points cannot be taken 
solely as evidence that detection was maximal at 4 hours since there was poor 
preservation of specimens as described above and although there was a consistent 
difference between anti-E-selectin and anti-DNP antibody, staining of specimens was 
variable in intensity. Since in vivo imaging experiments took place over 24 hours this 
made concurrent in vivo fluorescent imaging and immunohistochemical studies not 
possible within the same experiment. Combined with variable morphology from 
frozen sections, matching of specimens from separate experiments was also not 
always possible. 
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5.3.2 E-Selectin Targeted Fluorescence Imaging In Vivo: Quantifying 
Endothelial Activation In Collagen Induced Arthritis 
Having demonstrated E-selectin expression in mice with CIA by 
immunohistochemistry, the next part of the study aimed to assess E-selectin targeted 
fluorescence imaging in vivo in CIA. Arthritis was induced in DBA/1 mice by 
immunising with bovine type II collagen in CFA. Following the onset of arthritis 
animals were randomised into groups to receive either anti-DNP antibody or anti-E-
selectin antibody. The following Figure 5-12 shows that there was significant 
heterogeneity in the clinical score (Figure 5-12a) and paw thickness (Figure 5-12b). In 
many animals either a right or left hind paw developed arthritis, hence there were 
significant numbers of animals with a hind paw that had no evidence of arthritis as 
measured by conventional scoring parameters at the time of injection. 
 
 
 
 
 
 
 
Figure 5-12 CIA: clinical score and paw thickness for correlation in vivo 
fluorescent imaging study 
Graphs illustrate clinical score and paw thickness of all hind paws of DBA/1 mice with bovine collagen 
induced arthritis. Mice were randomised for injection with either anti-DNP or anti-E-selectin dye 
labelled antibody. Clinical score panel (a) and paw thickness (mm) panel (b) are shown at time of 
injection with dye labelled antibodies. RP-right paw; LP-left paw. 
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Mice with CIA were injected with either anti-E-selectin or anti-DNP antibodies 
labelled with Dylight 750 nm Near Infra Red fluorophore (5μg i.v.) and fluorescent 
images at different time-points post-injection were acquired. The following Figure 
5-13 demonstrates the MFI of DBA/1 mice 5-10 days following onset of CIA. This 
shows that with more severe arthritis there is increased signal in both anti-DNP and 
anti-E-selectin antibody injected animals. Figure 5-13c shows that there appears to be 
increased signal in the inflamed mouse paws of the anti-E-selectin injected mouse 
compared to the anti-DNP control antibody injected animal. In this case both mice 
(anti-E-selectin and anti-DNP injected) have a comparable clinical score and paw 
diameter. However taken together the represented examples demonstrate substantial 
heterogeneity in clinical score and paw diameter. This correlates with the visual 
images of MFI from all animals. Figure 5-13d shows that there appear to be similar 
levels of signal returned from animals for both groups that have not been immunised 
with bovine collagen and received either anti-E-selectin or DNP antibody injections. 
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Figure 5-13 CIA can be detected by detected by E-selectin targeted fluorescent 
imaging 
Following onset of arthritis induced with bovine collagen, DBA/1 mice with clinically distinct arthritis 
as assessed by clinical score and measurement of paw swelling were assigned into a group to receive 
either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm Near Infra Red fluorophore 
(5μg i.v.). Fluorescent images at different time-points post-injection following injection of labelled 
antibodies are shown from representative pairs of anti-E-selectin and anti-DNP injected mice with 
arthritis (a-c). The paw diameter (mm), and clinical score (score) are listed next to each paw for each 
animal. Panel (d) demonstrates fluorescent images of animals that had not received immunisation with 
bovine collagen. 
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Figure 5-14 E-selectin targeted signal can be detected in collagen-induced arthritis 
Following onset of arthritis induced with bovine collagen mice were injected with either anti-E-selectin 
or anti-DNP antibodies labelled with Dylight 750 nm Near Infra Red fluorophore (5μg i.v.). 
Representative images over a 24 hour period are shown in (a). Mean fluorescence intensity (MFI) 
scores of the hind paws and their relationship to the clinical score are shown in (b). The mean 
background of fluorescence intensity from control animals injected with either anti-E-selectin or anti-
DNP antibody but not immunised with bovine collagen has been subtracted). 
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The above Figure 5-14 represents a closer detail of Figure 5-13c. This demonstrates 
the relationship between the coloured fluorescent image and MFI quantification from 
both the inflamed and uninflamed paws in mice injected with either anti-DNP control 
antibody or anti-E-selectin antibody. The technique for quantification of MFI was 
identical to the method utilised in Section 4.3.1 using the TNF-induced paw oedema 
model. 
Quantification of the MFI of mouse paws demonstrates that there are marked 
differences in signal intensity between inflamed and uninflamed paws and that there is 
a higher measured MFI returned from the inflamed/arthritic mouse paw following 
injection of anti-E-selectin antibody than for either the uninflamed paw or for a mouse 
with arthritis and injected with anti-DNP antibody. The diameter and clinical score 
(3.2mm and 3.0mm respectively) is greater for the anti-DNP injected mouse 
compared to the diameter and clinical score for the anti-E-selectin injected animal 
(2.9mm and 2.5mm respectively). Since all mouse paws may be affected with arthritis 
following immunisation with bovine collagen, then using an unaffected paw as an 
internal control based on a clinical score of 0 may not be accurate. This paw may have 
subclinical arthritis and hence an increased MFI or there may be increased E-selectin 
expression in pre-arthritic uninflamed paws in animals injected with bovine collagen. 
In this example however, there are relatively small differences between anti-DNP 
control and anti-E-selectin injected animals although there does appear to be some 
heterogeneity in the fluorescent signal returned from the left paw of the E-selectin 
injected animal that had been given a clinical score of 0 (Figure 5-14a). 
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Groups of animals with CIA as depicted in Figure 5-12 were then further matched for 
clinical score and paw thickness to ensure that meaningful comparisons could be 
made between control DNP and E-selectin dye labelled antibody injected animals. 
Only mouse paws with clinically distinct arthritis and a hind paw thickness ≥2.2mm 
were compared. The selection of this level of paw swelling represents a threshold for 
paw thickness where there is moderate to severe, clinically definite arthritis. Clinical 
scores in anti-DNP and anti-E-selectin antibody injected groups were 2.1 ± 0.3 and 
2.1 ± 0.2 respectively (Pearson correlation coefficient = 0.85). Similarly, paw 
diameters in anti-DNP and anti-E-selectin antibody injected groups were 2.5 ± 0.3 and 
2.6 ± 0.2 respectively (Pearson correlation coefficient = 0.66). The matched groups 
are demonstrated in the following Figure 5-15. 
 
 
 
 
 
 
 
 
 
Figure 5-15 Matched clinical score and paw thickness for in vivo imaging of CIA 
Figure represents the clinical score and paw thickness (mm) for either anti-DNP or anti-E-selectin dye 
labelled antibody injected DBA/1 mice with bovine CII induced joint inflammation with characteristic 
oedema and erythema at days 2-10 following onset of arthritis. Mice with a hind paw thickness of 
≥2.2mm only were selected for comparison. 
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The following figure demonstrates the MFI from animals with a paw thickness of 
≥2.2mm and having clinically definite arthritis as demonstrated in the above Figure 
5-15. Healthy mice (not immunised with collagen) without arthritis were assessed for 
comparison. Significant differences were observed in the fluorescence intensity 
between healthy and arthritic animals injected with anti-E-selectin (p<0.001), and 
between arthritic animals injected with anti-E-selectin and anti-DNP (p<0.001). There 
were no significant differences between levels of MFI returned from healthy mice 
injected with either anti-DNP or anti-E-selectin injected antibody. For the subsequent 
analysis a mean background signal for both DNP and E-selectin injected animals was 
removed. The mean background signal was calculated from the mean signal returned 
from the paws of healthy animals (unimmunised with bovine collagen) injected with 
either anti-DNP or anti E-selectin antibody. 
 
 
 
 
 
 
 
 
 
Figure 5-16 E-selectin targeted signal can be detected in collagen-induced arthritis 
Following onset of arthritis induced with bovine collagen, mice with clinically distinct arthritis and 
paw thickness ≥2.2mm were injected with either anti-E-selectin or anti-DNP antibodies labelled with 
Dylight 750 nm Near Infra Red fluorophore (5μg i.v). Mean fluorescence intensity (MFI) scores for 
arthritic and healthy animals (non-immunised controls) are depicted. Data are mean ± SEM, and were 
analysed by 2-way ANOVA versus arthritic anti-E-selectin antibody-injected mice: *** p<0.001. 
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At the 8 hour time-point (after antibody injection) data demonstrate localisation of 
both antibodies to arthritic paws relative to non-arthritic paws, with a 2.34-fold 
increase in anti-E-selectin antibody fluorescence relative to DNP in inflamed paws 
(p<0.01). This is shown in Figure 5-17. Fluorescence signal following injection of 
anti-E-selectin antibody with subtraction of background signal (MFI of unimmunised 
mouse paw for anti-DNP and anti-E-selectin groups respectively) was combined with 
X-ray co-localisation. This demonstrated that areas of increased signal are often 
localised to the metatarsal heads and ankle joints. This corresponds with the increased 
levels of inflammation in these joints seen with immunohistochemistry. A 
representative example is shown in Figure 5-17b. 
 
 
Figure 5-17 E-selectin specific signal can be anatomically co-registered with plain 
X-ray imaging in collagen-induced arthritis 
Mice were injected with either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm 
Near Infra Red fluorophore (5μg i.v.). Panel (a) shows 8 hour time-point of mice with/without 
clinically definite arthritis and paw thickness ≥2.2mm. Background fluorescence levels from 
uninflamed paws of non-arthritic healthy mice for both anti-DNP and E-selectin animals have been 
subtracted. (b) Representative image of mouse with hind paw arthritis and corresponding image co-
registered with X-ray following subtraction of background fluorescence. Clinical scores of imaged 
paws are shown. Data are mean ± SEM, and were analysed by 1-way ANOVA versus arthritic anti-E-
selectin antibody injected mice: ** p<0.01, *** p<0.001. 
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The relationship between paw thickness and MFI in all mouse paws from animals 
where arthritis had been detected was also examined irrespective of whether they had 
reached a paw diameter of ≥2.2mm. Interestingly, in animals with CIA, both anti-
DNP and anti-E-selectin antibody fluorescence correlated with disease severity 
assessed as paw swelling (Pearson correlation co-efficient = 0.8605 and 0.863 
respectively; p<0.001). However, the anti-E-selectin antibody fluorescence was 
significantly different to that for anti-DNP (slopes 1676 ± 265.1 and 954.9 ± 160.7 
MFI arbitrary units per mm respectively, p<0.05). This is demonstrated in Figure 
5-18. 
 
 
 
 
 
 
 
 
Figure 5-18 E-selectin fluorescent signal correlates with mean paw thickness 
Mice were injected with either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm 
Near Infra Red fluorophore (5μg i.v.). At the 8 hour time-point the MFI of mice with/without arthritis 
was plotted against paw thickness. (Pearson correlation co-efficient = 0.8605 and 0.863 for anti-DNP 
and anti-E-selectin injected groups respectively; p<0.001). 
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5.3.2.1 E-selectin targeted signal detects subclinical arthritis 
To analyse whether E-selectin targeted signal demonstrates increased sensitivity for 
detecting subclinical arthritis, fluorescent images of paws were selected for analysis 
from the above CIA experiment that had been given a clinical score of 0, but in mice 
that had developed arthritis in other paws. These images were compared to the paws 
of control animals that had not been immunised with collagen to induce CIA. A 
representative image of a mouse with hind paw arthritis in one paw but no obvious 
arthritis in the second contralateral paw is shown in Figure 5-19b. Joints with a 
clinical score of 0 but with increased E-selectin signal were seen in animals that had 
arthritis in other paws (Figure 5-19c). The mean signal returned from these animals 
was 924 ± 37 arbitrary units. This was significantly different (p<0.01) to the mean 
signal from paws of animals that had not been immunised for CIA (mean signal 795 ± 
25). No significant differences were detected in the DNP signal returned from animals 
immunised for CIA (660 ± 43) compared to healthy controls (751 ± 46). Animals that 
had active arthritis in other paws were imaged, at between 5 and 10 days following 
arthritis onset (30-40 days following immunisation). The development of further 
arthritis in these paws would not be expected at this late stage of the experiment. 
Imaging also marked the endpoint of the experiment. 
A further experiment was performed to examine whether anti-E-selectin targeted 
antibody signal was detectable prior to the onset of arthritis (data not shown). 
Following injection of dye labelled antibody, imaging was undertaken at days 14 and 
21 following induction of arthritis. At day 14, none of the animals imaged had any 
detectable evidence of arthritis. None of the images showed any evidence of relative 
increased signal in any paws. At day 21, similarly, there were no animals where 
increased signal was visualised where arthritis was absent; i.e. this experiment did not 
demonstrate any predictive capability for detecting increased E-selectin expression 
prior to the onset of arthritis. Of the animals imaged at the day 14 time-point, 8 out of 
10 in the anti-E-selectin antibody injected group developed arthritis and 6 out of 10 in 
the anti-DNP antibody treated group developed arthritis. They developed arthritis 
sequentially from days 16 and 18 respectively. At day 21, in the anti-E-selectin 
injected group, 6 animals had no evidence of arthritis and 3 of those went on to 
develop arthritis 2, 3 and 5 days following imaging. In the anti-DNP antibody treated 
group imaged at day 21, 6 animals had no evidence of arthritis and 2 of these 
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developed arthritis 3 and 6 days following imaging. Repeated injection of dye labelled 
antibody was not considered in this experiment due to the comparatively long half life 
of the antibody in vivo making detection of small differences in signal not possible. 
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Figure 5-19 E-selectin targeted signal detects subclinical activation in CIA 
Mice were injected with anti-E-selectin labelled with Dylight 750 nm Near Infra Red fluorophore (5g 
i.v.). Paws were selected for analysis that had been given a clinical score of 0 in animals which had 
developed arthritis in other paws. These images were compared to the paws of age- and gender-
matched control animals that had not been immunised with collagen to induce CIA. (a) Representative 
image of mouse with arthritis in 1 of 2 hind paws (clinical scores and paw diameters are shown). (b) 
Picture and fluorescence image with co-registered X-ray of paw without visible arthritis. (c) 
Quantification of the mean fluorescence intensity (MFI) from immunised and control groups at 8 hours. 
Line shows mean value, and data were analysed by 1-way ANOVA: p<0.05. 
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5.3.2.2 Etanercept abrogates fluorescent signal in CIA 
 
 
 
 
 
 
 
 
Figure 5-20 Etanercept abrogates fluorescent signal in CIA 
Following onset of arthritis induced with bovine collagen, mice with clinically definite arthritis were 
either treated with etanercept (100μg i.p.) or left untreated. Groups were matched for clinical score and 
paw thickness, and injected with either anti-E-selectin or anti-DNP antibodies labelled with Dylight 
750 nm Near Infra Red fluorophore (50μg i.v.). Data are mean ± SEM, and were analysed by 1-way 
ANOVA versus arthritic mice: * p<0.05, ** p<0.01. 
Treatment with TNF-Fc fusion protein (etanercept; 100g i.p. on days 1, 4 and 7 
following onset of arthritis) abrogated arthritis. The clinical score at day 10 following 
arthritis onset was 4.43 ± 0.69 in untreated mice, compared to 0.15 ± 0.34 in 
etanercept-treated mice (p<0.05 by t-test, n=6 per group). This correlated with a 
significant reduction in E-selectin targeted fluorescence signal. This is demonstrated 
in the above Figure 5-20. A similar decrease in fluorescence signal was observed in 
the anti-DNP injected group. There were no significant differences between the E-
selectin and DNP etanercept-treated groups, and indeed between the E-selectin and 
DNP untreated groups.  
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5.3.3 Determining The Effect of The Human HER-1:HER-3 Epidermal Growth 
Factor Receptor Bispecific Ligand Trap on In Vivo E-selectin Targeted 
Fluorescent Imaging in CIA 
Studies performed at the Kennedy Institute sought to determine whether RB200 had a 
therapeutic effect when used for the treatment of CIA. Initial experiments suggested 
favourable results, demonstrating that the potent human EGFR extracellular domain 
heterodimer RB200 abrogates CIA. This was determined by measuring the effects of 
RB200 on conventional outcome measures such as paw swelling and clinical score. 
Further experiments were performed to assess whether low dose RB200 and 
combined blockade by the etanercept would have additional therapeutic benefit. I 
therefore also sought to determine the effect that this combination treatment had on in 
vivo E-selectin targeted fluorescent imaging.  
Disease was induced in 60 male DBA/1 mice (12 weeks old) as described in Section 
2.5.2. RB200 (gift from Dr Michael Shepard, Halozyme Therapeutics, San Diego, 
USA) was administered intra-peritoneally (i.p.) on day of disease onset (day 1), and 
then on days 4 and 7 of disease, at a dose of 0.5mg/kg or 10mg/kg, with equal 
volumes of PBS equivalent to etanercept given to control animals (n=6 per group. 
(Prior experiments performed at the Kennedy Institute had demonstrated significant 
efficacy of RB200 at 10 mg/kg, minimal efficacy at 1mg/kg and no significant 
difference in disease severity of CIA at 0.1mg/kg, unpublished observations). 
Etanercept was given (i.p.) on the day of disease onset (day 1), and then on days 4 and 
7, at a dose of 1mg/kg or 5mg/kg (equivalent to 20g and 100g per mouse 
respectively), with an equal volume of PBS equivalent to RB200 in control animals. 
(Similarly prior experiments had demonstrated significant abrogation of arthritis with 
100g (5mg/kg) of etanercept and minimal effect with 20g (1mg/kg) of etanercept; 
Kennedy Institute, unpublished observations). Combination treatment of 0.5mg/kg 
RB200 plus 1mg/kg etanercept was given i.p. on day of disease onset (day 1), and 
then on days 4 and 7. Arthritis was assessed by paw swelling or as clinical scores 
based on all 4 paws. Fluorescence imaging in vivo was performed on day 10, animals 
were injected with anti-mouse E-selectin MoAb labelled with DyLight 750nm near 
infrared probe (excitation/emission spectra 752nm/778nm respectively). In vivo 
imaging studies were undertaken at 2, 8 and 24 hours following i.v. injection of NIR 
labelled anti-E-selectin antibody. 
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Figure 5-21 Low dose etanercept and RB200 exert a synergistic effect on clinical 
score and paw swelling in acute collagen-induced arthritis  
Following onset of arthritis induced by bovine collagen, mice were treated i.p. on the day of disease 
onset (day 1), and then on days 4 and 7 of disease, with RB200 at a dose of either 0.5 (n=6) or 10mg/kg 
(n=8) or a combination of RB200 0.5mg/kg plus etanercept 1mg/kg (n=6). As controls, mice received 
5mg/kg etanercept (100μg) i.p. (n=6) or 1mg/kg (20μg) i.p of etanercept (n=7) or an equivalent volume 
of PBS (n=7). (a) Clinical score was assessed. (b) Paw swelling was measured with callipers over a 10 
day period, and data are both mean of the hind paws expressed as a difference from baseline. Results 
are expressed as mean ± SEM, and were analysed using 2-way ANOVA versus untreated mice: 
***p<0.001. 
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The above figures demonstrate the effects of either RB200 or etanercept on disease in 
mice with established CIA. This shows that at high dose both etanercept (5mg/kg) and 
RB200 (10mg/kg) have a significant effect on both progression of clinical score and 
paw swelling. Similarly low dose etanercept (1mg/kg) and RB2000 (5mg/kg) 
ameliorates clinical score and paw swelling. The combination of RB200 and 
etanercept at low dose has a marked effect on both measures of disease activity in 
CIA. Indeed the RB200 and etanercept combination was significantly different to 
either low dose etanercept alone (p<0.001 for both clinical score and paw swelling) or 
low dose RB200 alone (p<0.001 for both clinical score and paw swelling). 
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Figure 5-22 Low dose etanercept and RB200 exert a synergistic effect on E-selectin 
targeted in vivo fluorescent imaging in acute collagen-induced arthritis 
Following onset of arthritis induced by bovine collagen, mice were treated i.p. on the day of disease 
onset (day 1), and then on days 4 and 7 of disease, with RB200 at a dose of 0.5 mg/kg or a combination 
of RB200 0.5mg/kg plus etanercept 1mg/kg. As controls, mice received 1mg/kg of etanercept or an 
equivalent volume of PBS. For imaging mice were injected with near infrared dye labelled anti-E-
selectin antibody (5μg i.v.); images were obtained 8 hours following injection of the dye antibody 
conjugate. Left hand panel depicts mean fluorescent intensity of representative images following 
application of a colour wheel to depict signal intensity. Right hand panel demonstrates corresponding 
image co-registered with X-ray following subtraction of background fluorescence (mean signal 
intensity from animals not immunised for CIA). 
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Figure 5.22 (continued) 
Following onset of arthritis induced by bovine collagen, mice were treated i.p. on the day of disease 
onset (day 1), and then on days 4 and 7 of disease, with RB200 at a dose of 0.5 mg/kg or a combination 
of RB200 0.5mg/kg plus etanercept 1mg/kg. As controls, mice received 1mg/kg of etanercept or an 
equivalent volume of PBS. For imaging mice were injected with near infrared dye labelled anti-E-
selectin antibody (5μg i.v.); images were obtained 8 hours following injection of the dye antibody 
conjugate. Left hand panel depicts mean fluorescent intensity of representative images following 
application of a colour wheel to depict signal intensity. Right hand panel demonstrates corresponding 
image co-registered with X-ray following subtraction of background fluorescence (mean signal 
intensity from animals not immunised for CIA). 
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The above representative examples of fluorescent imaging demonstrate that the 
combination of low dose etanercept and RB200 apparently have a marked effect in 
decreasing the E-selectin targeted signal in animals with arthritis when compared with 
either treatment on its own. While both low dose etanercept (1mg/kg) and RB200 
(0.5mg/kg) had some overall therapeutic efficacy on the total amount of arthritic 
disease in each animal, it was only with combination treatment that there was 
complete abrogation of fluorescent signal. Quantification of MFI over 24 hours in the 
different treatment groups is demonstrated below. This shows that combination 
treatment returns the E-selectin targeted MFI to the same levels as that seen in control 
animals that have not been immunised for CIA. Comparing the effect of anti-DNP and 
anti-E-selectin in the treatment groups would help to answer whether there is a 
differential effect of combination treatment on E-selectin specific signal. This was not 
possible in this experiment due to the sizes and diversity of treatment groups 
constraining the number of animals that could be imaged. The following Figure 5-23 
demonstrates that the combination of low dose RB200 and etanercept have a 
significant additive effect on abrogation of E-selectin targeted fluorescent signal, 
when compared to either treatment administered in isolation. The mean fluorescence 
signal for each animal has been calculated by adding the mean fluorescence from both 
left and right hind paws. For the purposes of clarity mean fluorescent signal returned 
from animals treated with either high dose etanercept or RB200 have not been 
included on this graph, but are included in the following Figure 5-24. This figure 
demonstrates the mean signal returned from each paw of all animals in all treatment 
groups. 
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Figure 5-23 Low dose etanercept and RB200 exert a synergistic reduction in E-
selectin targeted signal in acute collagen-induced arthritis 
Following onset of arthritis induced by bovine collagen, mice were treated i.p. on the day of disease 
onset (day 1), and then on days 4 and 7 of disease, with RB200 at a dose of either 0.5 (n=6) or 10mg/kg 
(n=8) or a combination of RB200 0.5mg/kg plus etanercept 1mg/kg (n=6). As controls, mice received 
5mg/kg etanercept (n=6) or 1mg/kg of etanercept (n=7) or an equivalent volume of PBS (n=7). For 
imaging mice were injected with near infrared dye labelled anti-E-selectin antibody (5μg i.v.); images 
were obtained at 2, 8 and 24 hours following injection of the dye antibody conjugate. Results are 
expressed as mean ± SEM of both hind paws, and were analysed using 2-way ANOVA versus 
untreated mice: ** p<0.01, ***p<0.001. An additional comparison between mice treated with RB200 
0.5mg/kg plus etanercept 1mg/kg and etanercept 1mg/kg alone is also shown.  
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Figure 5-24 Low dose etanercept and RB200 exert a synergistic reduction in the 
incidence and severity of E-selectin targeted signal in acute collagen-
induced arthritis  
Following onset of arthritis induced by bovine collagen, mice were treated i.p. on the day of disease 
onset (day 1), and then on days 4 and 7 of disease, with RB200 at a dose of either 0.5 (n=6) or 10mg/kg 
(n=8) or a combination of RB200 0.5mg/kg plus etanercept 1mg/kg (n=6). As controls, mice received 
5mg/kg etanercept (n=6) or 1mg/kg of etanercept (n=7) or an equivalent volume of PBS (n=7). For 
imaging mice were injected with near infrared dye labelled anti-E-selectin antibody (5μg i.v.); images 
were obtained at 8 hours following injection of the dye antibody conjugate. Data was analysed by 1-
way ANOVA versus untreated mice (***p<0.001). 
The MFI returned from each individual mouse paw from each treatment group at the 8 
hour time-point is shown in Figure 5-24. This highlighted that the combination 
treatment results in a marked reduction in arthritis in all mouse paws. The mean 
fluorescent signal from other treatment groups showed that higher levels of signal are 
returned from a proportion of animal paws, suggesting that there remained elevated 
levels of inflammation in these groups. Further experiments with increased animal 
numbers would be required to delineate the additional benefit of combination 
treatment at differing relative doses. 
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5.4 Discussion 
CIA is an animal model that has significant similarities to RA and is characterised by 
progressive joint swelling and destruction. In this chapter, I have established that 
during the course of CIA, E-selectin expression on activated endothelium can be 
detected by immunohistochemistry. I have then shown that NIR dye labelled anti-E-
selectin antibody can be detected by fluorescent reflectance imaging in the inflamed 
paws of animals with CIA when compared to the uptake of NIR dye labelled isotype 
control antibody to similar sites of inflammation within the arthritic joint. 
Furthermore, subclinical levels of increased E-selectin signal are investigated. This is 
a novel method for detecting and quantifying the in vivo expression of E-selectin in 
CIA. Finally, I have demonstrated that NIR E-selectin targeted imaging can be used to 
investigate the effects of a novel therapy in CIA. This has quantified the effect of 
RB200 – a pan ligand EGFR trap - that demonstrated a significant synergistic 
blockade of E-selectin targeted fluorescent signal when used in combination with low 
dose etanercept. 
CIA was induced by immunising male DBA/1 mice with heterologous (bovine) type 
II collagen. Clinical observations and measurements of both paw swelling and clinical 
score have confirmed that CIA followed a typical clinical course of disease in these 
experiments. Similarly, histological analysis also confirmed the presence of arthritis 
and progressive joint destruction with worsening severity of arthritis. Synovial 
vascularisation was also assessed by microscopic examination of tissue sections 
probed for both E-selectin and CD31 by immunohistochemistry. Angiogenesis, the 
formation of new blood vessels, is one of the earliest histolopathologic findings in RA 
and appears to be necessary for pannus development (Kimball and Gross 1991) and 
also plays an active role in inflammation as a source of both cytokine and protease 
activity due to the increased number of blood vessels and infiltrating cells brought in 
by these vessels (Colville-Nash and Scott 1992). The expanded vascular bed volume 
resulting from angiogenesis may be further expected to have ongoing expression of 
cytokines including E-selectin. This has been confirmed by the 
immunohistochemistry experiments described in this chapter that show increased 
CD31 expression within areas of invading inflamed synovium around the arthritic 
joint and in addition also demonstrated E-selectin expression within these areas. 
Analysis of the immunohistochemistry specimens demonstrated that not all specimens 
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or areas of inflamed tissue demonstrated E-selectin expression. This emphasizes the 
difficulty of analysing immunoreactivity of antigens expressed on the endothelial 
surface following the fixation process for mouse paws as described in Section 2.6. A 
previous study that investigated the expression of E-selectin CIA noted occasional E-
selectin expression that may be due to underlying specimen preparation (Everts, 
Asgeirsdottir et al. 2003). However, analysis of E-selectin expression in different 
tissues in the pig following E-selectin staining showed most intense staining on the 
endothelium of arteries and veins of all sizes, with less expression on capillaries 
(Keelan, Licence et al. 1994). This observation indicates that there may be 
heterogeneity between the EC lining of different vessels in their capacity to respond 
to stimulation by inflammatory signals such as cytokines. They may therefore have a 
differing ability to react to leukocytes. Differences between the pattern of 
immunohistochemical staining for E-selectin expression and in vivo findings may 
occur for other reasons. A component of fluorescent signal in inflamed tissue may be 
due to the uptake of fluorescently labelled E-selectin antibody bound to soluble E-
selectin. Evidence does support there being a pool of soluble E-selectin and this is 
discussed in Section 1.2.2.3. Attempts were made to further analyse the distribution of 
E-selectin in the inflamed paw with fluorescent microscopy following injection of 
NIR dye-labelled antibody. This however proved challenging since there were 
limitations to the filter sets that were available in the NIR range and following 
specimen preparation there were significant levels of autofluorescence in the 
heterogenous tissue of the inflamed paw. The co-registration of fluorescent signal 
with plain X-ray however, has helped to delineate increased in vivo signal around the 
ankle and metatarsal heads. This corresponded with the sites of maximal tissue 
damage observed on histological specimens. More detailed analysis of these changes 
using the current imaging and X-ray device would be limited by the resolution of 
digital images obtained. There are alternative macroscopic fluorescent imaging 
devices that have a higher level of resolution compared to the apparatus used for these 
experiments. For example, two photon-excitation microscopy is a fluorescence 
imaging technique that allows imaging of living tissue up to a depth of one millimeter 
(Denk, Strickler et al. 1990). Compared to a confocal microscope, photon detection is 
much more effective since even scattered photons contribute to the usable signal. A 
number of limitations of two-photon microscopy exist: the pulsed lasers needed for 
two-photon excitation are much more expensive then the constant wave (CW) lasers 
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used in confocal microscopy; the two-photon absorption spectrum of a molecule may 
vary significantly from its one-photon counterpart; and for very thin objects such as 
isolated cells, single-photon (confocal) microscopes can produce images with higher 
optical resolution due to their shorter excitation wavelengths. In light scattering tissue, 
on the other hand, the superior optical sectioning and light detection capabilities of the 
two-photon microscope result in better performance. It is therefore a technique that 
with appropriate adaptations may be well suited to imaging peripheral arthritis in 
animal models. 
One of the significant challenges of this section of work was to ensure that there were 
sufficient animals within each comparator group so that levels of arthritis were closely 
matched for clinical score and paw swelling. The heterogeneity of CIA is a useful 
paradigm of RA, but this makes matching for changes in clinical score and paw 
thickness between groups of animals very challenging. My work in the previous 
chapter had shown that a significant component of the fluorescent targeting was due 
to the non-specific uptake of antibody to sites of inflammation. This occurs at sites 
where there is increased vessel permeability allowing leakage of macromolecules 
from the circulation into the inflamed area. The initial immunohistochemistry work in 
CIA had shown that E-selectin expression could be detected at both early, mid and 
late time-points during the course of arthritis. Overall analysis of the control and anti-
E-selectin antibody targeted groups did also confirm that they were matched for 
duration of arthritis and the time of imaging. Nevertheless this did not give precise 
information about the time course of E-selectin expression during the evolution of 
arthritis in the CIA model. The heterogeneity of CIA is also reflected when analysing 
the fluorescent emission from both arthritic and non-arthritic paws in CIA. This 
showed that there is considerable variation in signal intensity, between animals and 
between paws in the same animal. This is reflected in Figure 5-20 - while there are 
significant differences between etanercept treated and untreated groups there were no 
differences between E-selectin and DNP targeted untreated groups. There are likely to 
be a number of reasons for this. The number of animals in each of the groups was 
comparatively small (n=3-4 per group) so that despite matching of groups for clinical 
score there was significant heterogeneity in signal. Also, this experiment was 
performed prior to the experiments detailed in Section 4.3.4 that showed an injection 
of 5g dye labelled antibody had increased sensitivity for detecting differences in the 
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MFI between anti-DNP and anti-E-selectin dye labelled injected animals. Hence, in 
order to detect the E-selectin specific component of the fluorescent signal in CIA 
compared to trafficking of non targeted antibody, the number of animals was 
increased in each comparator group, the optimum dose of antibody was used and 
paws were closely matched for clinical score and the extent of paw swelling. By 
closely controlling for these parameters I have shown that E-selectin targeted signal 
can be detected during the evolution of arthritis in CIA in addition to the increases in 
signal from anti DNP injected antibody. This suggests that there is ongoing 
endothelial activation and E-selectin expression in the inflamed joint, in addition to 
changes in vascular permeability. Other workers have also recorded potential 
difficulties analysing data from CIA experiments due to low levels of incidence and 
disease heterogeneity. For example Palframan and colleagues did not generate enough 
data points to examine the distribution of fluorescently labelled certolizumab pegol at 
all stages of arthritis (Palframan, Airey et al. 2009) and paws were only analysed with 
a score of 2 which may significantly decrease the objectivity of comparisons between 
groups because of the subjective nature of clinical scoring. 
The heterogeneity of CIA was also a particular challenge when attempting to 
determine whether E-selectin targeted imaging could be utilised as a predictor of 
arthritis onset in any given animal. Since the onset of arthritis may be at any time-
point between 14-30 days following immunisation assessing at which time-point to 
image was problematic. Similarly, obtaining matched animals between groups when 
incidence of arthritis was variable was also challenging. Over a number of 
experiments it was also noted that at times a number of animals develop a transient 
arthritis that subsequently resolved. The reasons for this spontaneous regression or 
lack of arthritis progression are not understood. It may be possible that there is an 
imbalance between regulatory T-cell (Treg) numbers at various time-points during the 
evolution of arthritis. This supported by the finding that anti-CD3 therapy expands the 
number of CD4+ and CD8+ Treg cells and induces sustained amelioration of CIA 
(Notley, McCann et al.). Since it is possible to label anti-CD3 antibody one possibility 
would be to co-image animals following injection with two different fluorescently 
labelled targets such as anti-CD3 and anti-E-selectin antibody. These could be 
labelled with similar fluorophores but with sufficiently different excitation/emission 
wavelengths so that they could be discriminated in vivo. By injecting both antibodies 
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into the same animal it would be possible to measure their differing fluorescent 
emission over the time course of inflammation. It would also be of interest to 
investigate the early expression of E-selectin prior to the onset of arthritis further. 
This would obviously be of significant use clinically to determine appropriate targeted 
molecular therapy at an early stage in the evolution of arthritis. Further comparison 
regarding the change in anti-E-selectin versus anti-DNP dye labelled antibody signal 
changes over the time course of arthritis would also be of interest. This would provide 
information about in vivo dynamic changes in adhesion molecule expression 
compared to local permeability changes during the evolution of early arthritis. 
Injection of dye labelled control antibody does also detect changes in paw thickness 
and paw oedema in CIA. There is a linear correlation between paw swelling and the 
MFI returned from inflamed joints. The trafficking of macromolecules to sites of 
inflammation due to increased vessel permeability has previously been recognised to 
take place at the inflamed joint and this is discussed in Section 1.2.4. The NIR 
fluorophore Cy5.5 was visualised in arthritic knee joints following induction of 
antigen induced arthritis in mice (Hansch, Frey et al. 2004) showing a 1.5 fold 
increase in signal in the inflamed knee joint. This is similar to the increase in anti-
DNP antibody fluorescent signal - demonstrated at the 8 hour time-point in Figure 
5-17. However it is at this time-point that there is a further 2.34 fold increase in anti-
E-selectin targeted fluorescence signal which points to ongoing E-selectin expression 
on the activated endothelium in CIA. This suggests that there is continued recruitment 
of inflammatory cells to sites of inflammation in CIA during the progression of 
arthritis. 
This study however, did demonstrate that E-selectin targeted signal can be detected in 
animals immunised for CIA with subclinical arthritis suggesting that even in animals 
without overt arthritis there is a background level of vascular activation. Closely 
correlating increased signal in these animals with underlying histological change, may 
help to determine whether there are underlying histological abnormalities in these 
paws or whether increased signal represents a general or systemic increase in E-
selectin targeted signal. This may help to delineate be whether there has been 
complete abrogation of arthritis and vascular inflammation by targeted molecular 
therapy, or whether there was only amelioration of arthritis.  
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The effect of the fusion receptor protein etanercept on fluorescence imaging in CIA 
was also examined. In this experiment it was challenging to generate sufficient 
numbers in both treatment and control groups to adequately examine the differences 
between the reduction in isotype control (non-specific) fluorescent signal and the 
signal due to specific E-selectin targeting. In the previous chapter I demonstrated that 
E-selectin targeted imaging was significantly reduced by etanercept in the TNF-
induced paw inflammation model. Since there is likely to be a significant proportion 
E-selectin expression early in the course of this model then blockade of TNF is 
likely to have a significant effect on the E-selectin specific component. However in 
the CIA model E-selectin expression is likely to be at a continuous but lower level 
over the chronic course of arthritis, hence etanercept may have a proportionately less 
significant effect on selectin versus non-specific dye trafficking. 
The final section of work in this chapter examined the differential effect of the novel 
pan ligand EGFR blocker RB200 on both conventional clinical scoring and on E-
selectin targeted in vivo optical imaging. In order to determine the effects of both 
etanercept and RB200 at high and low dose, as well as the two in combination at low 
dose and obtain matched groups, I examined their respective effects on E-selectin 
targeting only. The combination of low dose RB200 and etanercept completely 
abrogates arthritis by both measures. It is interesting to note that this includes 
complete abrogation of the fluorescent signal to a level seen in healthy controls. 
Cellular heterogeneity, redundancy of molecular pathways and effects of the 
microenvironment are all likely to contribute to the disease heterogeneity seen in CIA. 
This makes it unlikely that therapy directed at one abnormally activated signalling 
pathway is likely to be sufficient (Citri and Yarden 2006). Therefore combined 
blockade of functionally linked and relevant multiple targets has become an attractive 
therapeutic strategy. The implications of this are discussed further in Chapter 6 
In summary in this chapter I have demonstrated that E-selectin targeted is a viable in 
vivo imaging technique in CIA with significant potential to investigate further the 
early molecular changes that occur in arthritis in the animal model. The combined 
approach of collectively targeting EGFR signalling, thereby inhibiting the potential 
for neoangenesis as well as blockade of the key cytokine TNF that may be produced 
both prior and following EGFR activation represents an opportunity to switch off the 
molecular aberrations in CIA and prevent the evolution of arthritis. Deploying a novel 
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molecular in vivo fluorescence imaging technique by targeting the endothelial 
expression of E-selectin may also be a highly specific method of monitoring the 
effects of dual targeted therapy. 
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6 GENERAL DISCUSSION 
Expression of leukocyte adhesion molecules such as E-selectin on the surface of EC is 
one of the first steps in the evolution of chronic inflammation, which underlies the 
pathogenesis of disease states such as RA. The first objective of this study was to 
demonstrate the use of a fluorescently labelled monoclonal antibody against E-
selectin to visualise endothelial activation by optical imaging in inflamed tissues in 
vivo. I have demonstrated that both E-selectin and DNP isotype control antibody can 
be reproducibly manufactured from cell culture and have ensured that labelling with a 
NIR dye was achieved reliably. The parameters of in vivo NIR imaging of arthritis 
have been explored so that specific and background signal from inflamed joints was 
determined. I have then demonstrated that E-selectin targeted in vivo optical imaging 
both in the TNF-induced model of paw inflammation and in acute CIA is a sensitive, 
specific and quantifiable molecular imaging technique. My second objective was to 
determine whether the effects of novel vascular targeted therapy can be interrogated 
by utilising E-selectin targeted in vivo fluorescent imaging. The effects of RB200, a 
pan ligand EGFR trap, were investigated. NIR E-selectin targeted imaging was able to 
delineate clear differences between both E-selectin and RB200 treatment groups and 
to demonstrate the abrogation of arthritic E-selectin generated signal with the 
combination of low dose etanercept and RB200. 
Developing a model of inflammation by injecting TNF into the hind paw to generate 
acute inflammation was a key component of the success of this project. This 
technique has previously been utilised to demonstrate the role of TNF in the 
development of acute inflammatory hyperalgesia (Cunha, Poole et al. 1992). The 
novel use of the TNF-induced paw model was utilised as an in vivo platform for 
targeted fluorescence experiments. Disease onset was acute, incidence was 100%, 
animal redundancy was minimised and the TNF dose-dependent inflammatory 
response was extremely reproducible. Furthermore imaging and anaesthetic protocols 
were developed and standardised, so that imaging could be performed safely on 
multiple animals at selected time points over 24 hours to investigate peak differences 
between control and target antibody injected groups. Labelling E-selectin with a 
fluorophore in the NIR range was also important for successful in vivo imaging. This 
ensured specific signal from inflamed paws was not subject to the significant 
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autofluorescence that occurs when imaging at lower wavelengths (Fischer, 
Gemeinhardt et al. 2006; Weissleder and Pittet 2008). Preliminary work demonstrated 
that at lower wavelengths autofluorescence would be a major limiting factor in 
detecting signal from a specific molecular target. Therefore imaging at higher 
wavelengths e.g. in the NIR range has helped to increase the sensitivity of optical in 
vivo imaging by decreasing background autofluorescence. The time course of NIR 
fluorophore-labelled anti-E-selectin antibody binding over 6-8 hours in this model is 
in keeping with previously found kinetics for E-selectin expression in vivo (Harari, 
McHale et al. 1999). Measuring levels of signal from uninflamed paws determined 
signal sensitivity (E-selectin antibody signal versus background), whereas comparing 
anti-DNP control antibody injected groups to those injected with anti-E-selectin 
antibody determined signal specificity. Subtracting background signal from 
uninflamed paws from the signal obtained from inflamed paws was one method of 
ensuring variations due to differences in injection volumes between animals were 
excluded. Furthermore this refined model allowed for a considerable reduction in the 
number of animals required for initial in vivo imaging techniques. Experiments could 
be designed and performed rapidly and the incidence of inflammation within each 
experiment was 100%. Consistent levels of paw swelling were also generated 
following injection of TNFα into the footpad and this further reduced the number of 
animals required. This adheres to the principles of good experimental practice for 
humane experimental techniques that have been instituted and developed for 
biomedical research in all specialties (Workman, Aboagye et al. 2010) This model 
also provided useful information about the differences between non-specific 
trafficking of dye labelled anti-DNP antibody compared to E-selectin targeted 
imaging. TNF-driven acute inflammation by direct injection in the footpad is likely 
to cause vascular permeability changes by upregulating a number of local pro-
inflammatory agents that lead to acute permeability changes in the vessels of the 
mouse paw. Interestingly, the TNF paw injection model was originally developed 
for investigating pain pathways in the foot. This is described further in Section 1.4.2. 
Previous work on this and other similar models of acute inflammation in the footpad 
have demonstrated that there may well be a significant neurogenic component to local 
paw swelling. In particular the tachykinin neuropeptide substance P has been shown 
to be a potent mediator of microvascular permeability. This is discussed further in the 
introductory Section 1.2.4. It is therefore likely that both DNP and a proportion of E-
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selectin labelled antibodies have similar initial trafficking into the inflamed mouse 
paw. Nevertheless, E-selectin upregulation (as demonstrated by 
immunohistochemistry) leads to additional targeting of anti-E-selectin labelled 
antibody as detected by fluorescence imaging. The differences between local or 
regionalised specificity of dye antibody trafficking versus EC specific targeting are of 
interest for both future molecular imaging as well as the potential for specific 
targeting of the inflamed synovium to enhance local delivery of novel therapeutics.  
The observations from the TNF-induced paw oedema model were then translated 
into the murine heterologous CIA model. This has several similarities with RA, 
including synovitis, pannus formation, erosion of cartilage and bone, fibrosis and joint 
rigidity (Holmdahl, Jansson et al. 1986; Holmdahl, Andersson et al. 1989). Despite 
much work in CIA focussing on disease pathways, the dynamic changes in leukocyte 
expression remain poorly defined. Immunohistochemistry to detect expression of 
antigens such as E-selectin, to inform on changes in leukocyte trafficking, can be 
challenging and difficult to quantify. Hence, for this project novel techniques for paw 
decalcification and specimen preparation were utilised to ensure that E-selectin and 
the vascular marker CD31 could be detected. This demonstrated that E-selectin could 
be detected at both early (day 2), mid (day 5), and late (day 10) of arthritis. When in 
vivo imaging was applied in the CIA model, with close matching of clinical groups 
for disease severity, E-selectin signal could be detected as early as 30 minutes and up 
to 24 hours following antibody injection with significant correlation between E-
selectin and clinical score. In CIA, as was the case with the acute paw oedema model, 
the differences between specific and non-specific trafficking of either anti-DNP or 
anti-E-selectin dye labelled antibody are of interest. In the TNF-induced model, 
early release of vasactive mediators following TNF injection generates acute 
permeability change leading to both non-specific trafficking of antibody as well as 
increased anti-E-selectin antibody binding as discussed above. However in the CIA 
model, where arthritis is well established, there are also likely to be other factors as 
well as expression of vasoactive substances that lead to ongoing permeability 
changes. In established CIA the invading synovium is rich in neoangiogenic blood 
vessels that have disordered architecture and increased vascular permeability . This is 
likely to be similar to the permeability change that occurs in neoangiogenic tumour 
blood vessels (McDonald and Baluk 2002). Primarily, the increased leakiness of 
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pathologic neoangiogenic vessels compared to normal vessels, is therefore also likely 
to play an important role in generating fluorescent signal in established CIA. The 
initial investigations of E-selectin targeted in vivo optical imaging in CIA focussed on 
analysing whether specific signal can be achieved compared to isotype control 
antibody in animals with established arthritis. In these animals there does appear to be 
ongoing E-selectin expression that can be detected by E-selectin targeted optical 
imaging. However, I have also shown that there was increased E-selectin upregulation 
in non-arthritic paws in these animals with no significant increase in anti-DNP 
antibody targeted signal. This may suggest that there is either local or systemic 
ongoing vascular activation in CIA which does not lead to substantial local 
permeability change (since this change would be represented by increased levels of 
control antibody signal due to non-specific macromolecular leakage into the inflamed 
synovium). Further analysis of these groups including histological correlation would 
be required to verify that this in vivo imaging technique could be used to investigate 
the differences between E-selectin upregulation and permeability change during the 
course of CIA. Analysis of anti-E-selectin binding prior to disease onset would also 
provide important details about early vascular changes occurring during the inception 
of arthritis. The disease heterogeneity seen in CIA to a degree reflects the complex 
pattern of disease seen in RA, which is characterised by more complex patterns of 
joint involvement and relative sparing of some joints, such as the distal 
interphalangeal joints in the hands. The reasons for tissue specific differences in 
disease expression and vascular permeability in RA or indeed in the animal model 
have not been fully elucidated but could be addressed further with vascular targeted 
optical imaging. More recent investigations into the mechanisms that may underlie 
joint specific inflammation have indicated that there are tissue specific cell adhesion 
molecules and vascular ‘addressins’, in addition to chemokine-receptor interactions 
(Pitzalis and Garrood 2006). In addition other evidence suggests that arthritogenic 
antibody transfer from K/BxN mice causes local macromolecular vasopermeability 
(Binstadt, Patel et al. 2006). This is also discussed in Section 1.2.4 in relation to the 
general permeability changes that occur due to the realease of local vasoactive amines 
and due to the pathologic architecture of neoangenic vessels.  
Few studies have investigated the changes in vascular permeability that occur in RA 
and other inflammatory diseases. One early study performed by Jayson and colleagues 
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in 1971 did analyse the rate of tissue fluid formation in the forearms of patients with 
RA, demonstrating that there were increases in the rate of oedema formation that was 
independent to pre-existing therapy (Jayson and Barks 1971). There are however clear 
differences between CIA and RA. Arthritis in the mouse paw occurs in association 
with oedema of the whole mouse paw – it is this change that is readily detected by 
fluorescent imaging where there is a linear correlation between paw swelling and 
mean fluorescent signal. In RA there may be localised joint swelling, but not swelling 
of the whole hand or foot. RA is also characterised by significant levels of bone 
marrow oedema that occurs at both early and established phases of disease. 
Longitudinal MRI analysis of bone marrow oedema in the wrists of patients with RA 
has been demonstrated to predict erosive progression (Palosaari, Vuotila et al. 2006). 
Bone marrow oedema (i.e. increased water content in the trabecular bone) can also be 
a non-specific and reversible finding that is frequently seen in patients following 
trauma and other conditions such as OA. Detecting differences between non-specific 
oedematous changes and those associated with progression to inflammatory joint 
disease would clearly be helpful. There are limitations to the current system since 
oedema from different tissues can only be viewed in two dimensions. But the facility 
to co-register images with digital X-rays of the target region further helped delineate 
anatomical localisation of fluorescence signal has been explored in this study. This 
helped to identify signal in specific areas such as around the ankle and forefoot joints. 
The ability to co-register images using different modalities such as optical and X-ray 
imaging is likely to be of significant use when using novel imaging platforms to 
detect underlying pathological molecular changes in arthritis. A multimodal 
nanoparticle contrast agent containing embedded luminophores and surface 
immobilised gadolinium chelates has been developed as a contrast agent for inflamed 
synovium in CIA (Kim, An et al. 2009). Multimodal imaging in a heterogeneous 
model such as CIA is likely to be of significant use so that accurate comparisons in 
individual animals can be made.  
The detection of subclinical activation in CIA may be useful for other reasons. Firstly, 
it may be that this can be developed as a method of detecting very early arthritis. 
Interestingly this compares with similar findings when radiolabelled E-selectin was 
used to image endothelial activation in RA and found to image specifically some 
clinically silent joints (Chapman, Jamar et al. 1996). Secondly, the detection of 
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ongoing subclinical levels of endothelial activation in CIA may be of use in detecting 
the efficacy of therapy. As targeted therapy evolves to complete blockade of arthritis, 
there will be a need to ensure that disease activity has been completely abrogated. It is 
well recognised in RA, that vascular inflammation leads to worsening cardiovascular 
morbidity and mortality. Standardised mortality ratios for cardiovascular disease in 
RA range from 1.2 to 5 and cardiovascular death accounts for up to 50% of mortality 
with life expectancy reduced by 10-15 years (Sattar, McCarey et al. 2003). There is 
also a similar trend in patients with systemic lupus erythematosus and other 
connective tissue diseases with a marked increase in stroke and myocardial infarction 
reported (Esdaile, Abrahamowicz et al. 2001). This is supported by both 
epidemiological data and in addition there is strong evidence that systemic markers of 
inflammation independently predict coronary heart disease events in men and women 
without pre-existing heart disease (Sattar, McCarey et al. 2003). The suspected 
pathogenesis of atherosclerosis has evolved from a lipid deposition disorder to a focal 
chronic inflammatory disease with upregulation of macrophage activating cytokines 
such as TNF, IL-1 and IL-6 (Pasceri and Yeh 1999). Hence, an in vivo imaging 
system that is able to target E-selectin expression on chronically activated 
endothelium and its abrogation by specific molecular therapy may be of considerable 
use in determining longer term responses to treatment. There are however limitations 
to the current system in this respect. Imaging has been possible in the relatively 
denuded mouse paw that is only a few millimetres thick, but attempts to imaging 
specific signal in other areas have been less successful. For example to image chronic 
inflammatory change in large vessels such as the aorta other tissue as well as mouse 
skin and fur would contribute to light scattering. The current imaging device would 
also lack resolution to detect signal change in specific vessels clearly. One solution 
may be to deploy alternative hardware devices that utilise tomographic techniques to 
generate images in multiple planes so that signal can be resolved at different depths in 
three dimensions. A recently published study utilised novel tomographic techniques to 
discriminate between DMARD and non-DMARD therapy in CIA. Although the 
tomographic technique allowed discrimination of different parts of the mouse paw, 
resolution may need to be improved further to delineate signal differences between 
large vessel walls and their lumen in CIA (Peterson, Labranche et al.). 
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Other studies also reflect similar kinetics for in vivo imaging of experimental arthritis 
with NIR fluorescence. Hansch et al examined early experimental arthritis with NIR 
fluorescence in a murine model of antigen induced arthritis; the target was the F4/80 
antigen present on the surface of macrophages. This demonstrated that there were 
peak differences in signal intensity at 2-6 hours following antibody injection with a 
reduction in responses to baseline levels of fluorescence at 72 hours following 
injection of isotype control antibody with still some residual level of fluorescence 
from Cy5.5 target antibody (Hansch, Frey et al. 2004). Changes in the level of the 
F4/80 antigen as detected by immunohistochemistry were not measured in this 
experiment. A cathepsin B activateable NIR fluorescent probe was used in a mouse 
model of osteoarthritis and showed a 3-fold difference in signal intensity between 
normal and osteoarthritic joints (Bhaumik and Gambhir 2002; Lai, Chang et al. 2004). 
My study, however, is the first to target the endothelium by a specific molecular 
marker and to quantify the temporal changes of both isotype control and targeted 
antibody trafficking in two differing murine models of arthritis. 
Using E-selectin targeted fluorescent imaging to test the action of the novel 
compound RB200 marked the second important objective of this study. This was 
firstly an opportunity to investigate the efficacy of this drug in CIA using a novel 
molecularly targeted in vivo imaging technique. Secondly this helped to delineate the 
possibilities for using a vascular targeted imaging technique to define the effects of 
therapy in vivo. This showed the additional abrogation of E-selectin targeted signal 
with combination therapy. Significant evidence points to a link between EGFR 
receptor blockade and downstream signalling pathways that lead to neoangiogenesis 
in the inflamed joint. Ligand binding to EGFRs causes autophosphorylation of the 
RTK domain and activation of a series of intracellular pathways leading to gene 
transcription. Therapeutic agents that target EGFR and/or ERBB2 generally induce 
cytostatic effects in vitro, and less frequently apoptosis (Baselga and Arteaga 2005; 
Mendelsohn and Baselga 2006). By contrast, in vivo data have shown that anti-EGFR 
therapy can induce tumour regression, an effect that might not be explained in full by 
inhibition of the tumour target (Hanahan and Folkman 1996). This discrepancy 
suggests that EGFR signalling affects both biological effects of the tumour cell and 
tumour-host interactions during angiogenesis. In addition direct angiogenic effects 
have been demonstrated in EGFR-expressing human microvascular EC which induce 
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tube formation in response to EGF or TGF- signalling. These processes are 
prevented by the tyrosine kinase inhibitor gefitinib (Okamura, Morimoto et al. 1992; 
Hirata, Ogawa et al. 2002). In addition human umbilical vein EC (HUVECs) which 
do not express EGFR, do not migrate in the presence of EGF or TGF-; however, 
these cells do migrate when co-cultered with cells expressing high levels of EGFR 
and they then produce VEGF and IL-8 following stimulation of EGF, thus inducing 
endothelial growth through paracrine mechanisms (Okamura, Morimoto et al. 1992). 
Other workers have investigated the effects of targeted combination therapy. 
Combined anti-TNF and anti-IL-1 therapy showed initial promise in animal models of 
arthritis (Bendele, Chlipala et al. 2000; Feige, Hu et al. 2000). However, this success 
was not replicated in RA patients treated with combination therapy who had failed to 
show clinical improvement following methotrexate therapy. In addition there was an 
increased incidence of infection in the combination treatment group (Genovese, 
Cohen et al. 2004). The data presented here suggest that combining drugs which 
target both a central component in the cytokine cascade (TNF) and abrogate 
neoangiogenesis (via modulation of EGFR and VEGF) may therefore hold significant 
promise in RA. 
Taken together the above work has validated E-selectin targeted optical in vivo 
imaging as a novel modality for investigating animal models of inflammation and 
arthritis. It has also demonstrated the practical use for measuring and interrogating the 
effect of novel therapeutic strategies that may ultimately be of benefit to patients with 
RA. The following sections detail how this technology could be deployed further. 
6.1 Future Work 
6.1.1 Short Term Objectives 
6.1.1.1 Methods of intensifying E-selectin targeted signal 
The technique of fluorescent imaging by a NIR labelled MoAb directed at E-selectin 
has demonstrated specificity as an in vivo imaging technique. However despite the 
affinity and specificity of anti-E-selectin for its intended target, there were still 
significant levels of background signal due to non-specific uptake of antibody into 
tissue and prolonged clearance from the blood. This reduced the target to background 
ratio. A potential advantage of optically labelled probes is that they can be activated 
or switched on by a variety of mechanisms at their intended target. This compares to 
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other imaging modalities such as radioisotopes where a constant (but gradually 
decaying) signal will be emitted. A number of different activatable optical probes 
have been described and the principles behind these are discussed in introductory 
Section 1.3.2.2.2. These are largely based on a quenching mechanism whereby 
enzymatic cleavage of fluorophore and quencher held in close steric alignment results 
in fluorescent activation as the fluorophore and quencher move away from each other.  
6.1.1.1.1 Investigation of altering fluorophore ratios to target moiety: 
increasing specificity of E-selectin targeted signal 
Another potential approach that may be possible to explore is the autoquenching that 
can occur between identical fluorescent molecules if they are held in close proximity. 
This has been investigated by Ogawa and colleagues. They have developed a 
molecular imaging probe consisting of multiple self quenching fluorophores (Cy5.5 or 
Alexa Fluor 680) conjugated to a MoAb (the HER-2 blocker trastuzumab). This agent 
only becomes fluorescently active after cellular internalisation where the fluorescent 
molecules dissociate from the antibody and then fluoresce without auto-quenching of 
adjacent fluorescent molecules. They demonstrated higher tumour to background 
ratios of fluorescent signal intensity for this conjugate with up to a nine fold increase 
in quenching with the addition of multiple fluorophores (Ogawa, Regino et al. 2009). 
→Further work would be required however, to delineate how this may translate into 
increased signal intensity at the intended target in vivo. Differing fluorophore 
combinations could be validated in the TNF induced paw inflammation model and 
compared to the labelling experiments already performed. 
Following expression on the activated endothelium it appears that E-selectin is rapidly 
internalised into endosomes (von Asmuth, Smeets et al. 1992). The internalisation of 
this glycoprotein was investigated on TNF-activated HUVEC. Internalisation studies 
were performed with radioiodinated antibodies in an acid elution endocytosis assay 
and by immunohistology. Kinetics of intercellular adhesion molecule-1 (ICAM-1) 
were compared in parallel experiments. A monoclonal antibody specific for E-
selectin, was internalized at a rate of approximately 1.7% of the membrane-bound 
monoclonal antibody per minute. In contrast, less than 0.1% of membrane antibody 
specific for ICAM-1 was internalized per minute. TNF-activated HUVEC were 
immunostained and examined by light microscopy and electron microscopy (EM). A 
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study by Subramaniam and colleagues demonstrated that P- and E-selectins are 
internalised differently following their expression (Subramaniam, Koedam et al. 
1993). The endocytosis pattern visualised by immunofluorescent staining in this paper 
are very similar to those seen following stimulation of PY4.1 cells with TNF at 4 
hours as described in Section 3.3.4.2. 
→The physiological significance of E-selectin internalization compared to the 
internalisation of a novel conjugated probe in the regulation of E-selectin membrane 
expression and clearance of E-selectin from the circulation would require further 
investigation. Similarly if multiple fluorophores were placed on the antibody the 
pharmokinetics and clearance of the novel conjugate would also require verification.  
6.1.1.1.2 Labeling to minimal E-selectin antibody fragment 
Labelling to a fragment of antibody can have advantages since the clearance from the 
blood pool may be quicker than a full sized monoclonal antibody. This may help to 
increase background to target levels. In addition antibody imaging methods can be 
problematic due to nonspecific adhesion, the human anti-mouse antibody (HAMA) 
response and uncertainty in the labelling site, which may interfere with the 
biospecificity. To investigate these properties, an anti E-selectin Fab fragment has 
been utilised to demonstrate that 
99m
Tc-anti-E-selectin Fab scintigraphy can be used 
successfully to image synovitis with improved specificity than 
99m
Tc-HDP bone 
scanning (Jamar, Houssiau et al. 2002). Other approaches include using humanised or 
chimeric monoclonal antibodies or smaller fragments such as single-chain variable 
fragment antibodies (sFV) which can be produced by bacterial systems (Huston, 
George et al. 1996). These are minimal antibody binding sites engineered as single 
polypeptide chains. The sFv can be as small as 26 kDa monomers or can be 
engineered as larger fusion proteins designed to self associate into dimeric or 
multimeric species. They typically exhibit rapid clearance that results in high 
targeting specificity within a matter of hours. In this study Huston and colleagues 
compared different modes of administration (i.v. and i.p) of radiolabelled sFVs to 
investigate their biodistribution and targeting properties. Administration by either the 
i.p. or i.v. route showed comparable long-term retention in the circulation, but the i.v. 
route showed an initially high peak blood level while i.p. injection did not. As with a 
single sFv dose, repeated bolus injections of sFv attained high target-to-background 
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ratios, whereas continuous sFv infusion reached a steady state level of free sFv in 
blood and kidney that exceeded that in tumor xenografts. 
→Investigation of the biokinetics of sFVs for fluorescent imaging in arthritis would 
also warrant investigation to determine whether this conferred additional accelerated 
clearance and targeting properties. 
6.1.1.1.3 Labelling to other smaller targeted molecules – aptamer based 
technology 
As oligonucleotide ligands, aptamers are comparable to antibodies in specificity and 
affinity for their target molecule, typically a protein (Gold, Polisky et al. 1995; 
Famulok and Mayer 1999). At 8-15 kDa, aptamers are intermediate in size between 
antibodies (150 kDa) and small peptides (15 kDa) and are slightly smaller than sFv 
(25 kDa). As polyanions, aptamers are quite different in composition from sFv. As 
synthetic molecules, aptamers readily support site-specific modifications that 
maintain structure and activity. Aptamers can be coupled to diagnostic or therapeutic 
agents and to bioconjugates, such as polyethyleneglycol (PEG) polymers, that can 
alter aptamer pharmacokinetics. The parameters for the in vivo activity of aptamers 
have been investigated in rats with an aptamer directed against L-selectin (Watson, 
Chang et al. 2000). Previous therapeutic work with aptamers has focused on blocking 
protein function; by far the most advanced work is represented by the use of a 
vascular endothelial growth factor aptamer, pegaptanib sodium (Macugen; Pfizer and 
Eyetech) (Ruckman, Green et al. 1998), now approved for treatment of macular 
degeneration (Csaky 2003). The small size and polyanionic nature of aptamers may 
lead to rapid blood clearance and tissue uptake and may minimize the residence in 
liver and kidney, providing some potentially useful features for imaging and 
radiotherapy. Initial experiments to address aptamer suitability for in vivo imaging 
have been reported (Charlton, Sennello et al. 1997; Hicke, Stephens et al. 2006). 
→Comparing the kinetics of optical in vivo targeted single chain dye labelled 
molecules to alternative targets such as aptamer based technology may therefore be a 
useful way of optimising inflamed/arthritic signal to background ratio thereby 
maximising signal specificity. 
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6.1.1.1.4 Indocyanine green (ICG) as an optical imaging agent 
Another method of achieving a greater ratio of specific targeting has also been 
deployed by Ogawa and colleagues. This utilises some of the unique spectral 
properties of indocyanine green (ICG). This is already routinely used in the clinic for 
retinal angiography (Slakter, Yannuzzi et al. 1995) and liver function testing 
(Cherrick, Stein et al. 1960; Weissleder and Ntziachristos 2003). Most recently, ICG 
has been tested for use during liver cancer surgery by two groups to identify small and 
macroscopically unidentifiable liver cancers in real time which were confirmed 
microscopically (Gotoh, Yamada et al. 2009; Ishizawa, Fukushima et al. 2009). ICG 
has also been tested in the real time identification of sentinel lymph nodes in small 
numbers of breast cancer patients (Sevick-Muraca, Sharma et al. 2008; Tagaya, 
Yamazaki et al. 2008; Troyan, Kianzad et al. 2009). As ICG is non-targeted, however, 
a small number of false positives were detected (Ishizawa, Fukushima et al. 2009). 
Conjugation of ICG to a molecule that would enable tumour-specific targeting would 
reduce this. However, ICG’s use as a conjugated NIR probe is limited as upon protein 
binding, fluorescence is lost. In an animal model, this property was exploited by 
conjugation with antibodies to CD25 which upon CD25 positive tumour cell binding 
become internalised leading to catabolism in lysosomes, with release of fluorescence 
from unbound ICG (Ogawa, Kosaka et al. 2009). ICG unbound to a target has been 
used to detect arthritis in a rat model of arthritis. This demonstrated that native dye 
was able to provide a significant increase in the fluorescent signal of arthritic joints 
compared to baseline values (Meier, Krug et al. 2010). Several translational optical 
imaging devices have recently been introduced to the clinic. This includes a custom 
built ICG enhanced optical imaging device that has recently been shown by Fischer et 
al to correlate well to MRI changes in the detection of pathological change in RA 
(Fischer, Ebert et al.). Five patients and a corresponding number of normal controls 
were studied using 0.1mg/kg by body weight of ICG as an unconjugated non-specific 
contrast agent. Fluorescence images were acquired continuously over a 15 minute 
period. Findings were also compared directly to contrast enhanced MR images taken 
concurrently. This demonstrated that ICG levels were increased in inflammatory 
joints although specific sensitivity and specificity was not clearly defined. They did 
conclude however, that NIR imaging was limited to the finger and foot joints because 
the strong scattering and absorption of light would preclude imaging beyond a few 
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centimetres of tissue depth. The specificity could be amplified beyond this by 
conjugating fluorescent dye to a particular target such as E-selectin. 
→A possible longer term goal of this work would be to consider targeting activated 
endothelium in humans by linking ICG to E-selectin and constructing the conjugate so 
that it could dissociate following internalisation into endosomes where the emission 
wavelength would increase into the NIR range. Because both the human E-selectin 
antibody and fluorophore are approved for human administration, the likelihood of 
clinical translation may be improved. The resulting conjugate may well have different 
toxicities to the individual molecules, however the presence of two approved agents in 
the conjugate bodes well for its eventual clearance for human use.  
6.1.1.1.5 Use of alternative imaging hardware 
The challenge of overcoming light scattering and propagation for the imaging of deep 
joints and tissues remains to be resolved (Ntziachristos, Ripoll et al. 2002). This issue 
may not pose such a great problem for imaging distal joint disease. One of the major 
limitations of optical imaging is the loss of signal specificity due to light scattering. 
Although this may be decreased by imaging peripheral arthritis such as the mouse 
paw, this factor can potentially limit analysis of more proximal joints such as the knee 
or deeper tissues. This can be overcome by use of more intense dyes or by 
maximising the sensitivity of the optical imaging device. Advances in imaging 
methods that offer novel ways of visualizing and quantifying fluorescent signal will 
also have significant impact on fluorescent in vivo imaging techniques (Ntziachristos 
2006) and many of these may be very useful for the future imaging of arthritis. 
→Novel imaging techniques and systems could readily be analysed using the TNF 
induced paw model for rapid turnover of experiments and validation of initial results 
from novel imaging platforms. For example exploring the specific signal returned 
from novel tomographic techniques for optical imaging would help to further 
determine the potential of this system to generate additional in vivo molecular 
information. 
6.1.1.2 Alternative animal models 
While CIA has served as an important model for investigating the aetiopathogenesis 
of RA, and for developing new treatments, it is not identical to RA. An ideal in vivo 
model of human synovitis would include human synovium but be readily available in 
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an animal host for study of the cellular mechanisms of disease and for assessment of 
novel molecular targets. 
Investigating the in vivo action of novel conjugates on RA synovium in the animal 
model is possible by examining the action of agents on rheumatoid synovial tissue 
transplanted into severe combined immunodeficient (SCID) mice. The SCID model, 
with defects in both humoral and cell-mediated immunity, can serve as a recipient for 
grafts derived from numerous human tissues (McCune, Namikawa et al. 1988). In this 
particular RA model synovial grafts are implanted subcutaneously. The transplants 
remain viable and become vascularised by mouse subdermal vessels. There are 
connections between the mouse and transplant vasculature, with the transplant 
vasculature maintaining the ability to express human cell adhesion molecules (Wahid, 
Blades et al. 2000). This model has provided direct evidence that intragraft injection 
of TNF upregulates the expression of human microvascular EC adhesion molecules. 
The model has also been used for investigating the use of NanoSPECT/CT imaging in 
the animal model. This has demonstrated that this imaging platform can be both 
sensitive and specific for the detection of 
111
In-labelled anti-E-selectin or isotype 
control antibody. 
→Hence novel human E-selectin targeted imaging agents with differing fluorophore 
combinations could be tested following direct stimulation of the grafts with TNF 
over an acute time period, (similar to the way that TNF injections into the paw have 
been used as an acute model of inflammation for initial optical imaging experiments).  
→This model has also been used for the identification of novel synovium-specific 
peptides by in vivo phage display selection (Lee, Buckley et al. 2002). It may be 
possible to compare the honing of these peptides to either the E-selectin or a minimal 
E-selectin fragment (sFV). With the latter being of comparable size to novel 
synovium specific peptides. It would then also be possible to generate a control for 
both novel fluorescently conjugated molecules for in vivo validation. 
6.1.2 Long Term Future Work and Clinical Perspectives 
The work suggested above has indicated that optical imaging in humans may hold 
potential. As optical imaging becomes more targeted through the use of specific 
antibodies, activateable probes, as well as brighter, more photostable dyes, human 
targeted fluorescence optical imaging is a realistic possibility. Indeed, non-specific 
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optical imaging of patients with RA has already taken place with some initial optical 
imaging studies undertaken following the injection of ICG into patients with RA as 
described above. The addition of TNF blockade to the therapeutic armamentarium 
for patients with RA has had a revolutionary impact on the treatment of both RA and 
other inflammatory diseases with differing molecular approaches used to target TNF 
(Isaacs 2009). This has paved the way for many other agents other than TNF 
blockade to be validated as therapeutic agents, but there still remains considerable 
uncertainty about which individual patients will respond to any particular treatment 
(Feldmann, Williams et al.). Increasingly as further agents become clinically available 
the complexity of individual treatment plans for patients with RA is likely to increase. 
Biomarkers are therefore required that enable both the early diagnosis of RA and help 
to identify particular patients that may respond positively to tailored biological 
therapy. Furthermore early synovitis destined to develop into RA is characterised by a 
distinct and transient cytokine profile that may be different to that in established 
disease (Raza, Falciani et al. 2005). There is much need therefore, to determine how 
levels of cytokines and other inflammatory mediators change during the evolution of 
disease both systemically and in local sites of inflammation. It is the latter that will be 
most amenable to examination by novel bioimaging techniques such as optical 
imaging. With the added molecular perspective to diagnosis, this may translate into 
improved targeting of treatments to particular patients depending on the phenotype of 
the disease thereby helping to determine appropriate treatment. 
E-selectin represents an excellent molecular imaging target in humans. E-selectin can 
be expressed at low levels in uninflamed tissue including synovial tissue (Fairburn, 
Kunaver et al. 1993) but is upregulated in inflammatory synovitis (Kriegsmann, 
Keyszer et al. 1995) and reduced following anti-TNF therapy (Paleolog, Hunt et al. 
1996; Tak, Taylor et al. 1996). It is also expressed on activated endothelium of 
patients with a variety of other inflammatory conditions (Bevilacqua and Nelson 
1993). Understanding the kinetics of trafficking of specific versus non-specific 
molecules to sites of inflammation in vivo can provide useful therapeutic information. 
For example, given there is a substantial proportion of antibody that tracks to sites of 
inflammation that is non targeted, it might be better to administer antibody targeted 
therapy prior to other immunomodulating drugs that decrease joint swelling in order 
to enhance local drug delivery to inflamed areas.  
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6.2 Conclusion 
In summary, I have shown that E-selectin targeted imaging of joints of mice with 
inflammatory arthritis using fluorescently labelled anti-E-selectin is feasible in vivo. 
Furthermore, I have applied fluorescence imaging to investigate the in vivo mode of 
action of vascular-targeted therapies in murine inflammatory arthritis.  
In summary E-selectin targeted in vivo optical imaging is an effective quantifiable 
imaging technique that is likely to be of significant use in the animal model and has 
potential to be translated into the clinic for targeted optical imaging of patients with 
arthritis and other inflammatory conditions. Utilising a targeted optical imaging 
technique to visualise endothelial activation during the evolution of inflammation in 
conditions such as RA will further assist in understanding disease pathogenesis and 
developing novel therapies. 
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